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Synopsis  
The gut-derived bacteria, endotoxin (lipopolysaccharide), have been 
observed to be raised in patients with type 2 diabetes mellitus (T2DM) and 
cardiovascular diseases (CVD) which appears to represent a source of diet induced 
inflammation exacerbating metabolic disease. To further the current studies on 
endotoxin induced inflammation investigations examined a cohort of adult Saudi 
Arabian women with obesity/weight gain and or T2DM to ascertain (1) the impact of 
a post-prandial high SFA rich meal on systemic inflammation; (2) the direct effect of 
a 3 month diet intervention on cardiometabolic health (3) and assess how subtle 
changes in dietary interventions can impact on metabolic risk in different patient 
groups and what dietary components appear important.  
A total of 92 Saudi adult women with varying metabolic states [18 non-
diabetic (ND) control subjects (Age 24.4±7.9 years; BMI 22.2±2.2 Kg/m2), 24 
overweight-plus obese (overweight+) subjects (Age 32.0±7.8 years; BMI 28.5±1.5 
Kg/m2) and 50 T2DM patients (Age 41.5±6.2 years; BMI 35.2±7.7 Kg/m2)] were 
recruited for this 3-month intervention study. Anthropometric data and fasting blood 
samples were taken at pre- and 3 months post-intervention with glucose, insulin, 
HOMA-IR, lipid profile and endotoxin measured. To establish whether a high-fat 
meal alters circulating endotoxin in different metabolic disease states, all subjects 
were given a high fat standardized meal (75g fat, 5g carbohydrate, 6g protein) after 
an overnight fast of 12–14 h. Blood samples were drawn via cannula at baseline (0 
hour) and post-prandially (1, 2, 3, and 4 hours). For the dietary intervention, 
participants were prescribed a 500Kcal deficit energy diet less than their daily 
recommended dietary allowances. Targeted macronutrient composition was 20%-
30% fat, <10% of saturated fatty acids, 50%-60% carbohydrates, 15%-20% protein 
and at least 15g of fibre per 1000 kcal. 
XIX 
 
At baseline and with the exception of HDL-cholesterol, all anthropometric, 
glycemic parameters, lipid profile and endotoxin were significantly higher in the 
T2DM group. For the high fat challenge, the most notable changes were the post-
prandial increases in the triglycerides, insulin, HOMA-IR and endotoxin levels, and 
subsequent significant decrease in HDL-cholesterol in all groups (p<0.05). These 
same patterns of changes were observed after 3 months in the overweight+ and 
T2DM group. Endotoxin was found to be significantly and positively associated with 
total and LDL-cholesterol (p<0.05), modestly with triglycerides and inversely with 
HDL-cholesterol (p=NS). For the dietary intervention, significant improvements 
were noted in all anthropometric measures in the T2DM group and BMI in the 
overweight+ group (p<0.01). The noted weight loss was secondary to the significant 
decrease in carbohydrates, fats and total caloric intakes (p<0.05) which translated to 
a better cardiometabolic health in both groups noted clearly through lipid profile 
changes. Endotoxin was found to be inversely associated with fiber intake (p<0.05). 
Fiber intake was found to be positively associated with HDL-cholesterol (p<0.05), 
which appeared to be an important dietary component to be associated with health 
improvements. 
This current thesis expanded our knowledge and understanding on how a 
high fat oral challenge exacerbates cardiometabolic and inflammatory conditions 
(including endotoxemia) in Saudi Arabian women with different metabolic states, 
and how a 3-month caloric restriction may induce weight loss that leads to improved 
cardiometabolic health. Observations from the present thesis highlight strategies that 
may potentially be of clinical use in future dietary intervention studies in patients 
with T2DM and obesity in the Middle Eastern region. 
XX 
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1.1 The Obesity pandemic and the Middle East 
According to the World Health Organization (WHO), the world-wide 
prevalence of obesity is alarmingly increasing with almost 400 million adults 
reported to be obese in 2005, with an estimated increase to reach more than 700 
million by the year 2015. Due to the worldwide-spread of obesity, it is now 
considered to have reached pandemic proportions; a fact that indicates a large health 
burden as obesity is an established independent risk factor for coronary artery 
disease (CAD), hypertension and diabetes mellitus (T2DM) (WHO, 2014). 
It is ironic that, whereas malnourishment and starvation prevail in some poor 
regions in the world, overweight and obesity are alarmingly increasing in other 
regions that include both developed and developing countries. It is indeed 
unfortunate that some cultures including many people in the Saudi society, consider 
excess body weight, whether overweight or obesity, as being healthy.  In the Western 
world however, many individuals believe that being overweight or obese increases 
one’s risk to develop major chronic diseases. At the same time, most overweight or 
obese individuals in the Saudi society do not recognize the types of food that are 
needed for their nutritional or weight loss goals (Al-Nozha et al., 2005). It is well 
known that the net result of the balance between energy intake and energy 
expenditure determines an individual’s body weight. If this balance is disturbed in 
favor of surplus in energy intake, the result will be excessive accumulation of fat that 
may impair health, which simply defines the states of overweight or obesity.  
Although T2DM, obesity and CVD are strongly considered as components of 
an increasing global epidemic, there are still regions of the world where the 
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corresponding health implications have not been fully acknowledged. In comparison 
with other countries, only a few published studies have focused on the impact of 
T2DM and obesity in Saudi Arabia, although the social and economic implications 
are vast. 
In a study conducted by Al Nozha and colleagues in Saudi Arabia over a 5-
year period- between 1995 and 2000- examining 17,232 adult Saudi subjects (30-70 
year old), from both genders and from selected households, it was observed  that the 
crude prevalence of overweight (BMI = 25-29.9 kg/m2) was 36.9%. In addition, 
overweight was found to be significantly more prevalent in males (42.4%) than 
females (31.8%; p<0.0001). The age-adjusted prevalence of obesity (BMI ≥30kg/m2) 
was 35.5% with an overall prevalence of 35.6%, while the prevalence of severe 
(gross) obesity (BMI ≥40 kg/m2) was 3.2%. Females were significantly more obese 
with a prevalence of 44% relative to males (26.4%; p<0.0001) (Al-Nozha et al., 
2005; AlQuaiz et al., 2014). 
Weight gain has been historically associated with wealth and prosperity in 
many traditional societies. This perception, coupled with the shift from fiber rich 
foods to a more “Western” diet, has contributed to the current health crisis facing the 
Saudi population. This acute change is clearly apparent not only in Saudi Arabia, but 
also across neighboring Gulf countries where the apparent “overnight wealth” has 
created an enormous health burden. The global study, REACH (Ohman, 2006), 
which evaluated data from 68,000 patients in 44 countries, revealed a significant 
difference in the potential burden of disease among the various nations examined. As 
far as the Middle East region is concerned, Musaiger and co-workers observed that 
within the last four decades, daily per capita fat content in the Middle Eastern diet 
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has tremendously increased, with a figure reaching 143.3% increase in Saudi Arabia. 
Moreover, the current situation has clear indications that this increasing trend would 
continue (Musaiger, 2002). These circumstances are by no means unique, as this 
trend is present in many other regions of the world. At present however, many 
regions worldwide lack sufficient reliable data on the current health status of the 
population, although they will be faced with the burden of obesity and associated 
diseases to manage in the future (Mathers et al., 2005). 
Obesity and T2DM are strongly associated, where an estimated 80% of 
patients with T2DM are obese. This association is translated into a huge health-care 
cost burden on governments. Currently the WHO indicates that each individual with 
T2DM in Saudi Arabia costs the government about $800–1000 per month (WHO, 
2011). As a result, with the recently-announced population of 25.7 million, and with 
approximately 30% of the population being diabetic, the actual annual treatment cost 
of T2DM in Saudi Arabia may greatly exceed the previous annual estimates of $7.7 
billion (Alhyas, et al., 2011; Al-Daghri et al., 2011). It becomes obvious that, with 
the dramatic rise and cost associated with the current prevalence of T2DM and its 
associated complications, medication alone will not be sufficient to reduce the 
epidemic. Alternatively, a combination of physical activity, diet changes and 
medication are necessary to halt the epidemic.  
Obesity and saturated-fat-rich-diets have long been associated with markedly 
increased insulin resistance and inflammation; both of which give rise to metabolic 
diseases, including T2DM (Mather et al., 2005; Al-Attas et al., 2014). Moreover, and 
despite the widespread use of statins to reduce circulating lipid levels, inflammation 
still persists in most subjects, and it is unclear what factors mediate the inflammatory 
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reactions. The International Obesity Taskforce has currently estimated that more 
than 312 million adults worldwide are obese (Haslam and James, 2005) and that the 
incidence of diabetes will rise by 32% in Europe and 72% in the USA by 2030 with 
the most dramatic projected increases (> 150%) predicted to be in the Middle East, 
India, Southeast Asia, Sub-Saharan Africa and Latin America (Hossain, 2007; Wild, 
2004). Furthermore, the cardiovascular complications associated with obesity and 
T2DM could potentially overwhelm countries that are unprepared, either in 
management or prevention strategies. Thus, a better understanding of why a healthy 
diet is important and its impact on diabetic risk is clearly necessary. 
1.2 Types of obesity  
Etiologically, obesity is commonly classified into several subgroups; namely: 
monogenic obesity, syndromic obesity, and polygenic or common obesity (Herrera et 
al., 2010). The monogenic obesity is an autosomal disease where about 20 single 
gene disruptions have been described thus far. Phenotypically, it is manifested as 
morbid obesity without developmental delays (O’Rahilly, 2009). Interestingly, the 
role played by the leptin/melanocortin pathway in the central nervous system (CNS) 
in the regulation of whole-body energy homeostasis has been granted a critical 
position in all these mutation In these cases, obesity seems to be the result of 
increased appetite and reduced satiety (Coll et al., 2004; Coll and Yeo, 2013). 
In contrast to monogenic obesity, syndromic obesity involves several genes, 
autosomal or X-linked, which manifest discrete genetic defects or chromosomal 
abnormalities. The phenotypic presentation of this subclass of obesity is 
characterized by clinically obese individuals who suffer from additional defects such 
as mental retardation, dysmorphic features and organ-specific developmental 
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abnormalities. Prader-Willi syndrome is one of the most well-known forms of 
syndromic obesity (Herrera et al., 2010). 
Common obesity, as the name implies, defines the most common form of the 
disease, and it is the result of a complex interplay of genetic, environmental, and 
social factors that results in a long-term positive energy balance leading to prolonged 
storage of excess energy in adipose tissue. The genetic factors in this subclass, if 
exist, are known to be polygenic. Metabolic defects such as insulin resistance and 
increased risk of CVD are common consequences (Achike et al., 2011). 
Obesity can also be secondary to systemic diseases; such as Cushing disease 
associated with trunk obesity, insulinoma resulting in frequent hypoglycemia which 
will in turn promote energy intake, and hypothyroidism manifested by a decrease in 
energy needs. In addition, binge eating disorder, a sedentary lifestyle, a high 
glycemic diet, and some medications such as psychotropic drugs, insulin, and 
corticosteroids, can all be considered etiological factors of obesity (Martinez et al., 
2002; Al-Zoairy et al., 2013). 
1.3 Measurement of Obesity 
Epidemiological studies which were carried out just after World War 
II concluded that the best practical formulae to reflect the range of body weight 
indices was dividing the weight in kilograms by the square of height in meters 
[Weight (kg) / height (m2)]. This ratio was called the Quetelet Index after Adolphe 
Quetelet (1796 – 1874), who was a Belgian social scientist and statistician and a 
pioneer in this kind of epidemiological studies. However, Quetelet Index was 
changed into Body Mass Index (BMI) by Ancel Keys in 1972 (Eknoyan, 2008) 
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which has become familiar to most people as a way to categorize the body weight 
into normal weight, overweight, or obese. Due to the broad range of body weight, the 
WHO has divided the BMI into categories as shown in the following table (Table 
1.3.1).  (http://www.who.int/bmi)                                 
 BMI(kg/m2) 
Classification Principal cut-off points Additional cut-off points 
Underweight <18.50 <18.50 
Severe thinness <16.00 <16.00 
Moderate thinness 16.00 - 16.99 16.00 - 16.99 
Mild thinness 17.00 - 18.49 17.00 - 18.49 
Normal range 18.50 - 24.99 
18.50 - 22.99 
23.00 - 24.99 
Overweight ≥25.00 ≥25.00 
Pre-obese 25.00 - 29.99 
25.00 - 27.49 
27.50 - 29.99 
Obese ≥30.00 ≥30.00 
Obese class I 30.00 - 34.99 
30.00 - 32.49 
32.50 - 34.99 
Obese class II 35.00 - 39.99 
35.00 - 37.49 
37.50 - 39.99 
Obese class III ≥40.00 ≥40.00 
Table 1.3.1 Categorising humans based on body mass index (BMI) into different 
groups, underweight, normal weight, overweight or obese classes.   
It is important to note that BMI and other similar anthropometric parameters 
as waist circumference (WC) and waist-hip ratio (WHR) are simple measurements 
that can give a relatively clear indicator of potential risk for obesity, and hence these 
measures are widely used by primary care physicians to assess and monitor their 
patients. It must be noted, however that these measures do not determine muscle 
mass: fat mass ratio; they only give an approximate idea concerning general total 
body weight. More accurate measurements of adipose tissue mass and distribution 
can be obtained by performing sophisticated analytical procedures; such as 
Computed Tomography (CT), Dual Energy X-ray Absorption (DEXA) and Magnetic 
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Resonance Imaging (MRI) (Bosello and Zamboni, 2000; Bozzetto et al., 2011; 
Gallagher et al., 2009; Kuk et al., 2005). 
1.4 Consequences of obesity  
As is the case with any ailment, obesity is a health condition that bears 
medical, psychological and economic consequences. The following sections will 
look at these aspects in more detail. 
1.4.1 Medical 
The scientific evidence of the medical consequences associated with obesity 
is rapidly mounting. It has been shown that obesity is linked to CVD such as 
myocardial ischemia and strokes (Arsenault et al., 2010; Lavie et al., 2009; Poirier et 
al., 2006). Obesity predisposes to T2DM (Dandona et al., 2005; Freemantle et al., 
2008; Lazar, 2005; Mokdad et al., 2003), and is associated with musculoskeletal 
disorders such as osteoarthritis (Anandacoomarasamy et al., 2008; Krul et al., 2009; 
Wearing et al., 2006). Some medical research has also linked obesity to development 
of certain types of cancers such as endometrial, colon and breast cancers (Fleming et 
al., 2009; Rapp et al., 2005; Roberts et al., 2010; Sinicrope and Dannenberg, 2011; 
van Kruijsdijk et al., 2009). 
1.4.2 Psychological 
Obese individuals are often stigmatised and it has been often socially 
acceptable to become the centre of ridicule. Even the modern media and film-
industry play a part in promoting this social attitude towards obese subjects. These 
social pressures manifest themselves in the form a range of psychological disorders 
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suffered by the obese individuals, including low-self-esteem, social isolation from 
the rest of the community, and even clinical depression. These psychological 
consequences often prelude to increased food intake as a compensatory measure for 
loneliness which creates a vicious cycle that revolves around obesity (Friedman et 
al., 2002; Gariepy et al., 2010; Pratt et al., 2007). 
1.4.3 Economic 
The world has started to realize the economic and financial implications of 
obesity. The WHO and governments of the industrialized world are feeling the 
burden of the increasing requirement to deal with obesity associated diseases; all of 
which presents a substantial burden in order to either treat current conditions or long-
term look into prevention programmes. In England, the economic cost of treating 
obesity and its associated ailments was estimated to over four billion pounds in 2007 
(FORESIGHT REPORT, 2006; DoH, 2008), whereas the estimates in the United 
States of America (USA) were over 75 billion dollars in 2000 (CDC, 2010).  
1.5 Diabetes 
Obesity predisposes to many conditions including T2DM. According to the 
WHO, T2DM is defined as “a chronic disease that occurs either when the pancreas 
does not produce enough insulin or when the body cannot effectively use the insulin 
it produces” (WHO, 2014). Insulin aids target tissues such as liver, adipose tissue 
and muscle, to uptake and metabolically utilize glucose from the blood stream. 
Besides T2DM, other types of the disease exist, and depending on the cause, 
Diabetes Mellitus is mainly classified into three different types as follows:- 
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I. Type 1 diabetes (T1DM) where the pancreas does not produce sufficient insulin 
for blood glucose metabolism. This type of diabetes can only be controlled by 
life-long and daily administration of insulin. 
II. T2DM where initially there is sufficient amount or even high amount of 
circulating insulin in the blood, but the target body tissues are not responsive 
enough to this circulating insulin. Controlled management of this type of diabetes 
ranges from lifestyle changes- physical activities and diet- to insulin sensitizers 
and agonists; and eventually insulin injections might be required. 
III. Gestational diabetes is defined as a state of increased blood glucose during 
pregnancy. This type of diabetes is pregnancy-related and can be cured if 
managed properly during pregnancy.  
There are also conditions which prelude to T2DM such as impaired glucose 
tolerance (IGT) and impaired fasting glycaemia (IFG); these two states form 
intermediaries, where blood glucose levels are bordering the cut-off points, between 
normality and diabetes. People with IGT and IFG are at higher risk than normal 
people in becoming diabetic in later life. 
1.5.1 Prevalence of Diabetes: 
 T2DM is the most common form of the disease comprising about 90% of 
diagnosed cases of DM. According to the current estimates, there are more than 220 
million diabetics worldwide and the number is rising annually (WHO, 2014). In 
England, the prevalence of diabetes has noted to be around 5.4% in 2009 whereas its 
prevalence in the USA has been estimated at about 7.8% in 2007 (NHS, 2009). 
Globally, the prevalence of diabetes show surprising results being most prevalent in 
developing countries.  
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In a recently published study by Al Daghri and colleagues (2011), the high 
prevalence of obesity coupled with T2DM among Saudis was highlighted. The study 
analysed demographic and anthropometric data obtained from a total of 9,149 Saudis 
(age range: 7-80 years) from both genders (5,357 males (58.6%) and 3,792 females 
(41.4%)). The overall prevalence of T2DM was 23.1% (95% confidence interval 
(95% CI) 20.47 to 22.15). This was age- and gender-related, as demonstrated in the 
age-adjusted prevalence of T2DM that was 31.6%, and by demonstrating a 
significant higher prevalence in males with an overall age adjusted prevalence of 
34.7% (95% CI 32.6 to 35.4), than in females, with an overall age-adjusted 
prevalence of 28.6% (95% CI 26.7 to 29.3) (P < 0.001). Similarly, a high overall 
prevalence of obesity (31.1% (95% CI 30.1 to 32.0)) was shown among the studied 
individuals. Again, this was age- and gender-related, as demonstrated in the age-
adjusted prevalence of obesity that was 40.0%, and by demonstrating a significant 
higher prevalence in females with an overall age adjusted prevalence of 36.5% (95% 
CI 35.1 to 37.83), than in males, with an overall age-adjusted prevalence of (25.1% 
(95% CI 23.7 to 26.3)) (P < 0.001). This study has also reported a high age-adjusted 
prevalence of hypertension (32.6% (95% CI 31.7 to 33.6)) and CAD (6.9% (95% CI 
6.4 to 7.4) among the studied subjects (Figure 1.5.1.1).  
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Figure (1.5.1.1) Trends in the prevalence of chronic noncommunicable diseases in 
the Kingdom of Saudi Arabia from 2000 to 2010. (A) Age adjusted prevalence of 
type 2 diabetes mellitus in Saudi Arabia according to gender (1997 (Al Daghri et al., 
2010), 2004 (Al Nozha et al., 2004), 2011 (Al-Daghri et al., 2011)). (B) Obesity. (C) 
Hypertension. (D) Coronary artery disease. Previous estimates shown are from the 
central region (Riyadh) and do not include other regions. 
1.5.2 Complications of Diabetes 
As T2DM progresses, it starts affecting different body tissues resulting in a 
wide and variable range of complications that have been well established (Fowler, 
2008; Mazzone et al., 2008; Moore et al., 2009). Subjects with T2DM have much 
higher risk of developing CVD (Fox et al., 2007; Kelly et al., 2009), neuropathy 
(Mert et al., 2010; Resnick et al., 2002), retinopathy (Fong et al., 2004; Bello et al., 
2014) and nephropathy (Parving et al., 2001; Schena and Gesualdo, 2005; Bello et 
al., 2014). Each of these complications may result in detrimental consequences. For 
instance; in neuropathy, the patient with T2DM starts losing peripheral sensation in 
limbs, most commonly in the feet, with devastating consequences that may end up in 
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limb amputation; in diabetic retinopathy, the patient’s eye sight begins to deteriorate 
and may culminate in blindness; and in nephropathy, progressive diabetes adversely 
affects the kidney functions resulting eventually in renal failure. Although it is 
evident that late stages of T2DM can be fatal, fatal consequences of T2DM can be 
triggered at any stage of the disease if it is uncontrolled such as in the case of 
developing diabetic ketoacidosis. Subjects with T2DM also have higher vulnerability 
to infections; and similar to obese subjects, patients with T2DM are prone to 
psychological depression (Lin et al., 2010). 
1.5.3 Global Impact 
Due to the increasing prevalence of T2DM and the wide range of associated 
complications, world economies expenditure on prevention and treatment is totalling 
billions of dollars (Yach et al., 2006; Zimmet et al., 2001; ADA, 2013). Therefore, 
there are many organisations and societies worldwide that are formed in response to 
the urgent need for advisory and research bodies to promote diabetes prevention and 
improve its treatment. 
1.5.4 Obesity-Induced Diabetes or Diabesity 
The link between obesity and diabetes is becoming ever evident as research 
progresses; which has prompted some researchers to coin a new term-Diabesity- 
elucidating this close link (Astrup and Finer, 2000; Freemantle et al., 2008; Farag 
and Gaballa, 2011). Although, obesity is a risk factor for developing T2DM, it 
should be noted that not all obese subjects will develop diabetes at later stage. 
Nevertheless, obesity is still the biggest single risk factor for T2DM. As mentioned 
earlier; obesity is a risk factor for CVD as well; and as such, morbid obesity coexists 
13 
 
with heart attacks, strokes, hypertension and T2DM. These associated factors led to 
the existence of a cluster of pathologies collectively termed metabolic syndrome or 
syndrome X (Bruce et al., 2011; Han and Lean, 2011; James et al., 2004; Weiss et 
al., 2004). WHO set five defining criteria for diagnosing metabolic syndrome. Those 
criteria were slightly simplified by the international diabetes federation (IDF) so that 
they become more practical and could be accommodated for use in the clinics by 
physicians (Table 1.5.4.1). 
 
Criteria for diagnosis of metabolic syndrome: 
 
1. Central obesity (waist circumference of ≥ 94 cm for European men and ≥ 
80 cm for European women, with ethnicity-related specific values for other 
ethnic backgrounds) 
 
 
In addition to any TWO of the following four factors: 
 
2. Raised triglyceride level:  (≥150 mg/dL or 1.7 mmol/L) 
Or specific treatment for this lipid abnormality 
 
3. Reduced high density lipoprotein, HDL: (<40 mg/dL or 1.03 mmol/L in 
males)  
and (<50 mg/dL or 1.29 mmol/L in females) 
Or specific treatment for this lipid abnormality 
 
4. Raised blood pressure: (systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg 
Or treatment of previously diagnosed hypertension 
 
5. Raised fasting plasma glucose, FPG: (≥100 mg/dL or 5.6 mmol/L 
Or previously diagnosed type 2 diabetes 
 
Table 1.5.4.1: The new International Diabetes Federation (IDF) definition, 2011 
The recommendation from the IDF has been that three out of the five criteria 
should be present in a patient for the condition to be diagnosed as metabolic 
syndrome. However, one single criterion is central to the diagnosis of metabolic 
syndrome, namely increased body waist circumference; meaning this criterion must 
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always be one of the three factors (James et al., 2004; Bener et al., 2013). This 
emphasis on abdominal obesity highlights the instrumental role by which obesity 
plays the lead compared with other morbidities; one of which is T2DM. An increase 
in waist circumference has been shown to be a valid indicator of morbid obesity and 
a risk factor associated with other diseases such as CVD and T2DM, hence the 
current emphasis on the measurement of the increase in body waist circumference. 
Another important aspect of measuring the waist circumference is its practicality and 
ease of its use in the clinic (Despres and Lemieux, 2006; Grundy, 2004; Yoshimura 
N. et al., 2011).  
Obesity-induced diabetes has been the theme of research for the last decade 
or so to elucidate the underlying mechanisms. The current answer to the question of 
how obesity causes T2DM directs us to the core of obesity, the role of adipose tissue. 
The widely accepted explanation is that chemical messengers secreted by adipose 
tissue interfere with the action of insulin in the target tissues leading to a 
phenomenon called insulin resistance (Bosello and Zamboni, 2000; Despres and 
Lemieux, 2006; Han and Lean, 2011; Weiss et al., 2004). 
In such condition, peripheral tissues such as liver, muscle and adipose tissue 
become insensitive to the normal levels of circulating insulin in the bloodstream. 
This will result in elevated levels of blood glucose (hyperglycaemia). The target 
tissue’s glucose starvation will stimulate new synthesis of glucose through the 
process of hepatic gluconeogenesis. The latter will increase the blood glucose even 
further, resulting in a vicious cycle. Adipose tissue in itself is a target tissue for 
insulin, and insulin resistance in adipose tissue may induce even more detrimental 
consequences on health such as, high levels of circulating free fatty acids (FFA), 
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increased triglycerides (TG; hypertriglyceridemia) and ectopic adiposity. 
Hypertriglyceridemia and high levels of circulating FFA add a compounding effect 
to insulin resistance by interfering with insulin action at the cellular level. Ectopic 
adiposity is the deposition of fat outside the adipose tissue such as liver, pancreas, 
muscle, heart and kidneys. It occurs when the adipose tissue is overloaded and 
excess fat is transferred to other sites for deposition. This condition exacerbates the 
pathologic effects of adipose tissue as it adversely affects the functionality of the 
other tissues which are not supposed to store such TG (Bosello and Zamboni, 2000; 
Yoshimura E. et al., 2011). For these reasons adipose tissue is the focus of on-going 
research.           
A cause-effect relationship of obesity and insulin resistance is suggested by 
many groups and is detailed in several review articles. The increased mass of adipose 
tissue that occurs in obesity is believed to play a key role in predisposing the human 
body to systemic insulin resistance. This takes place via the dysregulation of 
multiple interconnected pathways and signals, for instance the inflammatory, 
endocrine, neural and cell regulatory pathways as illustrated in Figure 1.5.4.1 
(Qatanani and Lazar, 2007; Cai et al., 2013).  
In the following section, we will focus on the endocrine and inflammatory 
mechanisms. 
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Figure (1.5.4.1): Obesity and insulin resistance relationship; the roles of 
inflammatory, endocrine, neuronal, and cell regulatory pathways. A: Obesity is 
associated with increase release of FAs which will act via increasing intracellular 
metabolites as DAG, the effects of which include activation of PKC, followed by 
other serine/threonine kinases that inhibit insulin signaling. B: Adipose tissue-
released adipokines modulating insulin signaling markedly change in obesity. C: 
Obesity is an inflammatory state, associated with increase accumulation of adipose 
tissue macrophages (ATMs). ATMs will further augment the inflammatory state 
with the release of inflammatory mediators that modulate insulin signaling. D: 
Serine/threonine kinases that inhibit insulin signaling are affected by endocrine and 
inflammatory mediators. E: Further exacerbation of insulin resistance is mediated 
through the NF-B-induced activation of inflammatory pathways. F: Adipokines-
induced Suppressors Of Cytokines Signaling (SOCS) family proteins increase 
insulin resistance through alteration of phosphorylation pattern of Insulin Receptor 
Substrate (IRS)-1 and IRS-2, and increase IRS-1 and IRS-2 degradation. G: FAs are 
ligands for the Toll like Receptor (TLR) 4 and hence will activate the innate immune 
mechanisms. H: Insulin resistance is also augmented via central mechanisms acting 
through obesity associated modulation of the central response to hormones and 
nutrients.  (Qatanani and Lazar, 2007). 
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1.6 Endocrine mechanisms 
1.6.1 Glucose-Fatty acids (FAs) cycle 
As mentioned earlier, obesity-associated increased adipose tissue mass due to 
hypertrophy of adipocytes and increase storage of TG will increase the fatty acids 
production into the circulation, i.e. FFA (McGarry, 2002; Boden, 2006; Har et al., 
2013) (Figure 1.6.1.1). These have been strongly linked to insulin resistance and 
dysregulation of glucose uptake and metabolism. The hypertrophied adipocytes are 
resistant to the insulin action; and as such they will manifest increased hormone-
sensitive lipase-induced lipolysis since the latter is normally inhibited by insulin. 
The increase amount of FFA will be taken up by the liver and the skeletal muscles, 
where they will compete with glucose as an energy source; this is referred to as 
imbalance in the glucose-FA (Randle) cycle with increased availability of FA and 
their oxidation products, and decrease utilization of glucose by cells. The FAs and 
potentially several metabolites including acyl-CoAs, ceramides, and diacylglycerol 
(DAG) act as signaling molecules activating protein kinases e.g. Protein Kinase C 
(PKC), Jun kinase (JNK), and the inhibitor of nuclear factor-κB (NF-κB) kinase-β 
(IKKβ). These kinases can then impair insulin signaling by increasing the inhibitory 
serine phosphorylation of insulin receptor substrates (IRS), the key mediators of 
insulin receptor signaling, leading to inhibition of insulin-mediated glucose uptake in 
the muscle and adipose tissue (Petersen and Shulman, 2006). In addition, the energy 
produced from FA oxidation will be utilized in the hepatic de novo synthesis of 
glucose (gluconeogenesis), since this pathway is energy-demanding and is now free 
from the normal suppression exerted by insulin. The increase in hepatic glucose 
production will obviously augment the hyperglycemia that is due to decrease glucose 
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uptake (Day and Bailey, 2011). However, the rate-limiting step for FA-induced 
insulin resistance is suggested by some to be the inhibited glucose uptake by 
peripheral cells of muscle and adipose tissue, rather than the disturbed intracellular 
glucose metabolism (Shulman, 2000). This accounts in part for the effect of 
lipotoxicity to impede the translocation of GLUT4 glucose transporters into the 
plasma membrane, reducing glucose transport. Since skeletal muscle accounts for 
> 70% of glucose disposal compared with about 10% into adipose tissue, the 
development of insulin resistance in muscle is a major feature of obesity-induced 
insulin resistance (Kahn et al., 2006; Arner and Langin, 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1.6.1.1) Factors affecting adipose depot: Circulating triglycerides (TG), 
principally from dietary triglycerides as chylomicrons and hepatically synthesized 
very-low-density lipoprotein (VLDL) are degraded by lipoprotein lipase (LPL) 
produced by adipose tissue. Many of the released fatty acids are incorporated into 
adipocyte TG. Subsequent lipolysis involving hormone-sensitive lipase (HSL) 
releases fatty acids into the circulation. These are taken up by muscle and liver (Day 
and Bailey, 2011). 
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 1.7 Inflammatory mechanism  
The concept of obesity as an inflammatory condition started more than 20 
years ago, when Hotamisligil and colleagues demonstrated an overexpression of 
inflammatory cytokines in obesity (Hotamisligil et al., 1993). Adipose tissue cellular 
repertoire is known to be heterogeneous, with different types of cells including 
mature adipocytes, preadipocytes, immune cells, and endothelial cells. This is the 
base for the rapid and dynamic response of adipose tissue to changes in nutrients 
availability. For instance, adipocytes hypertrophy and hyperplasia take place in 
response to excess nutrients (Halberg et al., 2008). Furthermore, as a result of 
obesity, the adipose tissue will suffer from hypoxia due to insufficient blood supply; 
hypoxia in turn will lead to adipose tissue necrosis and macrophage infiltration 
(Cinti et al., 2005). Macrophages overproduction of pro-inflammatory mediators 
such as cytokines and chemokines is the underlying mechanism first for the localized 
inflammatory milieu prevailing in obese adipose tissue (autocrine and paracrine 
effects), which will then be propagated into a systemic inflammation associated with 
obesity metabolic comorbidities (endocrine effects). (Trayhurn and Wood, 2004; De 
Heredia et al., 2012; Wang B and Trayhurn P, 2006; Trayhurn, 2013).  
1.8 Adipose Tissue: Heterogeneity and Functions. 
The presence of adipose tissue in mammals is vital for their life, since it 
provides them with the fatty acids to be used in energy and heat production during 
fasting state and in postprandial periods. In fact, mammals have two types of adipose 
tissue with different functions, localization, and cellular composition; the white 
(WAT) and the brown (BAT) adipose tissue (Gesta et al., 2007).  
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Adult human body’s adipose tissue is composed mainly of WAT; the 
function of which may be divided into two main areas: control of body metabolism 
and regulation of body’s inflammatory and immunological response. WAT is the 
major source of FFA, which upon oxidation will provide the body with the high 
energy phosphate molecule adenosine triphosphate (ATP) during the process of 
coupled oxidative phosphorylation. This is vital for maintaining the energy 
homeostasis essential for driving various metabolic pathways. Furthermore, WAT 
plays a key role in the body’s inflammatory and immunological response by 
secreting a plethora of active mediators; some are immune modulators, others are 
pro- or anti-inflammatory molecules (Wozniak et al., 2009; Juge-Aubry et al., 2005). 
These molecules will be discussed later in more details. Anatomically, WAT is 
found in different locations, mainly intra-abdominally for instance around the 
omentum, intestines, and abdominal organs; and subcutaneously as in the abdomen, 
buttocks, thighs, and other body locations (Gesta et al., 2007). Therefore, the WAT 
can be classified as subcutaneous, visceral, muscle, epicardial, peri-renal and peri-
vascular. In fact, different WAT anatomical subgroups are thought to exert specific 
functions, since it was demonstrated that excess accumulation of adipose tissue in 
the upper part of the body, the so called android or central obesity represents a strong 
risk factor for certain inflammatory and metabolic diseases, while accumulation of 
adipose tissue in the lower part of the body, the so called gynoid or peripheral 
obesity represents a minimal risk for these diseases (Cancello and Clement, 2006; 
Gesta et al., 2007).  
Similar to the variation in the anatomic locations of WAT, its cellular 
composition is also variable. The diverse cellular repertoire of WAT includes mature 
adipocytes, and a variety of other cells grouped under the description of stromo-
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vascular fraction or SVF. The cells of SVF include preadipocytes, macrophages, 
lymphocytes, fibroblasts and endothelial cells (Gesta et al., 2007; Cancello and 
Clement, 2006; Subramanian and Ferrante, 2009; Park et al., 2012). As previously 
mentioned, the adipose tissue is the source of several active mediators, the sources of 
which are mainly the mature adipocytes, the preadipocytes, and the macrophages. 
These mediators can exert their action on the adipose tissue itself, the so called auto- 
or paracrine effects, or on other tissues, the so called endocrine effects (Wozniak et 
al., 2009; Juge-Aubry,2005; Subramanian and Ferrante, 2009; Fantuzzi, 2008;Lago 
et al., 2007; Lago et al., 2009; Chudek and Wiςcek, 2006). The macrophages are 
particularly known to be the source of various inflammatory molecules that are 
responsible for the low-grade chronic inflammatory state prevalent in obesity and its 
related metabolic disturbances (Wozniak et al., 2009; Cancello and Clement, 2006; 
Subramanian and Ferrante, 2009; Fantuzzi, 2008;Zeyda and Stulnig, 2007).  
In contrast to WAT, BAT is not present in large amount in adult human 
body. However, recent Positron Emission Tomography (PET) studies have clearly 
demonstrated the presence of metabolically active BAT in specific locations in adult 
human bodies, such as the supra-clavicular, axillary, cervical and paraventral regions 
(Redinger, 2009; Frühbeck et al., 2001; Virtanen et al., 2009). The BAT depots in 
these sites were also found to be induced by cold and by autonomic nervous system 
activation, specifically the sympathetic system. Furthermore, and unlike WAT, BAT 
is mainly involved in thermogenesis and cold adaptation through uncoupling of 
oxidation and phosphorylation. Both WAT and BAT differ in appearance, 
composition, and cellular description. BAT possess smaller size adipocytes that are 
rich in mitochondria, the tissue as a whole is richer in its blood supply and hence in 
the autonomic nervous system regulation. These characteristics are responsible for 
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its brown colour. The unique function of BAT in heat vs. metabolic energy 
production has highlighted its potential role as a therapeutic target for obesity and 
related comorbidities (Frühbeck et al., 2007; Virtanen et al., 2009). 
  Obesity is usually associated with excess energy intake in the form of over 
nutrition. Visceral obesity in particular is associated with a state of disturbed 
metabolic homeostasis and stress (Karalis et al., 2009). Furthermore, in obesity a 
state of ongoing chronic inflammation exists, not only in the adipose tissue itself, but 
also in other metabolically active sites such as the liver and immune system 
(Cancello and Clement, 2006; Subramanian and Ferrante, 2009; Fantuzzi, 2008; 
Lago et al., 2007; Chudek and Wiςcek, 2006). Chronic inflammation is manifested 
by increased circulating levels of adipose tissue-derived hormone-like pro-
inflammatory cytokines, collectively known as adipokines (Wozniak et al., 2009; 
Lago et al., 2007; Lago et al., 2009; Luft et al., 2013). In response to the obesity-
associated stress, the hypothalamic-pituitary-adrenal axis is activated together with 
the autonomic nervous system, both central and peripheral components, to provide 
the body with adaptive responses (Chrousos and Gold, 1992). The result will be 
elevated levels of circulating glucocorticoids that will result in more proliferation 
and differentiation of fat cells, and hence more expansion to the adipose tissue. This 
will create a vicious cycle, especially with the prevalence of the chronic 
inflammatory state caused by the expanding WAT (Purnell et al., 2009).  It is this 
vicious cycle between the inflammatory, the immune, and the endocrine system that 
will eventually precipitate the obesity associated comorbidities (Karalis at al., 2009; 
Hotamisligil and Erbay, 2008). 
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Obesity is accompanied by a drastic change in the prevailing environment in 
WAT. Under normal conditions, an anti-inflammatory milieu prevails in WAT and is 
maintained by the specific type of resident tissue macrophages, M2 macrophages, 
known to produce the enzyme arginase responsible for the inhibition of nitric oxide 
synthase, iNOS), and the anti-inflammatory cytokines interleukin (IL)-10 and IL-
1Ra (Zeyda and Stulnig, 2007). This environment is protective against the 
development of obesity-related pathologies as insulin resistance (IR). Other factors 
exist that help maintaining the anti-inflammatory state, most notably are members of 
the nuclear receptor; peroxisome proliferator-activated receptors-(PPAR) 
(particularly PPAR-α and -γ) and liver X receptor- (LXR) families that are involved 
in nutrient transport and metabolism (Moller and Berger, 2003; Joseph et al., 2003; 
Pan et al., 2011). Recently, a new adipokine, the lipocalin-2 (LCN2) was 
demonstrated to contribute to the physiological anti-inflammatory status by 
upregulating PPARγ and increasing adiponectin secretion, while antagonizing TNF-
α effect on gene expression related to inflammatory and metabolic genes in both 
adipocytes and macrophages. In addition, knocking down LCN2 expression was 
demonstrated to decrease the expression of PPARγ and its target genes, adiponectin, 
and leptin (Zhang et al., 2008). 
 On the other hand, in obesity the adipose tissue resident macrophages 
population manifests a polarization toward the CD11c-positive inflammatory type, 
the M1 macrophages, that release iNOS and several pro-inflammatory cytokines 
(Zeyda and Stulnig, 2007; Gordon, 2007; Lumeng et al., 2008). A crosstalk between 
adipocytes and macrophages takes place in obese WAT (Wozniak et al., 2009; 
Subramanian and Ferrante, 2009; Zeyda and Stulnig, 2007), together with cellular 
remodeling characterized by an increase in number (hyperplasia) and size 
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(hypertrophy) of adipocytes, macrophage infiltration, and fibrosis (Spalding et al., 
2008; Bourlier et al., 2008; Henegar et al., 2008; Jernas et al., 2006; Maury et al., 
2007; Skurk et al., 2007). Two factors are involved in inducing the adipocyte 
hypertrophy: increased fat storage in fully differentiated adipocytes and increased 
expression of proinflammatory mediators (Jernas et al., 2006; Maury et al., 2007; 
Skurk et al., 2007). More inflammation takes place when the hypertrophic adipocytes 
shift the immune balance towards the production of proinflammatory molecules 
(Bourlier et al., 2008; Cancello et al., 2006; Harman-Boehm et al., 2007; Sengenѐs et 
al., 2007; Weisberg et al., 2003; Blüher, 2013). It was shown that 20 % of the 
expansion in total fat mass is due to the visceral depot, while the remaining 80% is 
due to subcutaneous adipose tissue expansion (Mlinar and Marc, 2011).  
The shift in the cytokines profile creates a tissue milieu responsible of the 
strong modification of the WAT macrophages pool from M2 type to M1 type (Zeyda 
and Stulnig, 2007; Gordon, 2007; Lumeng et al., 2008; Bourlier et al., 2008; 
Cancello et al., 2006; Harman-Boehm et al., 2007; Sengenѐs et al., 2007;Weisberg et 
al., 2003). Furthermore, while adipose tissue from lean individuals may 
preferentially secrete anti-inflammatory adipokines such as adiponectin, 
transforming growth factor  (TGF), interleukin 10 (IL-10), IL-4, IL-13, IL-1Ra 
and apelin; in obesity pro-inflammatory adipo-cytokines such as TNFα, IL-6, leptin, 
visfatin, resistin, angiotensin II and plasminogen activator inhibitor 1 (PAI-1) are 
released, as well as several other interleukins (Ouchi et al., 2011) coupled with a 
reduction in secretion of anti-inflammatory adipokines. 
It would also appear that adipokines have different functions in normal-
weight individuals and in the obese. In lean individuals, adipokines mediate 
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physiological functions while in states of metabolic disease the adipokines have 
altered effects, modulating insulin resistance either directly by affecting the insulin 
signaling pathway or indirectly via stimulation of inflammatory pathways. As 
previously mentioned, serine phosphorylation of IRS-1 by various adipokines 
directly or via inflammatory pathways including the JNK pathway and IKKβ/NF-kB 
pathway disrupts the insulin signalling pathways, possibly giving rise to insulin 
resistance (Pirola et al., 2004, Tilg & Moschen, 2008, Kalupahana et al., 2012).  
1.9 The Adipokines 
Adipokines are biologically active substances that, by definition, are released 
from adipose tissue, although not exclusively. Other tissues and organs, unrelated to 
adipose tissue were found to release some of these substances (Lago et al., 2007; 
Lago et al., 2009). The term adipokines includes hundreds of molecules 
encompassing more than 50 cytokines, chemokines, hormone-like substances and 
other effector molecules (Wozniak et al., 2009; Lago et al., 2007; Lago et al., 2009). 
A number of functions have been attributed to adipokines. Those functions are 
performed by adipokines through their local and systemic network-like effects 
regulating vital areas such as inflammation, insulin action and glucose homeostasis. 
They were shown to play a role in controlling appetite and satiety, glucose and lipid 
metabolism, inflammation and immune responses, and blood pressure regulation 
(Wozniak et al., 2009; Lago et al., 2007; Lago et al., 2009). Obviously, this intricate 
network system is altered in obesity, and as a consequence, is manifested as 
inflammation and defective metabolism not only in the adipose tissue, but also in the 
body as a whole. 
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Adipokine secretion is controlled by various mechanisms. A complex 
networking is involved that includes both extracellular and intracellular mediators. 
FFAs are among the primary extracellular factors involved in inducing the 
proinflammatory adipokines (Cnop, 2008). Chronic elevation of FFAs in obesity is a 
main contributing factor for what is called lipotoxity. This chronic elevation is due to 
the defective inhibitory effect of insulin on lipolysis, and the excessive consumption 
of dietary lipids (Ghanim et al., 2008; Di Zhao, 2013). 
Innate immunity receptors, such as Toll-like receptor (TLR)-4 and -2, are 
expressed in WAT (particularly by adipocytes, preadipocytes, macrophages, and 
endothelial cells) and are involved in this obesity-related inflammatory process. 
Their expression is increased and induced in obese subjects (Ghanim et al., 2008; 
Vitseva et al., 2008). FFA and other molecules produced by hypoxic conditions 
during obesity activate these receptors, particularly TLR-4 (Ghanim et al., 2008; 
Vitseva et al., 2008). Hence, FFAs particularly via TLR-4 induce the pro-
inflammatory adipokine production in adipocytes (Nguyen et al., 2005; Shi et al., 
2006). 
Lipopolysaccharide (LPS) is another factor able to activate TLR-4 (Cani et 
al., 2007a; Balistreri et al., 2009). A key source of LPS is the gut microbiota (Cnop, 
2008). It is continually produced within the gut by death of Gram-negative bacteria 
and is absorbed into intestinal capillaries to be transported by lipoproteins (Cani et 
al., 2008; Leuwer et al., 2009). On the other hand, it has been observed that a high 
fat diet given to mice increases the proportion of gut LPS (Cani et al., 2008; Leuwer 
et al., 2009). These data indicate the gut microbiotia may have an important role in 
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the induction of chronic obesity-related inflammation (Cani et al., 2008). The role of 
LPS will be discussed further in details in the following sections. 
In obese WAT the cells and the intracellular organelles are also exposed to 
increased stress, mainly as a result of metabolic overload (Hotamisligil and Erbay, 
2008). In particular, mitochondria and the endoplasmic reticulum appear to be the 
most sensitive organelles to metabolic stressors. In addition, the development of 
hypoxic conditions in the expanded WAT during obesity results in an increased 
production of reactive oxygen species and the corresponding development of 
oxidative stress (Houstis et al., 2006; Trayhurn, 2013). 
Signals mediated by both extracellular and intracellular factors culminate 
predominantly in the activation, principally via TLR-4 receptor, of NF-κB 
transcriptional factor, responsible for the production of inflammatory mediators, as 
well as the direct inhibition of insulin signaling (Ghanim et al., 2008;Vitseva et al., 
2008; Shoelson et al., 2003).  
Hence, NF-κB pathway represents the crucial and major factor responsible of 
obesity-induced inflammation. Other pathways also exist to amplify inflammation-
mediated inhibition of insulin action, such as those mediated through the suppressor 
of cytokine signaling-(SOCS)-proteins and nitric oxide synthase iNOS (Rui et al., 
2002; Mooney et al., 2001; Cruz et al., 2013) which produce nitric oxide (NO) that 
induces the degradation of IRS1 and iNOS activity results in reduced activity of Akt, 
a principal mediator of IRS signaling (Zeyda and Stulnig, 2009) (Figure 1.9.1).  
Furthermore, obesity, and abdominal adiposity in particular, seems to 
accelerate ageing process. It has been demonstrated that obese women have 
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telomeres of 240 bp shorter than lean women of a similar age. In view of the 
hypothesis that telomere length in vivo represents cellular turnover and exposure to 
oxidative and inflammatory damage, this difference in telomere length between 
being lean and being obese might correspond to 8.8 years of ageing (Valdes et al., 
2005; Cui et al., 2013). 
 
 
The increased evidence on obesity, as a stronger predictor of metabolic 
diseases, has led to assess the mortality risk correlated with abdominal obesity (Baik 
et al., 2000; Carmienke et al., 2013). In 2008, a large European study reported that 
both general (BMI) and abdominal adiposity (WC; WHR) are strong predictors of 
mortality risk (Pischon et al., 2008). 
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Figure (1.9.1) Simplified illustration for the negative impact and consequences 
of obesity showing the involved cells and the underlying molecular and cellular 
dysfunction. TNF-α: tumour necrosis factor alpha; IL-6 : interleukin 6; NO: nitric 
oxide; ROS: reactive oxygen species; JNK: c-jun N-terminal kinase; IKK : Inhibitor 
of k kinase; PKR: protein kinase R.(Emanuela et al., 2012). 
 
 
 
In the following section, the attention will particularly focus on adipokines 
involved in the obesity-related inflammatory disease. 
1.9.1 Leptin 
Leptin was one of the first proteins discovered to be secreted from adipose 
tissue, by the identification and sequencing of the ob gene from the ob/ob mouse 
(Zhang et al. 1994). Daily injection of leptin peptide in ob/ob mice resulted in a rapid 
reduction in food intake, body mass and percentage body fat but maintained lean 
muscle mass, increased energy expenditure and restored euglycaemia and 
reproductive function, confirming that it had an important role in energy 
homoeostasis and storage (Campfield et al., 1995; Holmström et al., 2013). 
However, leptin levels were noted to be increased in obese subjects, with little or no 
impact to regulate energy homoeostasis, which coined the well-established phrase 
‘leptin resistance’ in obesity (Friedman & Halaas, 1998; Myers et al., 2010; Al Disi 
et al., 2010; Schwartz and Baskin, 2013). While this has dominated much of the 
literature on leptin, leptin was initially shown to have a pro-inflammatory function 
when studies observed that recombinant leptin-activated human T lymphocytes and 
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monocytes (Santos-Alvarez et al., 1999; Martín-Romero et al., 2000). More recently, 
leptin has also been shown to activate human B cells to secrete TNF-α, IL-6 and IL-
10 (Agrawal et al., 2011). The pro-inflammatory nature of leptin has been noted in 
several studies, with i.v. injection of endotoxin inducing a sudden rise in leptin levels 
(Landman et al., 2003; Xiao et al., 2003). Furthermore, endotoxin-induced fever and 
anorexia in rats resulted in an increase in leptin levels as part of the inflammatory 
response (Sachot et al., 2004). 
 
1.9.2 Tumor necrosis factor alpha (TNF-α.) 
TNF-α is a pleiotropic pro-inflammatory cytokine originally thought to be 
secreted mainly by adipocytes, yet shown later to be secreted mainly by 
macrophages (Weisberg et al., 2003). In humans, both circulating and adipose tissue 
levels TNF-α are higher in obesity, and they decrease upon weight loss (Ambeba et 
al., 2013; Ziccardi et al., 2002). TNF-α promotes the secretion of other pro-
inflammatory cytokines such as IL-6, and reduces anti-inflammatory cytokines such 
as adiponectin (Wang and Trayhurn, 2006). It can also induce adipocytes’ apoptosis 
(Bennett et al., 2014). TNF-α induces insulin resistance in adipose tissue and muscle, 
but not in liver, through inhibition of tyrosine phosphorylation of insulin receptor 
and IRS-1, and thus inhibiting the insulin signaling pathway (Hotamisligil et al., 
1994; Hotamisligil et al., 1996; Nowotny et al., 2013). 
TNF-α levels were also found to positively correlate with other markers of 
insulin resistance (Hivert et al., 2008); nonetheless acute treatment with TNF-α 
inhibitor in obese subjects with type 2 diabetes reduced other systemic inflammatory 
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markers without reducing insulin resistance (Dominguez et al., 2005). More recently, 
assessment of anti-TNF-α inhibitor treatment, over the long term, given to subjects 
with metabolic syndrome, has shown to improve fasting blood sugar and also to 
increase adiponectin levels, confirming a role for TNF-α in obesity-related insulin 
resistance in humans (Stanley et al., 2011). 
1.9.3 Interleulin-6 (IL-6) 
Both macrophages and adipocytes of WAT are primary sources of circulating 
IL-6. IL-6 plays an important role in the regulation of whole-body energy 
homeostasis and inflammation. It was shown to inhibit the lipoprotein lipase activity 
both in vitro and in vivo. In addition, IL-6 was demonstrated to affect the appetite 
and the intake of energy by affecting the hypothalamus, and its receptor, IL-6 
receptor, is shown to be expressed in several regions of the brain including the 
hypothalamus (Stenlöf et al., 2003). 
Interestingly, IL-6 is demonstrated to have dual functions, depending on the 
tissue and metabolic state. In skeletal muscle, during exercise, it acts to increase 
glucose uptake resulting in muscle hypertrophy and myogenesis and AMPK 
mediated fatty acid oxidation, as well as having an anti-inflammatory effect (Starkie 
et al., 2003; Kelly et al., 2004). While in adipose tissue and hepatic tissue, IL-6 is 
shown to be a pro-inflammatory adipokine. It increases insulin resistance by up-
regulating suppressor of cytokine signalling 3 (SOCS3), which in turn, impairs 
insulin-induced insulin receptor and IRS-1 phosphorylation (Senn et al., 2002, 2003; 
Rotter et al., 2003; Lukic et al., 2014). IL-6 is positively correlated with increasing 
body mass and plasma-FFAs (Fried et al., 1998), with reduction in circulating IL-6 
following weight loss (Bastard et al., 2000; Ziccardi et al., 2002; Peters et al., 2013). 
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Moreover, IL-6 has been shown to be raised in subjects with T2DM and also 
increases the risk of future development of T2DM (Pradhan et al., 2001).  
1.9.4 Adiponectin 
Adiponectin is a hormone secreted by adipocytes that regulates energy 
homeostasis, body weight, lipid and glucose metabolism; increases insulin sensitivity 
and protects against chronic inflammation. Adiponectin levels have shown to be 
increased in weight loss studies, while its level decreased in animal models of 
obesity and insulin resistance (Liu M. and Liu F., 2010; Ohashi et al., 2014). 
Furthermore human analysis has shown that insulin resistance, hyperinsulinemia and 
the development of type 2 diabetes is associated with hypoadiponectinemia, 
independent of fat mass (Fumeron et al., 2004).  
In a study designed by Su and colleagues (2011) to investigate plasma 
circulating pro-inflammatory cytokines, adiponectin and high-sensitive C-reactive 
protein (hsCRP) in young men with type 2 diabetes (divided into a non-obese group 
(NOYDM, body mass index, BMI ≦ 25 kg/m2, N = 23) and an obese group 
(OBYDM, BMI ≧ 25 kg/m2, N = 24). Twenty-four non-obese non-diabetic young 
men served as controls. Compared with controls, significantly greater HOMA-IR 
(7.9 ± 1.9 and 10.4 ± 2.5 vs. 1.5 ± 0.3, P < 0.001) and fasting insulin (103.3 ± 21.1 
and 209.9 ± 24.4 vs. 48.5 ± 6.7 pmol/l, P < 0.01 and P < 0.001, respectively) were 
observed in NOYDM and OBYDM. There were significantly lower plasma 
adiponectin and higher hsCRP and TNF-α levels in OBYDM, whereas higher TNF-α 
and IL-6 were shown in NOYDM (Su et al., 2011). 
33 
 
Furthermore, adiponectin concentration was found to be positively associated 
with HDL-cholesterol level in type 2 diabetic Chinese subjects aged between 40-70 
years. Adponectin concentration was the only main predictor of HDL-cholesterol 
level (β = 0.321, p = 0.002) after adjusting other factors for homogeneous type 2 
diabetic subjects, this demonstrates that adiponectin concentration might be a 
valuable marker of atherosclerosis in type 2 diabetic patients (Hsu et al., 2012). 
1.9.5 Resistin 
Resistin is a cytokine with a molecular structure similar to adiponectin (Patel 
et al., 2004) and has a clear role in mice, affecting glucose homoeostasis and acting 
as a mediator of insulin resistance (Steppan et al., 2001, Schwartz & Lazar, 2011). 
However, its role in human adipose tissue has had a much more conflicted history 
(Nagaev& Smith 2001, Savage et al., 2001, McTernan CL et al., 2002; McTernan 
PG et al., 2006, Schwartz & Lazar, 2011). While initially considered not to be 
present in the adipocyte, subsequent studies have shown its presence and regulation 
(Nagaev& Smith, 2001; Savage et al., 2001; McTernan PG et al., 2002a, b; 
McTernan PG et al., 2003; Al-Daghri et al., 2005; Baker et al., 2006; Kusminski et 
al., 2007), although its role in humans appears more related to an inflammatory role 
than being an important factor regulating glucose metabolism. 
In vitro studies in isolated abdominal subcutaneous adipocytes have shown 
an increase in resistin secretion following treatment of the adipocyte with endotoxin 
(LPS). In addition, treatment of adipocytes with recombinant human resistin 
increased release of IL6, TNF as well as expression of TLR2, IKK and JNK, 
suggesting a possible role for resistin in pro-inflammatory mechanisms in the 
adipocyte via both the NF-B and the JNK pathways (Kusminski et al., 2007). 
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1.9.6 New adipokines 
The following sections represent some brief insights into recent additions to the 
adipokine family, which, akin to other adipokines, appear to impact on inflammation 
and insulin resistance (Table 1.9.6.1). 
Apelin is a peptide that is produced in a wide range of tissues with positive effects 
on insulin sensitivity, glucose uptake and lipolysis in skeletal muscle as well as 
adipose tissue (Boucher et al., 2005; Dray et al., 2008; Yue et al., 2011; Attane´ et 
al., 2012). However, studies in humans have shown an increase in plasma apelin 
levels in obesity, morbid obesity, impaired glucose tolerance and T2DM with a 
reduction in apelin levels accompanying weight loss following diet or bariatric 
surgery. These findings suggest the presence of resistance to apelin, in a similar 
fashion to insulin and leptin (Heinonen et al., 2005; Li et al., 2006; Castan-Laurell et 
al., 2008, 2011; Erdem et al., 2008; Soriguer et al., 2009; Zhang Y et al., 2009). 
Apelin has also been shown to have a pro-inflammatory role with a close positive 
correlation demonstrated between apelin and TNF levels, as well as other 
proinflammatory cytokines (Malyszko et al., 2008; Heinonen et al., 2009; Yu et al., 
2012). Apelin expression also closely correlates with TNF in adipose tissue of lean 
and obese individuals, and in vitro studies of cultured human adipose tissue explants 
show an up-regulation of apelin in response to TNF (Daviaud et al., 2006). Further 
in vitro studies in human umbilical vein endothelial cells (HUVECs) suggest an 
increase in adhesion molecules (VCAM and ICAM) by apelin via the NF-B and 
JNK pathways, further supporting its role as a pro-inflammatory adipokine (Lu et al., 
2012). 
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Omentin is another new peptide that is produced in omental but not subcutaneous 
adipose tissue and exists in two isoforms, omentin 1 and omentin 2. Omentin 1 
represents the predominant circulating form and positively affects insulin sensitivity, 
which is reduced in subjects with obesity and T2DM compared with lean subjects 
(de Souza Batista et al., 2007; Shibata et al., 2012). Omentin is thought to be an anti-
inflammatory adipokine and acts by inhibiting TNF-α induced expression of 
adhesion molecules in endothelial cells by inhibiting the ERK/NF-kB pathway 
(Zhong et al., 2012), while in vascular smooth muscle cells omentin inhibits TNF 
action via inhibition of p38 and JNK pathways (Kazamaet al., 2012). Taken together, 
this suggests that omentin may have a positive role to play to reduce inflammation in 
normal physiology. 
Chemerin is a novel adipokine that has been shown to play a role in the regulation 
of adipogenesis and adipocyte metabolism (Goralski et al., 2007), as well as a role in 
glucose homoeostasis – as noted by studies on glucose intolerance in ob/ob and 
db/db mice (Ernst et al., 2010). In humans, however, chemerin seems to have a direct 
action on inflammation in adipocytes rather than glucose homoeostasis, as use of 
recombinant TNF seems to induce chemerin secretion from adipocytes (Catala´net 
al., 2011, 2013). In other inflammatory cell types, such as macrophages, chemerin 
causes a pro-inflammatory action through increasing macrophage adhesion to 
VCAM-1 and fibronectin (Hart & Greaves, 2010). As such, in subsequently 
considered coronary artery disease patients, where inflammation had progressed, 
circulating chemerin levels were noted to be positively correlated with multiple 
markers of inflammation including TNF, IL6, C-reactive protein (CRP), leptin and 
resistin, affirming its proinflammatory function (Lehrke et al., 2009). In separate 
studies of T2DM subjects at risk of CVD, analysis of their circulating chemerin 
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levels also revealed positive associations with inflammatory markers, including 
TNF CRP, leptin and resistin (Weigert et al., 2010, Yu et al., 2012). These 
combined studies indicate a pro-inflammatory function for chemerin, which appears 
exacerbated in metabolic disease states. 
 
 
 
Table 1.9.6.1: List of adipokines. Adapted and updated from Fruhbeck et al. (2001) 
and Kusminski et al. (2007) 
Adipokine Function/effect Distribution Effect of obesity Evidence 
Leptin Satiety signal. 
Promotes increased 
energy expenditure 
Secreted 
predominantly by 
WAT, Sc AT > Om 
AT. Also derives 
from BAT, skeletal 
muscle, stomach and 
plasma 
In human 
obesity, 
correlates with 
BMI, 
after fasting or 
weight loss 
Meier & 
Gressner 
(2004) and 
Mantzoros et 
al. (2011) 
Adiponectin Improves energy 
homoeostasis, 
insulin sensitivity 
and glucose uptake. 
Anti-in ammatory 
properties 
Secreted exclusively 
by adipocytes. 
mRNA and protein 
in Sc AT > Om AT. 
2–3x greater 
secretion 
in females 
In mouse 
models of 
obesity and 
insulin 
resistance (ob/ob 
and 
db/db). In 
human 
obesity and 
T2DM. 
Fisher et al. 
(2002), 
Spranger et 
al. (2003) 
and 
Whitehead 
et al. (2006) 
TNFα Reduces insulin 
secretion 
and insulin 
sensitivity. 
Stimulates lipolysis 
Predominantly 
expressed by 
macrophages. Also 
expressed by WAT 
adipo-cytes, Sc AT > 
Om AT 
After weight 
loss 
Correlates with 
BMI,        In 
human obesity: 
obese (2X) > lean.  
 Adipose 
differentiation 
Hotamisligil 
et al. (1993), 
Hube & 
Hauner 
(1999) and 
Tzanavari et 
al. (2010) 
IL6 
 
Affects glucose and 
lipid 
metabolism. 
Improves 
insulin sensitivity 
and 
glucose tolerance 
 
35% of the basal 
supply is derived 
from WAT. 
Produced by 
macrophages, 
broblasts, 
endothelial cells and 
skeletal muscle 
In morbidly 
obese 
patients.  
After weight 
loss 
Fried et al. 
(1998), 
Bastard et al. 
(2000) and 
Eder et al. 
(2009) 
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Resistin 
 
 
Affects glucose 
metabolism and 
causes insulin 
resistance in 
rodents. In humans, 
it acts more as a 
pro-in ammatory 
cytokine 
In rodents, secreted 
by 
WAT. In humans, 
secreted in 
macrophages and 
WAT 
In human 
obesity, metabolic 
syndrome, 
T2DM and CVD 
McTernan et 
al. (2002a, 
2006) and 
Schwartz & 
Lazar (2011) 
PAI-1 Potent inhibitor of 
brinolytic pathway 
Expressed by Sc and 
Om AT. Positive 
correlation with 
abdominal adiposity 
In human 
obesity, 
metabolic 
syndrome and 
T2DM 
Shimomura 
et al. (1996) 
and Alessi et 
al. (2007) 
RANTES 
 
 
 
 
 
Pro-in ammatory Secreted by T cells, 
monocytes and to a 
lesser degree in 
WAT 
No correlation of 
serum 
levels with 
obesity, although 
gene expression 
in adipose tissue 
Madani et al. 
(2009) 
 
Visfatin/PBEF/  
NAMPT 
 
 
Pro-in ammatory 
and 
insulin mimicking 
 
 
Secreted by 
adipocytes 
In obesity 
 
Chang et al. 
(2011) and 
McGee et al. 
(2011) 
Chemerin 
 
 
 
Affects 
adipogenesis, 
in ammation as 
well as glucose 
metabolism 
Secreted by WAT 
 
In obesity 
 
Catalán et al. 
(2011) and 
Roman et al. 
(2012) 
Vaspin 
 
 
Improves insulin 
sensitivity 
Secreted by WAT 
OmOSc.  
Also secreted in skin, 
hypothalamus, 
pancreatic 
islets and stomach 
In obesity, 
insulin resistance 
and T2DM 
 
Blüher 
(2012) 
Nesfatin Acts centrally to 
reduce 
appetite 
 
Secreted in brain 
tissue, 
β cells and adipose 
tissue 
 
In obesity, 
T2DM and 
PCOS 
Li et al. 
(2010), 
Ramanja-
neya et al. 
(2010) and 
Deniz et al 
(2012) 
Omentin Increases insulin 
sensitivity 
 
Secreted by omental 
adipose tissue 
 
In obesity 
 
de Souza 
Batista et al. 
(2007) 
Apelin Improves insulin 
sensitivity 
mainly acting in 
skeletal 
muscle and 
adipocytes 
in mice 
Produced in a wide 
range of tissues 
In obesity, 
impaired glucose 
tolerance and 
T2DM. 
After weight 
loss 
following diet or 
bariatric 
surgery 
Boucher et 
al. (2005), 
Castan-
laurell et al. 
(2012) 
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CRP is another pro-inflammatory factor positively correlated with BMI in 
otherwise healthy individuals, and its elevation in obesity may be a consequence of 
IL-6 production. IL-6 is secreted by subcutaneous adipose tissue and increases 
hepatic CRP production. In addition, serum CRP is positively correlated with 
adipose tissue expression of IL-6, and IL-6 is necessary for human CRP gene 
expression in transgenic mice (Fontana et al., 2007; Bremer and Jialal, 2013). 
 
1.10 Inflammatory characteristics of the gram negative bacteria’s 
endotoxins (LPS)  
The activation of the human adipose tissue immune cells may represent a 
mechanism for increased inflammation in that tissue (Haara et al., 2004; Blüher, 
2013). Previously-published works have demonstrated that elevated circulating 
levels of the gut-derived bacteria endotoxins (the lipopolysaccharide; or LPS) may 
contribute to the increased activation of the innate immune pathway. LPS is a 
component of the outer cell wall of the gut-derived bacteria (Haara et al., 2004; 
Yoshimura E et al., 2011; Hui et al., 2012; Conde et al., 2011). The chemical 
composition of LPS comprises an antigen-O specific chain, a core region which 
represents a hetero-oligosaccharide, and a lipid A region that is highly conserved and 
representing the toxic part of the LPS (Osborn et al., 1964) (Figure 1.10.1). 
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Figure (1.10.1) (A) General chemical structure of bacterial endotoxins. (B) 
Proinflammatory sequence of events taking place upon activation of an immune cell 
with LPS bound to LPS-binding protein. LPS: Lipopolysaccharide; LBP: 
Lipopolysaccharide-binding protein; mCD14: membrane cluster of differentiation 
14; TLR4: toll-like receptor 4; MD2: myeloid differentiation protein-2; NFκB: 
nuclear factor κ B; IL-6: interleukin-6 (Laugerette et al., 2011a) 
It is well documented that endotoxin stimulates the innate immunity pathway 
through the activation of the Toll like Receptors (TLRs) through several proteins, 
including the LPS-binding protein (LBP), CD14, myeloid differential protein 2 
(MD2) and myeloid differentiation factor 88 (MyD88). This leads to intracellular 
activation of NF-κB and resulting pro-inflammatory cytokines (Creely et al., 2007; 
Baker et al., 2009; Youssef-Elabd et al., 2012). However, understanding of how gut-
derived endotoxin affect metabolic function has changed in recent years, as studies 
have considered the direct impact of endotoxin as a systemic inflammatory insult. 
Based on the known strong affinity of endotoxin for chylomicrons (which are the 
lipoprotein particles responsible for dietary fat transportation across the intestinal 
wall), endotoxin is believed to cross the gastrointestinal mucosa coupled to these 
lipoproteins. Once in the circulation, endotoxin has been shown to mediate metabolic 
dysfunction in several tissues including adipose tissue, liver and muscle. In addition 
to the long-established list of metabolic risk factors including hyper triglyceridemia, 
reduced HDL-C and hyperglycemia; all are associated with insulin resistance; other 
mediators as LPS may prove relevant as well. Within this context, chronic low grade 
inflammation has been added to this list, coupled with obesity, insulin resistance and 
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an activated immune response in mediating several metabolic diseases (Ouchi et al., 
2011). 
 In vitro studies, using human adipocytes have demonstrated the impact of 
adipose tissue on the immune response. For instance, endotoxin was demonstrated to 
stimulate TLRs and NF-κB inflammatory pathways, resulting in secretion of pro-
inflammatory adipokines. Consequently, the body weight will be affected. (Creely et 
al., 2007; Dixon et al., 2008). Human body hosts gut microbiota which are 
considered a source of endotoxin. Due to the high affinity of endotoxin to 
chylomicrons, the gut-microbiota-induced endotoxin will be absorbed through these 
lipoprotein particles. However, monocytes, and in particular the hepatic Kupffer 
cells will rapidly remove the endotoxin. Therefore, under normal conditions, only 
small amounts of endotoxin will reach the systemic circulation due the protective 
role of the healthy liver.  On the other hand, a compromised liver, due to ectopic fat 
deposition, has diminished capacity to remove the endotoxin, which can directly 
aggravate liver disease exacerbated by weight gain (Rao et al., 2004; Harte et al., 
2010), leading to increased circulating endotoxin, or what is termed: metabolic 
endotoxemia to be distinct from the exogenous bacterial infection or sepsis-induced 
endotoxemia (laugerette, 2011a).  
Thus, a combination of dietary lipoprotein patterns and an increase in 
circulating endotoxin mediate chronic low-grade systemic inflammation that could 
activate the TLR pathway to induce downstream insulin resistance. As lipoprotein 
patterns would appear to alter circulating endotoxin levels, recent studies have begun 
to evaluate this across different insulin resistance states to examine the impact of 
feeding. Interestingly, a single high-fat meal did alter endotoxin levels across the 
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different subgroups analyzed, where endotoxemia was ~20% more in the IGT 
subjects and obese groups relative to the non-obese control (NOC) group. On the 
other hand,  subjects with T2DM experienced as much as 125% higher endotoxin 
levels than NOC; an effect that remains in the T2DM group even 4 hours after the 
meal (Harte et al., 2012). In addition, previous cross-sectional in vivo studies have 
shown that endotoxin appears to correlate with markers and conditions of insulin 
resistance, with endotoxin appearing to act as a predictive metabolic biomarker of 
T2DM (Dixon et al., 2008; Al-Attas et al., 2009; Miller et al., 2009; Harte et al., 
2010; Pussinen et al., 2011). 
Studies on experimental animals have also reported an association between 
endotoxin and insulin resistance. Similar to the results obtained through infusing 
endotoxin to those animals, feeding animals a high-fat diet has lead to the same 
effect (Cani et al., 2007a). Gut permeability has been shown to be affected by both 
insulin resistance and weight gain. (Brun et al., 2007; Harte et al., 2010; Ghanim et 
al., 2009).  The capacity of endotoxin to affect the inflammatory pathways is 
strongly suggested by studies using either bolus infusion of endotoxin or the 
endotoxin derived from the gut secondary to dietary changes (Ghanim et al., 2009; 
Deopurkar et al., 2010). 
Taken together, the in vivo and in vitro studies highlight the impact of 
endotoxin on the inflammatory pathways to promote secretion of pro-inflammatory 
adipocytokines to exacerbate the insulin-resistant state (Brun et al., 2007; Creely et 
al., 2007; Dixon et al., 2008; Al-Attas et al., 2009; Baker et al., 2009; Miller et al., 
2009; Harte et al. 2010, 2012). 
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However, the gut-derived bacteria acts as a "primary insult" that activates the 
inflammatory state contributing to metabolic diseases as implicated by some clinical 
studies. Furthermore, cross sectional studies demonstrate elevation of endotoxin 
level in conditions such as obesity, coronary artery disease, T2DM and fatty liver 
disease. (Baker et al., 2009; Creely et al., 2007; Brun et al., 2007; Dixon et al., 2008; 
Al-Attas et al., 2009; Miller et al., 2009; Harte et al., 2010). In addition, these studies 
demonstrated a positive association between circulating endotoxin and WC, WHR, 
insulin levels, inflammatory cytokines and lipids, including total cholesterol, TG, 
and LDL cholesterol; and negative association with HDL cholesterol (Baker et al., 
2009; Creely et al., 2007; Brun et al., 2007; Dixon et al., 2008; Al-Attas et al., 2009; 
Miller et al., 2009; Harte et al., 2010). The combined importance of dietary lipids 
and LPS in determining inflammatory risk may arise, since as previously mentioned 
endotoxin has a strong affinity for chylomicrons (Ghoshal et al., 2009; Amar et al., 
2008; Moreno et al., 2010). As such, atherogenic risk and inflammation may arise as 
a result of increase in circulating level of endotoxin combined with dietary 
lipoprotein exacerbated by feeding patterns (Hall et al., 2009; Wyness, 2009). 
Therefore, a well-designed dietary intervention that results in altering the lipid 
profile may reduce endotoxin level and the arising inflammatory response. The 
dietary effect of high-SFA, high carbohydrate meal on circulating endotoxin levels  
have been explored in recent human studies, which found a substantial increase in 
circulating endotoxin in healthy subjects given a high-fat meal, in conjunction with 
markers of inflammation (as noted from mononuclear blood cells) (Cani et al., 
2007b; Ghanim et al., 2009). 
1.11 Links between high fat diets, inflammation and endotoxin  
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Several metabolic disorders are related to the glucose homeostasis and to the 
development of CVD (Alberti et al., 2005; Matareze et al., 2007). During the past 
decade, it became clear that a low-grade inflammation contributes to the 
development of the pathologies associated with obesity (Heilbronn and Campbell, 
2008) which is consistent with many experimental and clinical studies that showed a 
cause effect relationship between inflammation and inflammatory signaling 
responses to the development of metabolic disorders associated with obesity. The 
analysis of the nutritional disorders associated with obesity reveals that the 
prolonged positive energy balance mostly through the ingestion of high-fat diet is 
associated with adverse health consequences of weight gain and obesity. However, 
the mechanism by which feeding high-fat diet promotes low grade inflammation is 
poorly understood. (Cani et al., 2009) (Figure 1.11.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
Figure (1.11.1) Obesity and associated metabolic disorders: Several metabolic 
disorders are associated with obesity related to glucose homeostasis and CVD that 
has been associated with low grade of inflammation (Cani et al., 2009). 
The inflammatory Response to exogenous LPS can be affected by extrinsic 
factors such as diet, as shown in mice where their sensitivity to LPS injection has 
increased when submitted to high saturated fat and cholesterol diet (Huang et al., 
2007). However, the effect of dietary fat in inducing the absorption of endogenous 
endotoxin with subsequent inflammatory response has been supported by recent 
studies.  
 
 
The pioneering article by Cani et al. reported that a four week high fat diet in 
mice (72% energy as fat) increases plasma endotoxin levels (endotoxemia) in 
comparison with a control diet, and that chronic low-dose infusion of LPS leads to 
weight gain and insulin resistance (Cani et al., 2007a). In turn CD14-KO mice 
resisted to increased weight gain, endotoxemia and insulin resistance induced by a 
high fat diet (Cani et al., 2007a). Importantly, Shi et al. have also shown that TLR4-
KO mice is protected from NFқB-induced inflammation and development of insulin 
resistance (Shi et al., 2006). These studies thus show a link between innate immunity 
and lipid-induced insulin resistance. (Figure 1.11.2). 
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Figure (1.11.2) High-fat diet feeding changes gut microbiota, promotes metabolic 
endotoxemia and triggers the development of metabolic disorders, via a CD14/TLR4 
dependent mechanism. 
(1) High-fat diet feeding changes gut microbiota in a complex way and (2) 
specifically decreases Bifidobacterium spp. (3) This phenomenon is associated with 
a higher plasma LPS content (metabolic endotoxaemia), a LPS-dependent secretion 
of proinflammatory cytokines. High fat feeding and LPS promotes low-grade 
inflammation-induced metabolic disorders (insulin resistance, diabetes, obesity, 
steatosis, adipose tissue macrophages infiltration) (Cani et al., 2009). 
Moreover, in mice fed a diet containing 35% energy as fat, plasma LPS was 
found to be lower as compared with counterparts fed a high-fat diet. (Amar et al., 
2008). In humans, Amar et al. found a positive correlation between energy intake 
and endotoxemia which reveals a link between food intake and plasma endotoxin.  
(Amar et al., 2008). 
Erridge and colleagues have studied this link on an acute basis, and 
demonstrated that an acute high fat bolus (50 g butter on toast) given to humans 
(lean to obese) who are occasional smokers was sufficient to transiently promote an 
increase in endotoxemia as early as 30 min after ingestion (Erridge et al., 2007). 
Since smoking might play a role in plasma endotoxin level via the LPS absorption in 
lungs (Hasday et al., 1999), and to correct for this possibility, Eridge and colleagues 
examined endotoxemia for 4 h under four different settings; namely with no meal, 
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with a high-fat meal, with no meal and 3 cigarettes, and lastly with a high-fat meal 
and 3 cigarettes. Their results demonstrate that fat was the only significant variable 
influencing postprandial endotoxemia (Erridge et al., 2007) (Figure 1.11.3). 
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Figure (1.11.3) Possible impact of dietary lipids on postprandial lipid and LPS 
absorption and metabolic outcomes. Obesity and Type 2 Diabetes are 
characterized by altered profile of intestinal microbiota and by altered lipid 
metabolism. During lipid digestion, endotoxins from microbiota are absorbed along 
with lipids and can be vehicled by chylomicrons. In a healthy pattern, lipids are 
mostly oxidized and endotoxins are cleared by the liver. In a metabolic dysfunction 
pattern (obesity, type 2 diabetes), lipids are more oriented towards storage in the 
adipose tissue and more circulating endotoxins can contribute to generate low-grade 
inflammation (Laugerette et al., 2011a). 
A recent study by Harte et al (2012) showed that exposure to a high-fat meal, 
as early as 1hr postprandial, elevates circulating endotoxin irrespective of metabolic 
state, this increase was more substantial in IGT and type 2 diabetes , which suggests 
that metabolic endotoxemia is exacerbated after high fat intake, and that in a 
compromised metabolic state such as type 2 diabetes, a continual snacking routine 
will cumulatively promote their condition more rapidly than in other individuals 
because of the greater exposure to endotoxin (Figure 1.11.4). 
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Figure (1.11.4) Changes in circulating endotoxin levels (A) and triglyceride levels 
(B) in NOC, IGT, obese, and type 2 diabetic (T2DM) subjects. Endotoxin and 
triglyceride levels were measured at baseline and then, after a high-SFA meal, at 
each hour postprandially over a 4-h duration. Each point on the graph represents the 
mean value for each cohort (± SEM) (Harte et al., 2012). 
Overall, these results demonstrate that the repeated ingestion of single fat 
meal would trigger the increased endotoxemia. In fact, lipids and chylomicrons 
secretion is capable of promoting intestinal absorption of LPS from the gut 
microbiota. (Laugerette et al., 2011b; Ghoshal et al., 2009; Estadella et al., 2013), 
which could contribute to postprandial inflammatory responses (Lundman et al., 
2007; Mehta et al., 2010) and thus to the onset and persistence of chronic low-grade 
inflammation. 
A recent study by Lira et al (2012) showed the importance of life style 
changes (i.e. nutritional modification) in reducing the pro-inflammatory state in 
obese individuals. This study demonstrated that after interdisciplinary therapy, 
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endotoxinemia, pro-inflammatory status and insulin resistance were decreased. (Lira 
et al., 2012). Previous work published by the same group has shown that long-term 
therapy is effective in reducing body fat (particularly visceral fat), TNF-α and IL-6; 
and in increasing IL-10 and adiponectin. In addition, a positive correlation between 
pro-inflammatory cytokines (IL- 6 and TNF-α) and visceral fat was observed (Lira at 
al., 2011).  
1.12 Benefits of Weight Loss    
Weight loss occurs when energy expenditure exceeds energy intake. An 
energy deficit of 500-1000 kcal /day will result in a loss of ̰ 1-2 pounds/week. As 
such moderate weight loss can improve insulin action, decrease fasting blood 
glucose concentrations and reduce the need for T2DM medications as well as 
improve other risk factors related to cardiovascular disease (Pi-Sunyer, 1993; 
Goldstein, 1992; Williams and Kelley, 2000; Torgerson et al., 2004). This has been 
affirmed by ‘LOOK AHEAD’ (Action for Health in Diabetes) a randomized clinical 
trial examining the long-term effects of life-style interventions on cardiovascular 
morbidity and mortality in 5,145 overweight or obese participants with T2DM. This 
trial has revealed that the magnitude of weight loss at 1 year was strongly (P < 
0.0001) associated with improvements in glycaemia, blood pressure, triglycerides, 
and HDL cholesterol but not with LDL cholesterol (P = 0.79). Compared with 
weight-stable participants, those who lost 5 to <10% ([mean ±SD] 7.25±2.1 kg) of 
their body weight had increased odds of achieving a 0.5% point reduction in HbA1c 
(odds ratio 3.52 [95% CI 2.81–4.40]), a 5-mmHg decrease in diastolic blood 
pressure (1.48 [1.20 1.82]), a 5-mmHg decrease in systolic blood pressure (1.56 
[1.27–1.91]), a 5 mg/dL increase in HDL cholesterol (1.69 [1.37–2.07]), and a 40 
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mg/dL decrease in triglycerides ( 2.20[1.71-2.83]). The odds of clinically signi cant 
improvements in most risk factors were even greater in those who lost 10–15% of 
their body weight (Wing et al., 2011). 
1.13 Diet Modification 
 Dietary modification is considered the cornerstone in the management of 
T2DM. More than three out of every four adults with T2DM are at least overweight 
(Ali et al., 2013) and nearly half of individuals are obese (Nguyen et al., 2011). Due 
to this relationship between body weight (i.e., adiposity) and insulin resistance, 
weight loss has long been a recommended strategy for overweight or obese adults 
with diabetes (ADA, 2014) and several large scale studies have tried to assess the 
impact diet and exercise can have on health.   
The Finnish Diabetes Prevention study (FDP) randomized 522 overweight 
subjects with IGT to usual care or diet and exercise recommendations. The dietary 
goals in the interventional group were a low fat-diet (<30% fat energy as fat) with, 
10% saturated fatty acids (SFA) and dietary fiber >15g/1000Kcal. Participants in this 
group were instructed to increase physical activity to attain the target of weight loss 
to nearly 5% of baseline weight. The cumulative incidence of T2DM was 23% in the 
control group and 11% in the intervention group. Interestingly, risk reduction was 
directly proportional to the magnitude of lifestyle changes. Despite the success of 
many lifestyle trials, an important question remained to be answered. Weight loss 
appeared to be the driving force to reduce incidence of T2DM. Thus it is unclear 
whether diet with its macronutrient composition or exercise alone plays a significant 
role in preventing T2DM (Tuomilehto et al., 2001). 
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Salas-Salvadó and colleagues concluded -after reviewing epidemiologic and 
clinical trial evidences relating nutrients, foods and dietary to T2DM risk as well as 
the differential effects of carbohydrates and fat quantity and quality – that there is no 
universal dietary strategy to prevent T2DM or delay its onset. Furthermore, 
maintaining ideal body weight and consumption of the so- called prudent-diet 
(characterized by high intake of plant-based foods and lower intake of red-meat, 
sweets, high-fat dairy products and refined grains or a Mediterranean dietary pattern 
rich in olive oil, fruits and vegetables, including whole grains, pulses and nuts, low-
fat dairy, and moderate alcohol consumption (mainly red wine)) appears as the best 
strategy to decrease T2DM risk, especially if dietary recommendations takes into 
account individual preferences, thus enabling long-time adherence (Salas-Salvadó, 
2011). Furthermore, the low-fat eating pattern is one that has often been encouraged 
as a strategy to lose weight or to improve cardiovascular health within the U.S. In the 
Look AHEAD trial (Look Ahead Research Group, 2013), an energy reduced low-fat 
eating pattern was encouraged for weight loss, and individuals achieved moderate 
success (Pi-Sunyer et al., 2007). However, in a systematic review (Wheeler et al., 
2012) and in four studies (Brehm et al., 2009; Davis et al., 2009; Guldbrand et al., 
2012; Papakonstantinou et al., 2010) and in a meta-analysis (Kodama et al., 2009), 
lowering total fat intake did not consistently improve glycaemic control or CVD risk 
factors. The benefit gained from a low-fat diet appears to be more likely to occur 
when energy intake is also reduced and weight loss occurs (Pi-Sunyer et al., 2007; 
Look Ahead Research Group, 2013). 
A variety of diets have been proposed to treat obesity. Although many 
different dietary approaches may result in short term weight loss, the limitation of 
most diets is the poor long-term compliance and weight regain. There is no “ideal” 
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conclusive eating pattern that is expected to benefit all individuals with diabetes 
(Wheeler et al., 2012). 
Despite all these promising results, few studies have addressed the effects of 
dietary intervention and life style changes on dietary fat intake and endotoxin levels 
and their correlation with insulin resistance, therefore our study sought to establish 
whether a high-fat meal increased circulating endotoxin and inflammatory markers 
and whether this is altered in different metabolic disease states, as well as to study 
the effectiveness of dietary intervention through low fat, complex carbohydrate diets 
in decreasing inflammatory markers related to obesity among metabolically 
dysfunction states . 
Currently we have very limited evidence in the field of metabolic disease 
regarding the importance of dietary intervention, what works, and how diets 
exacerbate inflammatory risk. However, this study, while challenging, has the 
appropriate infrastructure, including primary care networks, to provide novel and 
exciting data. The work detailed in this study will generate a large body of 
significant data with potential ramifications for clinical practice as we reassess the 
effects of feeding and dietary patterns. Based on pilot data, this study will highlight 
the factors that may increase our inflammatory risk, their temporal profile, and how 
they differ among NOCs, overweight and subjects with T2DM. We will also 
examine how, over time, a change in diet may reduce our inflammatory risk. As such 
we anticipate that a low fat diet will reduce inflammatory status impacting long-term 
pathological outcome such as CVD. Obviously, this is expected to have a 
fundamental impact on targeting therapeutic approaches for T2DM towards treating 
the inflammatory component of the disease, especially after verifying the results in a 
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larger patients population. Reducing the pathogenesis of T2DM by dampening the 
inflammatory response, which may also have an impact on insulin resistance status 
and general health of the individual, will have clear benefits. This could have 
profound effects on preventative T2DM management, as well as current T2DM care 
without excessive cost for the wider Saudi health economy.  
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1.14 Study hypothesis and Aims of the study  
Our hypothesis is that gut-derived bacterial endotoxin, also known as 
lipopolysaccharide (LPS), may act as a potential mediator of inflammation in 
overweight and T2DM subjects, and that this can be altered acutely by feeding and 
metabolic status with long term metabolic effects. 
To test this hypothesis; we will study the postprandial impact of lipids on 
circulating factors, such as endotoxin, that affect insulin sensitivity, glucose 
metabolism and diet may impact patients with and without type 2 diabetes. We will 
assess the role of potential mediators of chronic low level inflammation, such as 
saturated fatty acids (SFA), dietary changes and endotoxin. We will specifically 
examine the following: 
1. The impact of a postprandial diet high in SFA on systemic inflammation, to 
establish that a high fat diet raises circulating endotoxin levels  
2. The direct effect of diet on CVD risk factors to lower endotoxin levels and thus 
reduce inflammation on cardiometabolic risk.  
3. How the different types of diet can influence insulin resistance and 
inflammation, postprandially, over time. 
 
 
 
 
 
 
 
 
Chapter Two 
 
Materials and Methods 
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2.1 Research methodology 
Ethical approval had been granted by the Ethics Committee of King Saud 
University, Riyadh, Kingdom of Saudi Arabia, prior to the commencement of the 
research (Appendix I). The number of subjects recruited was based on the previous 
studies in this area (Ceriello et al., 2002; Dixon et al., 2008). A total of 214 female 
Saudi adults aged 18-50 years were recruited at the beginning of the study, 110 were 
excluded (54 subjects didn’t meet the inclusion criteria while 56 refused to 
participate) (Figure 2.1.1). Finally a total of 92 female Saudi adults aged 18–50 years 
consisted of 18 healthy non-diabetic (ND) control subjects (n=18) (age 24.4±7.9; 
BMI 22.2 ± 2.2), overweight plus (overweight+) subjects (n= 24) (age 32.0±7.8; BMI 
28.5±1.5) and patients with T2DM (n= 50) (age 41.5±6.2; BMI 35.2±7.7), were 
recruited after informed consent was obtained from all the subjects who agreed 
voluntarily to participate in the study (Appendix II). Subjects were randomly 
selected from different regions of Riyadh city.  
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Figure 2.1.1 CONSORT (Consolidated Standards for Reporting of Trials) 
statement describes the flow of participants through our clinical trial  
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2.2 Medical screening  
 Subjects were medically screened at primary health care centers where a 
physician completed a medical examination of vital signs and clinical interview 
which include questions to determine eligibility based on inclusion and exclusion 
criteria, detailed health information obtained from all subjects using preset heath 
questionnaire. For collecting data for the study, a pre-coded questionnaire was 
designed. A pilot study was conducted to test the clarity of the questions with 10 
participants. Some questions were modified, omitted or added to the questionnaire 
taking into the consideration the participants understanding. The questionnaire was 
judged for its face validity through review by 4 experts in nutrition, biochemistry 
and community health along with the research supervisors. The interview 
questionnaire which was previously used in large-scale epidemiologic survey in 
Saudi Arabia consists of socio-demographic data, past medical and treatment history, 
sleeping hours and level of physical activity (Al-Daghri et al, 2011) (Appendix III). 
2.3 Exclusion & inclusion criteria  
Patients with acute medical illness; malignancy, a history of cardiovascular 
disease (CVD) or those on chronic medication, as well as patients with 
hypertriglyceridemia (as steroids and lipid lowering drugs may affect the 
intervention trial), previous myocardial infarction to established CHD, and other 
chronic inflammatory disorders e.g. rheumatoid arthritis, crohn’s disease, age under 
18 and inability to give informed consent on grounds of competency. 
All subjects were matched for age, BMI, and lipid profile as closely as 
possible. Only females, non-smokers, pre-menopausal, with a normal resting ECG 
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and blood pressure and with no history of vascular disease were selected. In addition, 
subjects with known long standing diabetes and receiving medication, or those with 
fasting glucose > 11 mmol/l, were excluded. Moreover subjects with a fasting 
triglycerides > 4 mmol/l were excluded from the study. 
The infrastructure to undertake these studies forms part of an ongoing 
research program, and active facilities are available to facilitate this research. These 
studies were conducted over a three month period utilizing only women for this part 
of the study to increase the compliancy rate. 
2.4 Anthropometry 
Participating subjects were requested to return to their respective primary 
health care centre after an overnight fast (> 10 hours) for anthropometry and blood 
withdrawal. Anthropometric data was collected with emphasis on clinical markers of 
adiposity. These included height (cm) (to the nearest 0.5 cm), and weight (kg) (to the 
nearest 0.1 kg) from which BMI was calculated [weight (kg)/height (m2)]. Waist 
(cm) and hips (cm) was also measured utilizing a standardized measuring tape in cm 
and its ratio was determined. Blood pressure (mmHg) was taken using a 
conventional mercury sphygmomanometer. Subjects were age and BMI matched as 
closely as possible. All these measurements were repeated post intervention at 3 
months. 
2.5 Clinical intervention (dietary regimen) 
Patients were brought to the clinic two times over a three month period. For 
each visit the subjects had fasted overnight (12–14 hours) and blood samples were 
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collected pre and post meal. A standardized high-fat meal consists of whipping 
cream and contains 75g of fat, 5 g of carbohydrates, and 6 g of protein (Ceriello et 
al., 2002) was allocated to the subjects to drink it within 10 minutes. Baseline blood 
samples and post fat meal blood samples were taken over a 4 hour period (0, 1, 2, 3, 
4 hours), with blood pressure noted. Subjects were divided according to the assigned 
dietary regimen into low fat and balanced diet groups (described in a later section). 
The same process was repeated after a 3 month period to repeat blood collection. 
Food frequency questionnaire was obtained from the subjects in each group at 
baseline and follow up visits. 
All subjects were given health advice according to their assigned dietary 
regimen. Energy intake was set at the levels recommended by the dietary reference 
intake for subjects with low levels of physical activity at the same gender and age 
(DRI, 2008/2011). 
 All patients selected were provided with group information on the food 
pyramid, weight loss diets, food labels, fat free and low calorie foods, fast food, 
calories and nutritional composition, good nutritional choices in special occasions, 
functional foods, as well as health consequences of obesity and related diseases and 
some traditional Saudi cuisine that can be cooked with healthy low calorie, low fat 
choices. (Figure 2.5.1) shows the summary of the dietary recommendations. 
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Figure 2.5.1 The healthy eating plate helps to create healthy & flavorful meals. 
Created by nutrition experts at Harvard School of Public Health in conjunction with 
Harvard Health Publications, The Healthy Eating Plate addresses key flaws in the 
U.S. Department of Agriculture’s MyPlate (www.hsph.harvard/nutritionsource). 
The monthly group sessions were interactive between the dietitian researcher 
and the subjects, allowing questions to be answered and explained. In addition, all 
patients received individual consultation during the intervention program, as well as 
printed dietary materials and handouts were designed and provided to all participants 
to go home according to their assigned dietary regimen to facilitate implementation 
of the dietary interventional program (Appendix V). To support their compliance 
health advice was confirmed by phone calls (once/week), messages and visits during 
the study if needed. Women were asked to record all food eaten daily for 3 months. 
Food records were collected by the dietitian and returned with feedback, weekly self-
weighing and session attendance were tracked to promote adherence to the diet 
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intervention. In addition food frequency questionnaire (FFQ) which has been used 
previously (Al Disi et al., 2010) was the dietary tool that had been used to assess the 
food intake of the subjects prior and post the dietary intervention. The researcher 
interviewed the participants individually and the information was collected using a 
pre-designed questionnaire (Appendix IV) to assess the qualitative and the 
quantitative aspects of the food consumed by the participants over a period of 7 days. 
The FFQ included examining the intake around the five major food groups (starch & 
grains, meat & beans, dairy products, fruits and vegetables) along with the 
consumption of the junk food which are defined as heavily processed, highly 
palatable and hyper energetic and are often deprived of the vitamins and essential 
nutrients found in whole unprocessed foods (Bayol et al., 2007) since it poses the 
greatest risk to health and wellbeing (Blackburn and Gorge, 2001); energy–dense, 
nutrient-poor products were also included  illustrated through the consumption of fat 
(cream, ghee and nuts), sweets (cakes, honey, jam, ice-creams, donuts and 
chocolates), salty snacks (pop-corn), soft drinks and caffeinated drinks (coffee, black 
& green tea). 
    Nutrient intake was calculated using USDA database (18th - 21st Ed, 2009, 
2010) Program, as for the Saudi Arabic traditional dishes were analyzed using the 
Arabic food analysis program (version 1, 2006). The evaluation of the daily food 
intake was made by the means of the total energy and the total nutrient intake, the 
percentage of the total calories derived from fat, protein and carbohydrates. 
Dietary nutrients values were compared with dietary reference intake (DRI) 
for specified age and gender for macronutrients (carbohydrates and protein) as well 
as for micronutrients (DRI, 2008/2011).  
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As for daily energy requirement (Kcal/day) was estimated using WHO equation 
(2005, 2007) (Sylvia Escott-Stump, 2011) according to age group and metabolic 
status. Dietary fat percentage has been estimated as 25% from daily energy 
requirement (Hooper et al., 2011) (Appendix VI). 
As described earlier, subjects were divided into two groups according to their 
dietary regimen as follows: 
1. Low fat diet group: fat is the most energy-rich of all energy-providing nutrients, 
therefore reducing fat intake in reducing total energy intake to induce weight 
loss. This diet defined as total fat intake < 30% of total energy intake and 
saturated fat intake <10%. Emphasizes vegetables, fruits, starches (e.g., 
breads/crackers, pasta, whole grains, starchy vegetables), lean protein, and low-
fat dairy products (National Heart, Lung, and Blood Institute, 2005). Participants 
in this group were directed to avoid fried and processed foods and were provided 
with low fat recipes and substitutes (Appendix V). 
2. Balanced diet (the composition of this diet was similar to the Mediterranean diet 
style, so-called prudent diet ) which includes abundant plant foods (fruit, 
vegetables, breads, other forms of cereals, potatoes, beans, nuts, and seeds), fresh 
fruit as the typical daily dessert, olive oil as the principal source of fat, dairy 
products (principally cheese and yogurt), and fish and poultry consumed in low 
to moderate amounts, zero to four eggs consumed weekly, red meat consumed in 
low amounts, and wine consumed in low to moderate amounts, normally with 
meals. This diet is low in saturated fat (< or = 7-8% of energy), with total fat 
ranging from < 25% to > 35% of energy (Willett et al., 1995) (Appendix V).  
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- A third non-diabetic, non-obese group was proposed to serve as a reference or 
control group. 
The following figure details schematically the different arms of the 
interventional trial proposed (Figure 2.5.2).  
 
Figure 2.5.2 The different arms of the interventional trial proposed: Type 2 
diabetes  mellitus and overweight+ subjects were subdivided into two groups 
according to the assigned dietary regimen (LF = Low fat diet) group and (BD = 
Balanced diet) group 
63 
 
Figure 2.5.3 Summary of clinical intervention applied in the study: Data 
collected for the study includes: interview questionnaire, anthropometric 
measurements and biochemical parameters  
2.6 Biochemical assessment  
Fasting bloods were used to assess biochemical parameters which included: 
glucose, triglycerides, cholesterol, HDL, LDL, insulin, HOMA-IR and endotoxin.  
Blood Sample Collection:  These were collected with the patients in the fasting state 
using sterile vacutainer blood collection apparatus (BD). Whole blood, serum, 
EDTA plasma and fluoride tubes were collected from subjects. All samples were 
aliquoted and stored in –20oC freezer facilities in preparation for subsequent 
analysis. 
2.6.1 Laboratory Techniques 
 Serum samples were stored in a -20 °C freezer prior to analysis. Fasting 
glucose and lipid profiles were measured using a chemical analyzer. This 
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biochemical analyzer was calibrated routinely prior to the analysis of all serum 
samples using quality control samples provided by the manufacturer (ThermoFisher 
Scientific, Espoo, Finland). Serum free insulin concentrations were determined by 
electochemiluminescence method (ELICA) (COBAS E 411;Roche Diagnostics, 
Mannheim, Germany). Serum endotoxin was analyzed using a commercially 
available QCL-1000 LAL Endpoint Assay (Lonza, New Jersey, USA). 
2.6.2 Insulin and HOMA-IR measurements  
2.6.2.1 Insulin determination  
Serum free insulin concentrations were determined by electro- 
chemiluminescence method (ECLIA) (COBAS E 411; Roche Diagnostics, 
Mannheim, Germany). The instruments were calibrated prior to analysis using 
quality control samples provided with the kits. 
2.6.2.1.1 Test Principle  
-  Sandwich principle. Total duration of assay: 18 minutes. 
•  1st incubation: Insulin from 20 µL sample, a biotinylated monoclonal insulin-
specific antibody, and a monoclonal insulin-specific antibody labeled with a 
ruthenium complex form a sandwich complex. 
•  2nd incubation: After addition of streptavidin-coated microparticles, the complex 
became bound to the solid phase via interaction of biotin and streptavidin. 
• The reaction mixture was aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the electrode. 
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Unbound substances are then removed with ProCell. Application of a voltage to 
the electrode then induced chemiluminescent emission which was measured by a 
photomultiplier. 
•  Results were determined via a calibration curve which is an instrument-
specifically generated by 2-point calibration and a master curve provided via the 
reagent barcode. 
2.6.2.2 HOMA-IR measurements 
-  Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated 
as fasting insulin (µU/mL) × fasting glucose (mmol/L)/22.5 (Bonora et al, 2002). 
2.6.3 Lipids assay 
- Triglycerides are hydrolysed by lipase to glycerol and fatty-acids. The glycerol is 
phosphorylated to glycerol-3-phosphate, which then is oxidized to 
dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide 
reacts with 4-aminoantipyrine and 4-chlorophenol forming a quinoneimine dye. 
The absorbance of the formed color is measured at 510 nm (Figure 2.6.3.1). The 
results were calculated automatically by the Konelab analyzer using a calibration 
curve. 
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Figure 2.6.3.1 Triglyceride assay: Triglycerides are hydrolysed by lipoprotein 
lipase (LPL) to glycerol and fatty-acids. The glycerol is phosphorylated to glycerol-
3-phosphate by Glycerokinase (GK), glycerol-3-phosphate is then oxidized to 
dihydroxyacetone phosphate and hydrogen peroxide mediated by Glycerol-3-
phosphateoxidase (GPO). The hydrogen peroxide reacts with 4-aminoantipyrine and 
4-chlorophenol forming a quinoneimine dye mediated by Glycerol-3-
phosphateoxidase (GPO). 
- Cholesterol esters are enzymatically hydrolysed by cholesterol esterase to 
cholesterol and free fatty acids. Free cholesterol, including that originally 
present, is then oxidized by cholesterol oxidase to cholest-4-en-3-one and 
hydrogen peroxide. The hydrogen peroxide combines with HBA and 4-
aminoantipyrine to form a chromophore (quinoneimine dye) which may be 
quantitated at 500-550 nm. (Allain et al 1974) (Figure 2.6.3.2).  
 
Figure 2.6.3.2 Cholesterol Esters test principle:  cholesterol esters are 
enzymatically hydrolysed by cholesterol esterase (CE) to cholesterol and free fatty 
acids. Free cholesterol, including that originally present, is then oxidized by 
cholesterol oxidase (CO) to cholest-4-en-3-one and hydrogen peroxide. The 
hydrogen peroxide combines with Hydroxybenzoic Acid (HBA) and 4-
aminoantipyrine (4AAP) mediated by peroxidase (POD) to form a chromophore 
(quinoneimine dye). 
67 
- HDL-cholesterol test was undertaken as a homogeneous enzymatic colorimetric 
test, which was in the presence of magnesium sulfate, dextran sulfate which 
selectively forms water- soluble complexes with low density lipoprotein (LDL), 
very low density lipoprotein (VLDL) and chylomicrons, which are resistant to 
PEG modified enzymes. The cholesterol concentration of HDL-cholesterol was 
determined enzymatically by cholesterol oxidase coupled with PEG to the amino 
groups (approx. 40%) (Figure 2.6.3.3). The results are calculated automatically 
by the Konelab analyzer using a calibration curve. 
 
Figure 2.6.3.3 HDL- Cholesterol Esters assay: The method uses magnesium 
sulfate, dextran sulfate which selectively forms water- soluble complexes with low 
density lipoprotein (LDL), very low density lipoprotein (VLDL) and chylomicrons, 
which are resistant to PEG modified enzymes. The cholesterol concentration of 
HDL-cholesterol was determined enzymatically by cholesterol oxidase coupled with 
PEG to the amino groups. 
- LDL-cholesterol was calculated by the following equation:  
LDL = T. Cholesterol - HDL - (0.16* Triglyceride)  
2.6.4 Glucose assay 
To measure glucose concentration in human serum or plasma, this method 
employed glucose oxidase (GOD) and a modified Trinder colour reaction, catalysed 
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by the enzyme peroxidase (POD). Glucose was oxidised to D-gluconate by glucose 
oxidase with the formation of an equimolar amount of hydrogen peroxide. In the 
presence of peroxidase, 4-aminoantipyrine and phenol are oxidatively coupled by 
hydrogen peroxide to form a quinoneimine dye, coloured in red. The intensity of 
color in the reaction was measured at 510 nm and it was proportional to the glucose 
concentration in the sample (Figure 2.6.4.1).              
 
Figure 2.6.4.1 Glucose assay Glucose was oxidised to D-gluconate by glucose 
oxidase (GOD) with the formation of an equimolar amount of hydrogen peroxide. In 
the presence of peroxidase (POD), 4-aminoantipyrine and phenol are oxidatively 
coupled by hydrogen peroxide to form a quinoneimine dye, coloured in red. 
2.6.5 Endotoxin assay  
Endotoxin concentration was measured using a chromogenic kinetic Limulus 
amebocyte assay (LAL assay, BioWhitaker,Walkersville MD) which had been 
validated previously (Creely et al., 2007) ( Figure 2.6.5.1). 
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Figure 2.6.5.1 Endotoxin Assay: The Chromogenic Limulus Amebocyte Lysate 
(LAL) Test is a quantitative test for gram-negative bacterial endotoxin. A sample is 
mixed with the LAL supplied in the test kit and incubated at 37°C (±1°C) for 10 
minutes. A substrate solution is then mixed with the LAL-sample and incubated at 
37°C (±1°C) for an additional 6 minutes. The reaction is stopped with stop reagent. 
If endotoxin is present in the sample, a yellow color will develop. The absorbance of 
the sample can be determined spectrophotometrically at 405-410 nm 
The use of LAL for the detection of endotoxin evolved from the observation 
by Bang that a Gram-negative infection of Limulus polyphemus, the horseshoe crab, 
resulted in fatal intra-vascular coagulation (Bang, 1956). Levin and Bang later 
demonstrated that this clotting was the result of a reaction between endotoxin and a 
clottable protein in the circulating amebocytes of Limulus (Levin and Bang, 1964a, 
1964b). Following the development of a suitable anticoagulant for Limulus blood, 
Levin and Bang prepared a lysate from washed amebocytes which was an extremely 
sensitive indicator of the presence of endotoxin (Levin and Bang, 1968). Solum and 
Young, Levin and Prendergast have purified and characterized the clottable protein 
from LAL and have shown the reaction with endotoxin to be enzymatic (Solum, 
1970; Solum, 1973; Young, Levin and Prendergast, 1972). 
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 The present LAL method utilizes the initial part of the LAL endotoxin 
reaction to activate an enzyme which in turn releases p-nitroaniline (pNA) from a 
synthetic substrate, producing a yellow color. 
2.6.5.1 Principle of the endotoxin assay  
Gram-negative bacterial endotoxin catalyzes the activation of a pro-enzyme 
in the Limulus Amebocyte Lysate (LAL) (Young, Levin and Prendergast, 1972). The 
initial rate of activation was determined by the concentration of endotoxin present. 
The activated enzyme catalyzes the splitting of pNA from the colorless substrate Ac-
lle-Glu-Ala-Arg-pNA. The pNA released was measured photometrically at 405-410 
nm after the reaction was stopped with stop reagent. The correlation between the 
absorbance and the endotoxin concentration is linear in the 0.1-1.0 EU/ml range. The 
concentration of endotoxin in a sample was calculated from the absorbance values of 
solutions containing known amounts of endotoxin standard. 
For assessment of endotoxin in the lab all areas were cleaned with an 
antibacterial reagent, microsol in conjunction with 70% ethanol. Additionally all 
reservoirs to contain the endotoxin assay reagents were bought sterilised and 
endotoxin free and all plastics utilised were suitable for endotoxin measurement. 
LAL water was used for preparation of all samples to be analysed and all solutions 
used in the experiments. A standard curve as was prepared each time using LAL 
water in sterile 15ml tubes-the standard curve in the range from 0-1 EU/ml or 0-10 
EU/ml dependent on the dilution of the samples. Standards were 10, 5, 2.5, 1.0, 0.5, 
0.25 and 0.1 EU/m. The plate was pre-warmed to 37ºC before the loading of the 
samples (app. 10 minutes). The endotoxin protocol as detailed below was followed:  
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2.6.5.2 Reagent preparation  
Reagents were allowed to equilibrate to room temperature prior to use. Four 
standard endotoxin solutions were used as in the table below which shows the 
dilution scheme for the construction of these standards from the endotoxin supplied 
in the kit. The initial dilution from the endotoxin stock is 1/X, where X equals the 
concentration of the endotoxin vial. This yields an endotoxin solution containing 1.0 
EU/ml. For example, if the potency was 23 EU/ml, the initial dilution was 1/23 or 
0.1 ml of endotoxin stock into 2.2 ml of LAL Reagent Water (Table 2.6.5.2.1). 
Endotoxin 
concentration 
EU/ml 
Endotoxin 
stock solution 
Endotoxin 
Std. solution 
1 EU/ml 
LAL Reagent 
Water 
1.0 0.1 ml  (X-1)/10 ml 
0.5  0.5 ml 0.5 ml 
0.25  0.5 ml 1.5 ml 
0.1  0.1 ml 0.9 ml 
Table 2.6.5.2.1 Dilution scheme for the construction of standards from the 
endotoxin supplied in the kit (X = endotoxin concentration of the vial). 
1. A solution containing 1.0 EU/ml endotoxin was prepared by diluting 0.1 ml of 
the endotoxin stock solution with (X-1)/10 ml of LAL reagent water in a suitable 
container, where X equals the endotoxin concentration of the vial. The solution 
was vigorously vortexed for at least 1 minute before proceeding. 
2. 0.5 ml of this 1.0 EU/ml solution was transferred into 0.5 ml of LAL reagent 
water in a suitable container and labeled 0.5 EU/ml. This solution was 
vigorously vortexed for at least 1 minute before use. 
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3. 0.5 ml of the 1.0 EU/ml solution was transferred into 1.5 ml of LAL reagent 
water in a suitable container and labeled 0.25 EU/ml. This solution was 
vigorously vortexed for at least 1 minute before use. 
4. 0.1 ml of the 1.0 EU/ml solution was transferred into 0.9 ml of LAL reagent 
water in a suitable container and label 0.1 EU/ml. This solution was vigorously 
vortexed for at least 1 minute prior to use.  
2.6.5.3 Microplate endotoxin Method  
1. To pre-equilibrate the microplate, the microplate was placed it the heating block 
adapter at 37°C ± 1°C  
2. While leaving the microplate at 37°C ± 1°C, 50µl of sample or standard was 
carefully dispensed into the appropriate microplate well. Each series of 
determinations included a blank plus the four endotoxin standards ran in 
duplicate. The blank wells contained 50 µl of LAL reagent water instead of 
sample. All reagent additions and incubation times were identical. 
3. At time T = 0 (zero), 50 µl of LAL was added to the first column of microplate 
wells as a multi-channel pipettor was used. Timing started as the LAL was 
added. Once the LAL has been dispensed into all microplate wells containing 
samples or standards, the microplate was removed from the heating block 
adapter and repeatedly tapped the side of the plate to facilitate mixing. Then, the 
plate was returned to the heating block adapter with the cover being replaced. 
4. At T = 10 minutes, 100 µl of substrate solution was added (pre-warmed to 37°C 
± 1°C) by pipetting the substrate solution in the same manner as in Step 3, with a 
consistent pipetting rate. Once the substrate solution had been dispensed into all 
microplate wells, the microplate then removed from the heating block adapter 
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and repeatedly the side of the plate tapped to facilitate mixing. Then the plate 
was returned to the heating block adapter with the cover being replaced. 
5. At T = 16 minutes, 100 µl of stop reagent was the added while maintaining the 
same pipetting order as in Steps 3 and 4. Once the stop reagent has been 
dispensed into all microplate wells, the plate was removed and repeatedly the 
side of the plate was tapped. 
6. The absorbance of each microplate well was read at 405-410 nm (distilled water 
was used to adjust the photometer to zero absorbance). 
2.6.5.4 Calculation of endotoxin concentration  
The absorbance at 405-410 nm was linear in the concentration range of 0.1 to 
1.0 EU/ml endotoxin. There are two methods to determine the endotoxin 
concentration of samples, graphic and calculator methods. For all samples it was 
important to subtract the mean absorbance of the blank from the mean absorbance 
value of the standards and samples then mean Δ absorbance could be calculated. 
2.6.5.4.1 Graphic Method  
 The mean Δ absorbance for the four standards was plotted on the y-axis vs. the 
corresponding endotoxin concentration in EU/ml on the x-axis. A best fit straight 
line was drawn between these points to determine endotoxin concentrations of 
samples graphically (Figure 2.6.5.4.1). 
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Figure 2.6.5.4.1 Graphic Method The mean Δ absorbance for the four standards 
was plotted on the y-axis vs. the corresponding endotoxin concentration in EU/ml on 
the x-axis. A best fit straight line was drawn between these points to determine 
endotoxin concentrations of samples graphically. 
2.6.5.4.2 Calculator Method 
A calculator equipped with linear regression capability can also be used. The 
mean Δ absorbance and the corresponding concentrations of the four standards 
were entered. The corresponding endotoxin concentration of the samples from 
their absorbance by linear regression was determined. 
2.7 Data Analysis 
Data was analyzed using SPSS version 16.5 (SPSS, Chicago, IL, USA). All 
continuous variables were presented as mean ± standard deviation. Frequencies were 
75 
 
expressed as percentages (%). With the exception of triglycerides, insulin and 
HOMA-IR, all other variables including the macronutrients were normally 
distributed. For comparison between groups (T2DM, overweight+ and control), 
Analysis of Variance (ANOVA) with post-hoc analysis and Kruskal-Wallis (for 
triglycerides, insulin and HOMA-IR) were used. Age and BMI were used as 
covariates. For comparison between pre- and post-intervention, paired T-test and 
Wilcoxon-Rank tests (for triglycerides, insulin and HOMA-IR) were used. For 
comparison within groups according to successive hours, repeated measures 
ANOVA (General Linear Model) with post-hoc analysis and Friedman’s two-way 
analysis of variance (for triglycerides, insulin, HOMA-IR) were used. To determine 
associations between endotoxin and variables of interest post prandial, Spearman 
bivariate correlations and linear regressions were utilized. Significance was set at 
p<0.05. 
G*Power was used for the calculation of sample size ascertaining difference 
between two dependent means (matched pairs). A sample size of N = 30 with α = 
0.05 and effect size of 0.50 has a power of 0.75 to detect difference. 
 
 
  
 
 
Chapter Three  
 
Effects of high fat meal on metabolic 
endotoxemia amongst Saudi women with and 
without metabolic disease  
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3.1 Introduction 
The nutritional transition and the rapid urbanization in the Middle East has 
introduced energy-dense, refined carbohydrates and increased saturated fat intake 
(Musaiger and Al-Hazzaa, 2012). This transition has paralleled the increased in life-
style related chronic diseases such as type 2 diabetes mellitus (T2DM) (Al-Shoshan, 
1992; Amuna and Zotor, 2008).  
 Whilst obesity represents the single most influential risk factor for T2DM, 
weight gain itself is a result of a complex interaction between genetic and 
environmental factors. Amongst the latter, a high fat diet appears involved in the 
increased occurrence of obesity and T2DM which are principal features of metabolic 
syndrome. The major metabolic consequence of high–fat diet is that effect on insulin 
action, where the regulatory mechanisms of body weight become impaired through 
lipotoxic effects (Magnan et al., 1999). In addition, obesity is also coupled with 
insulin resistance and associated with low grade chronic systemic inflammation 
(Wellen and Hotamisligil, 2005). Whilst trying to untangle the individual effects of 
obesity, insulin resistance and inflammation is difficult, previous models of diet-
induced and genetic obesity has shown that adipose tissue presents an important 
source of pro-inflammatory cytokines such as tumor necrosis factor (TNF)- α 
(Hotamisligil et al., 1993; Weisberg et al., 2003), interleukin (IL)-1 (Hotamisligil et 
al., 1993; Weisberg et al., 2003), and IL-6 (Weisberg et al., 2003) during weight 
gain. These cytokines appear deleterious for muscle insulin action; for example, 
TNF-α has been shown to cause insulin resistance by increasing serine 
phosphorylation on insulin receptor substrate-1 (Hotamisligil et al., 1996), leading to 
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its inactivation. The consequent insulin resistant state will favour hyperinsulinaemia 
conditions and excessive hepatic and adipose tissue lipid storage. 
However the triggering factors linking inflammation to high-fat diet–induced 
metabolic syndrome remains to be fully determined. However postprandial 
lipidaemia has emerged as a potential candidate following the discovery that 
ingestion of a high-fat meal causes systemic increases of a wide range of 
inflammatory mediators (Aljada et al., 2004; Blanco-Colio et al., 2000; van Oostrom 
et al., 2004; van Oostrom et al., 2003). Previous studies have shown that following a 
high-fat meal, there is an increased expression of nuclear transcription factor-кB 
(NF-кB) in leukocytes (Aljada et al., 2004; Blanco-Colio et al., 2000), a key 
transcription factor in the inflammatory cascade that regulates the transcription of 
numerous pro-inflammatory adipokines (Youssef-Elabd et al, 2012; Creely et al., 
2007). To date, the cause of these postprandial inflammatory events remains poorly 
understood. One potential candidate factor that has arisen is bacterial endotoxin 
[lipopolysaccharide (LPS)], a potent inflammatory bacterial antigen that is present in 
large quantities in the human gut (Berg, 1996). Endotoxin circulates in the blood of 
healthy human subjects at low concentrations (between 1 and 200 pg/mL 
(Weidermann et al., 1999; Goto et al., 1994; Hasday et al., 1999; Boelke et al., 2001; 
Niebauer et al., 1999). However, Clinical studies have implicated gut-derived 
endotoxin as a "primary insult" to activate the inflammatory state, contributing to 
metabolic disease, with cross sectional data showing elevated systemic endotoxin 
levels in obesity, T2DM, coronary artery disease and fatty liver disease (Baker et al., 
2009; Creely et al., 2007; Brun et al., 2007; Dixon et al., 2008; Al-Attas et al., 2009; 
Miller et al., 2009; Harte et al., 2010). 
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Endotoxin has an immediate impact on the innate immune pathway in human 
adipose tissue, acting via key receptors known as Toll-like receptors which leads to 
intracellular activation of NF-кB, leading to a rapid response within adipose tissue 
that may be exacerbated by increased adipose tissue mass (Lin et al., 2000; Kopp et 
al., 2009; Song et al., 2006; Shoelson and Goldfine, 2009; Wellen and Hotamisligil, 
2005). 
The importance of the dietary lipid intake and LPS in determining 
inflammatory risk may arise due to the strong affinity of endotoxin for chylomicrons 
(lipoproteins that transport dietary long-chain saturated fatty acids [SFAs]through 
the gut wall) as the endotoxin crosses the gastrointestinal mucosa (Ghoshal et al., 
2009; Amar et al., 2008; Moreno-Navarrete et al., 2010). Recent human studies 
showed a substantial increase in circulating endotoxin among healthy individuals 
given a high-fat meal in conjunction with markers of inflammation (Cani et al., 
2007a; Ghanim et al., 2009; Piya et al., 2013a; Piya et al., 2013b). Furthermore, 
Murine studies have identified an association between insulin resistance and 
endotoxin, with insulin resistance and weight gain both affecting gut permeability 
(Ghanim et al., 2009; Deopurkar et al., 2010). 
However, it remains to be established whether the feeding pattern in Saudi 
subjects affects endotoxin absorption in different metabolic states, whether 
circulating levels of endotoxin and systemic lipid changes correlate together post-
prandially, and whether this correlation is more apparent in insulin-resistant states.  
Therefore, this chapter will establish whether a high-fat meal increased 
circulating endotoxin and whether this is altered in different metabolic disease states.  
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3.2 Research Design and Methods 
  The study comprised of 3 groups: healthy control subjects (n=18), 
overweight plus (overweight+) subjects (n= 24) and patients with early onset of type 
2 diabetes (n= 50).  
All subjects were Saudi pre-menopausal females, randomly selected from 
different regions of Riyadh city, nonsmokers, with a normal resting ECG and blood 
pressure and with no history of vascular disease. In addition, subjects with known 
long standing diabetes and/or receiving anti-diabetic medication, those with fasting 
glucose levels >11 mmol/L, or with fasting triglycerides levels > 4 mmol/L were 
excluded from the study. 
Screening fasted blood tests at baseline were performed both to qualify subjects for 
the study, and to assess glucose control; blood tests also examined lipid profiles. In 
addition, all subjects had their weight, height and waist and hip circumferences 
measured. Weight (in kilograms) was measured in light clothing to the nearest 0.1 
kg. Height was measured using a digital stadiometer to the nearest centimeter. Waist 
circumference was measured at the level of the iliac crest at the end of normal 
respiration, and hip was measured at the widest circumference around the buttocks 
using measuring tape. Waist to hip ratio as well as BMI (were calculated. Blood 
samples were taken from the right or left antecubital vein in a sitting position. Blood 
pressure checked with a blood pressure monitor on the left arm. Ethical approval had 
been granted by the Ethics Committee of King Saud University, Riyadh, Kingdom of 
Saudi Arabia, prior to the commencement of the research and all patients gave 
written consent. 
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All research subjects (n = 92) with and without T2DM were given a high fat 
meal (standardized meal: 75 g fat, 5 g carbohydrate, 6 g protein) after an overnight 
fast of 12–14 h. 
The cohort consisted of 92 Saudi women [18 non-diabetic (ND) control 
subjects (Age 24.4±7.9yr; BMI 22.2 ± 2.2kg/m2), 24 overweight+ subjects (Age 
32.0±7.8yr; BMI 28.5±1.5Kg/m2) and 50 overweight or obese T2DM patients (Age 
41.5±6.2yr; BMI 35.2±7.7kg/m2)]. Blood samples were drawn via cannula at 
baseline (0 h) and post-prandially (1, 2, 3, and 4 h), and endotoxin and lipid levels 
were measured. 
3.2.1 In vivo assessment of the biochemical profile 
On the assigned date, fasting blood samples were collected from participating 
subjects, and both plasma glucose and lipid profiles (triglycerides, total cholesterol, 
HDL and LDL) were determined using routine laboratory methods undertaken in the 
biochemistry laboratory. In brief, glucose was measured using a glucose oxidase 
method in an autoanalyzer (Konelab, Espoo, Finland). Serum free insulin 
concentrations were determined by electro-chemiluminescence method (COBAS-E-
411; Roche Diagnostics, Mannheim, Germany). The instruments were calibrated 
prior to analysis using quality control samples provided with the kits. Homeostasis 
model assessment for insulin resistance (HOMA-IR) was then calculated for all 
patients using the HOMA formula: HOMA-IR = fasting insulin (mU/L) x plasma 
glucose (mmol/L)/22.5 (Bonora et al, 2002). 
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3.2.2 Analysis of circulating endotoxin  
Serum endotoxin was analyzed using a commercially available QCL-1000 
LAL End Point Assay (Lonza, Allendale, NJ). The assay, and the values given by the 
manufacturer for intra-assay coefficient of variation (CV) (3.9  0.46%) and inter-
assay CV (9.6  0.75%), have been validated as detailed previously by the team 
(Creely et al., 2007). 
3.3 Data Analysis 
Data was analyzed using SPSS version 16.5 (SPSS, Chicago, IL, USA). All 
continuous variables were presented as mean ± standard deviation and were 
normalized prior to parametric analyses. For comparison between groups (T2DM, 
overweight and control), Analysis of Variance (ANOVA) with post-hoc analysis and 
Kruskal-Wallis (for triglycerides) were used. Age and BMI were used as covariates. 
For comparison between pre- and post-intervention, paired T-test was used. For 
comparison within groups according to successive hours, repeated measures 
ANOVA and Friedman’s two-way analysis of variance (for triglycerides, insulin, 
HOMA-IR and endotoxin) were used. To determine associations between endotoxin 
and variables of interest post prandial, Spearman bivariate correlations was utilized. 
Significance was set at p < 0.05. 
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3.4 Results 
3.4.1 General Characteristics of Subjects 
A total of 92 subjects (N = 18 controls, N = 24 overweight+ group, and N = 
50 T2DM group) were included in this cross-sectional study. Table 3.4.1.1 shows the 
general characteristics of subjects according to group, with the T2DM group having 
a mean duration of T2DM at 2.04 years. Furthermore, the T2DM subjects were 
significantly older as compared to both control (p<0.001) and overweight+ group 
(p<0.001), with the overweight+ group also being significantly older than the 
controls (p=0.002).  
Table 3.4.1.1 Anthropometric and Metabolic Characteristics of Subjects According 
to Group 
 Control Overweight+ DMT2 P-Value 
N 18 24 50  
Age (years) 24.39 ± 7.92 32.04 ± 7.78* 41.50 ± 6.23*! < 0.001 
DM Duration (years) -- -- 2.04 (0-9)   
BMI (kg/m2) 22.20 ± 2.21 28.54 ± 1.49* 35.24 ± 7.67*! < 0.001 
Waist (cm) 80.64 ± 7.23 95.75 ± 7.42* 112.3 ± 13. 43*! < 0.001 
Hip (cm) 98.69 ± 7.26 109.67 ± 5.01* 117.11 ± 
11.59*! 
< 0.001 
WHR 0.82 ± 0.05 0.87 ± 0.05* 0.96 ± 0.07*! < 0.001 
Glucose (mmol/l) 4.81 ± 0.86 4.7 ± 0.41 7.9 ± 2.73*! < 0.001 
Triglycerides (mmol/l)# 1.03 ± 0.44 1.27 ± 0.8 1.9 ± 1.0*! 0.001 
Total Cholesterol 
(mmol/l) 
4.22 ± 0.71 4.5 ± 0.98 5.4 ± 1.07*! 0.003 
HDL-Cholesterol 
(mmol/l) 
1.29 ± 0.25 1.1 ± 0.4 0.96 ± 0.2*! < 0.001 
LDL-Cholesterol 
(mmol/) 
2.76 ± 0.65 2.8 ± 0.67 3.66 ± 0.8*! < 0.001 
Note: Data presented as mean ± standard error; # denotes non-Gaussian distribution; 
P-values at extreme right denotes over-all significance according to group; “*” 
denotes significance as compared to controls; “!” denotes significance as compared 
to overweight+ group; p-value significant at < 0.05. 
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As expected, the T2DM group also had the highest anthropometric indices 
(BMI, waist and hip circumferences as well as WHR) than the overweight+ group 
and controls, with the overweight+ group being significantly higher than the controls 
in all indices as well. With regards to serum markers, the T2DM group as expected 
had the highest mean serum glucose levels (7.9±2.73mmol/l) than the overweight+ 
(4.7±0.41mmol/l, p<0.01) and controls (4.81±0.86mmol/l, p<0.001). The T2DM 
group also had the highest levels of serum triglycerides (1.9±1.0mmol/l), total 
cholesterol (5.4±1.07mmol/l) and LDL-cholesterol (3.66±0.8mmol/l), and the lowest 
in mean HDL-cholesterol (0.96±0.21mmol/l) than the overweight+ and controls (all 
p<0.001). Serum glucose and lipid levels of overweight+ and controls were not 
significantly different from one another (Table 3.4.1.1). 
3.4.2 Effects of High Fat Meal in Different Groups 
Table 3.4.2.1 highlights the glucose, insulin, HOMA-IR, lipids and endotoxin 
changes of subjects over time. In this section, the metabolic parameters are 
highlighted for each group as discussed below.  
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Table 3.4.2.1 Metabolic Changes pre and post a high fat-meal 
 0 Hour 1 Hour 2 Hours 3 Hours 4 Hours 
 GLUCOSE 
T2DM [N = 50] 7.9 ± 2.7 7.76 ± 2.49 7.52 ± 2.5* 7.29 ± 2.7 *!§ 7.0 ± 2.8 *!§† 
Overweight+[N=24] 4.7 ± 0.4 4.6 ± 0.38 4.63 ± 0.40 4.6 ± 0.39 4.63 ± 0.7 
Control [N = 18] 4.8 ± 0.86 5.1 ± 2.28 5.02 ± 1.68 4.76 ± 1.51 4.79 ± 1.6 
 TRIGLYCERIDES# 
T2DM [N = 50] 1.9 ± 1.0 1.83 ± 0.7 2.4 ± 0.94*! 2.7 ± 1.1*!§ 2.7 ± 1.3*!§ 
Overweight+[N=24] 1.3 ± 0.8 1.4 ± 0.8 1.7 ± 0.9*! 2.0 ± 1.1*!§ 1.9 ± 1.3*!§ 
Control [N = 18] 1.03 ± 0.43 1.17 ± 0.55 1.41 ± 0.91 1.44 ± 0.91 1.54 ± 1.0 
 TOTAL CHOLESTEROL 
T2DM [N = 50] 5.4 ± 1.1 5.3 ± 1.0 5.4 ± 1.07 5.3 ± 1.08 5.4 ± 1.1 
Overweight+[N=24] 4.5 ± 1.0 4.5 ± 0.88 4.4 ± 0.8 4.4 ± 0.8 4.4 ± 1.0 
Control [N = 18] 4.22 ± 0.71 4.06 ± 0.68 4.12 ± 0.65 4.1 ± 0.62 4.2 ± 0.72 
 HDL-CHOLESTEROL 
T2DM [N = 50] 0.96 ± 0.21 0.96 ± 0.2 0.94 ± 0.19 0.91 ± 0.21*! 0.89 ± 0.2*!§† 
Overweight+[N=24] 1.20 ± 0.32 1.1 ± 0.32 1.1 ± 0.33 1.14 ± 0.4*! 1.11 ± 0.4*!§ 
Control [N = 18] 1.29 ± 0.25 1.25 ± 0.29 1.25 ± 0.28 1.21 ± 0.28 1.23 ± 0.28 
 LDL-CHOLESTEROL 
T2DM [N = 50] 3.7 ± 0.8 3.6 ± 0.8 3.4 ± 0.9* 3.2 ± 0.9* 3.3 ± 0.9* 
Overweight+[N=24] 2.8 ± 0.7 2.7 ± 0.6 2.5 ± 0.6* 2.4 ± 0.6* 2.4 ± 0.6* 
Control [N = 18] 2.72 ± 0.63 2.57 ± 0.58* 2.58 ± 0.55* 2.59 ± 0.55 2.66 ± 0.62 
 Endotoxin 
T2DM [N = 50] 3.4 ± 0.8 3.0 ± 0.8 3.4 ± 0.9! 3.5 ± 0.9! 3.6 ± 0.9! 
Overweight+[N=24] 3.0 ± 0.5 2.9 ± 1.4 3.5 ± 0.9 3.84 ± 1.6 3.5 ± 1.9 
Control [N = 18] 1.54 ± 0.09 1.79 ± 0.10* 1.71 ± 0.8* 1.94 ± 0.17* 2.11 ± 0.2* 
 Insulin# 
T2DM [N = 50] 11.7 ± 5.5 21.9 ± 17.7* 19.3 ± 12.6* 16.2 ± 12.3* 14.3 ± 8.2* 
Overweight+[N=24] 5.0 ± 3.4 15.6 ± 16.2* 16.9 ± 16.0* 13.1 ± 8.0* 10.3 ± 5.3* 
Control [N = 18] 5.8 ± 0.64 10.3 ± 1.7 9.6 ± 3.4 8.2 ± 1.6 10.2 ± 2.6 
 HOMA-IR# 
T2DM [N = 50] 3.7 ± 2.0 8.7 ± 12.0*‡ 6.6 ± 6.0*‡ 5.6 ± 5.4‡ 3.9 ± 2.4 
Overweight+[N=24] 1.12 ± 0.7 3.5 ± 4.1* 3.9 ± 4.1* 2.8 ± 1.9* 2.1 ± 1.2 
Control [N = 18] 1.3 ± 0.15 1.9 ± 0.4 2.1 ± 0.7* 1.9 ± 0.4 2.2 ± 0.6 
Note: # denotes Non-Gaussian distribution; * denotes significance compared to 0 
hour; ! denotes significance compared to 1; § denotes significance as compared to 2; 
† denotes significance as compared to 3; ‡ denotes significance as compared to 4; p 
significant at ≤ 0.05. 
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3.4.2.1 Post-Prandial Changes in Glucose Levels in Subjects with 
Different Metabolic States  
In the T2DM group, mean glucose level was observed highest at 0 hour and 
subsequently decreased over time. Mean glucose level was lowest after 4 hours, and 
this was significantly lower than the rest of the individual hours (p<0.01). 
Consequently, the mean glucose level after 3 hours was also significantly lower than 
the previous 3 hours (hours 1, 2 and 3; p< 0.05). The mean glucose level at hour 2 
was significantly lower than 0 hour (p<0.05). In both the control and overweight+ 
group, no significant differences were noted over time for glucose (Table 3.4.2.1.1). 
As expected, the mean glucose levels of the T2DM group was significantly higher 
than either the overweight+ or control group (p< 0.01) (Figure 3.4.2.1.1). 
 
Figure 3.4.2.1.1 Baseline mean glucose levels adjusted for age and BMI according 
to group. ** denotes p<0.01.  
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3.4.2.2 Post-Prandial Changes in Triglyceride Levels in Subjects 
with Different Metabolic States 
In contrast to glucose levels, the mean triglycerides for all groups followed 
an increasing trend over time. The mean triglyceride level in the T2DM group was 
highest after 3 and 4 hours, and this was significantly higher as compared to hours 0, 
1 and 2 (p<0.01). In the overweight+ group, mean triglyceride level was highest at 
hour 3 followed by hour 4, and both were also significantly higher as compared to 
hours 0, 1 and 2 (p<0.01). In the control group, although similar increasing trend was 
noted over time, the mean triglyceride values were comparable to one another. 
Comparing all groups, the T2DM group had significantly higher mean triglyceride 
level as compared with either the overweight+ or control groups (p<0.01) (Figure 
3.4.2.2.1). 
 
Figure 3.4.2.2.1 Baseline mean triglyceride levels adjusted for age and BMI 
according to group. ** denotes p<0.01. 
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3.4.2.3 Post-Prandial Changes in Total Cholesterol Levels in 
Subjects with Different Metabolic States 
Across all groups, no significant trends were noted over time for cholesterol, 
and although the mean total cholesterol of the T2DM group was higher than 
overweight+ and control groups, the mean did not reach statistical significance 
(Figure 3.4.2.3.1). 
 
Figure 3.4.2.3.1 Baseline mean total cholesterol levels adjusted for age and BMI 
according to group.  
3.4.2.4 Post-Prandial Changes in HDL-Cholesterol Levels in 
Subjects with Different Metabolic States  
There was a decreasing trend in the mean HDL-cholesterol levels of both 
T2DM and overweight+ group over time post feeding, with no significant change in 
the control group. In the T2DM group, mean HDL-cholesterol was lowest after 4 
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hours, and this was significantly lower as compared to hours 0, 1, 2 and 3 (p<0.01). 
Mean HDL-cholesterol level at hour 3 was also significantly lower than hour 0 and 1 
(p<0.05), and hour 2 significantly lower than hour 0 in the T2DM group (p<0.05). 
Similarly, the mean HDL-cholesterol in the overweight+ group was significantly 
lowest at hour 4 in comparison to hours 0, 1 and 2 (p<0.01). The next lowest was at 
hour 3, being significantly lower than hours 0 and 1 (p<0.05). While no observed 
changes were noted in the control group, their mean HDL-cholesterol levels were 
significantly higher than the T2DM and overweight+ groups (p<0.01) (Figure 
3.4.2.4.1). 
 
Figure 3.4.2.4.1 Baseline mean HDL-cholesterol levels adjusted for age and BMI 
according to group. ** denotes p<0.01. 
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3.4.2.5 Post-Prandial Changes in LDL-Cholesterol Levels in 
Subjects with Different Metabolic States 
There was an apparent decreasing trend observed in the mean LDL-
cholesterol levels in all groups post feeding, with mean LDL-cholesterol levels noted 
to be highest at 0 hour. In the T2DM group, mean LDL-cholesterol level at 0 hour 
was significantly higher as compared to succeeding hours 1, 2, 3 and 4 (p<0.05). In 
the overweight+ group, the 0 hour mean LDL-cholesterol was also significantly 
higher than hours 2, 3 and 4 (p<0.05). In the control group, the 0 hour mean LDL-
cholesterol level was significantly lower than hours 1 and 2 only (p<0.05). T2DM 
had significantly higher mean LDL-cholesterol than both groups (Figure 3.4.2.5.1). 
 
Figure 3.4.2.5.1 Baseline mean LDL-Cholesterol levels adjusted for age and BMI 
according to group.  
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3.4.2.6 Post-Prandial Changes in Endotoxin Levels in Subjects with 
Different Metabolic States  
An increasing trend in mean endotoxin levels were observed in all groups and 
this trend is with respect to hour 0 compared to hour 4. The highest mean endotoxin 
levels were noted at hour 4 in all groups, which was statistically significant 
compared to hour 1 in the T2DM group and hour 0 in the control group (p<0.01). No 
significant changes were observed in the overweight+ group. T2DM and overweight+ 
groups had significantly higher endotoxin than controls (Figure 3.4.2.6.1). 
 
Figure 3.4.2.6.1 Baseline mean endotoxin levels adjusted for age and BMI 
according to group.  
3.4.2.7 Post-Prandial Changes in Insulin levels in Subjects with 
Different Metabolic States 
In the T2DM group, the highest mean insulin levels were noted at hours 1 
and 2, decreasing at hours 3 and 4, and hour 0 being significantly lower as compared 
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to mean insulin levels across time (p<0.01). This pattern is similarly observed in the 
overweight+ and control group, with 0 hour having the lowest mean insulin level as 
compared to other hours. Across groups, the mean insulin level in the T2DM group 
is significantly higher in both the overweight+ and control groups (p<0.01) (Figure 
3.4.2.7.1).  
 
Figure 3.4.2.7.1 Baseline mean insulin levels adjusted for age and BMI according to 
group.  
3.4.2.8 Post-Prandial Changes in HOMA-IR Levels in Subjects with 
Different Metabolic States 
The mean HOMA-IR for all groups similarly followed the patterns observed 
in the mean insulin levels in all groups. In both the T2DM and overweight+ groups, 
HOMA-IR was lowest at hours 0 and 4, with the T2DM group showing the highest 
mean HOMA-IR at hour 1, and the overweight+ group at hour 2. There were no 
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significant changes observed in the control group. Across group, the mean HOMA-
IR of the T2DM group was significantly higher than the overweight+ and control 
group (p<0.01) (Figure 3.4.2.8.1). 
 
Figure 3.4.2.8.1 Baseline mean HOMA-IR levels adjusted for age and BMI 
according to group.  
3.4.3 Associations of Metabolic Parameters to Endotoxin after High-
Fat Meal  
Table 3.4.3.1 shows how endotoxin is correlated to the cardiometabolic 
parameters in all groups across time. In all subjects, endotoxin is positively 
associated with LDL cholesterol (R=0.38; p<0.05) and this was observed 3 hours 
after high fat meal. In the T2DM group, endotoxin was significantly associated with 
triglycerides in 3 and 4 hours post-prandial high fat meal (R values 0.52 and 0.50; 
p<0.05, respectively). In the overweight+ subjects, endotoxin was highly associated 
with triglycerides (R=0.63; p<0.05) and total cholesterol (R=0.71; p<0.05) at zero 
hour. No endotoxin associations were observed in the control group. 
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Table 3.4.3.1 Bivariate Associations between Lipids, Glucose and Endotoxin 
  
ALL SUBJECTS 
Glucose Triglycerides Total Cholesterol HDL-Cholesterol LDL-Cholesterol 
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 
-0.17 0.04 0.13 0.08 0.00 -0.13 0.10 0.14 0.22 0.20 0.16 -0.08 0.00 -0.07 -0.21 -0.16 0.15 -0.01 -0.08 -0.06 0.22 -0.06 0.05 0.38 -0.12 
DMT2 SUBJECTS (N = 50) 
-0.20 0.23 0.29 0.23 0.08 -0.12 0.32 0.26 0.52 0.50 0.18 0.04 0.02 0.0 -0.08 -0.28 -0.15 -0.14 -0.30 -0.05 0.30 0.02 0.005 -0.06 -0.19 
OVERWEIGHT+ SUBJECTS (N = 24) 
0.23 0.14 0.08 0.0 -0.18 0.63 0.04 0.08 0.26 0.25 0.71 -0.08 0.10 -0.13 -0.33 -0.13 0.41 0.13 -0.07 -0.18 0.36 0.14 0.43 0.64 0.28 
CONTROL SUBJECTS (N = 18) 
-0.36 0.15 0.22 0.24 0.14 -0.20 0.16 0.30 -0.14 -0.17 -- 0.01 0.14 -0.05 -0.26 -0.28 -0.20 -0.39 -0.16 -0.31 -0.02 0.08 0.24 0.07 -0.09 
 
Note: Data presented as coefficient (R); bold and red denotes significance at p < 0.05. 
 
 
 
 
 
 
94 
 
3.5 Discussion 
In this chapter, the effects of a saturated fat meal on glucose, lipid, insulin 
and HOMA-IR and endotoxin levels of patients with T2DM, overweight+ and 
control were examined. This study highlighted even in the absence of high fat meal 
the presence of sub-chronic inflammation was apparent with noted difference in 
circulating endotoxin which was highest in the T2DM group, affirming prior studies 
that suggests that components of the gut microbiota, in particular endotoxin, are 
altered in the presence of insulin-resistant diseases such as T2DM (Shen et al, 2013). 
These studies also highlighted the impact of a high fat meal in Saudi women 
suggesting that endotoxin appears raised in the obese and T2DM states post feeding 
compared with the non-diabetic control subjects. Furthermore that at least in these 
cohorts the resulting increase in endotoxin appeared similar in both the overweight 
and T2DM states unlike previous studies in white Caucasians (Harte et al, 2012).   
In addition to endotoxin these studies also considered the impact of elevated 
glucose and cholesterol levels as they represent other factors associated with sub-
chronic inflammation, considered important in the development of coronary artery 
disease, T2DM and obesity. It has also been suggested that high fat meals regardless 
of the individual’s metabolic status, also induce inflammatory changes (Herieka and 
Erridge, 2014; Harte et al, 2012). The changes observed in the lipid profile and 
insulin resistance after a high fat meal in this present study, resulted in lipidaemia, 
furthermore circulating triglyceride levels increased in all groups regardless of their 
metabolic status which appears consistent with previous studies (Wojczynski et al, 
2011; Harte et al, 2012; Camargo et al, 2014; Meher et al, 2014). Analysis of the 
effect of a high saturated fat meal has been observed to cause deleterious changes in 
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the proteome level, in terms of DNA damage and pro-coagulant state (Camargo et al, 
2013). The dramatic changes in triglycerides after a high fat meal has been studied 
in-depth using lipidomic methodologies and revealed that triglycerides response 
showed the most dynamic changes during post-prandial phase as compared to other 
lipids regardless of the individual’s metabolic status and are dependent on the type of 
fat diet used (Bonham et al, 2013). Clinically this is relevant. As observed in the 
present study and other studies, higher post-prandial hypertriglyceridemia and 
hyperlipidemia are observed among patients with T2DM as compared to their 
healthier counterparts (Pirillo et al, 2014). Therefore dietary strategies defining the 
type of dietary fat within the diet appears important to lead to better management of 
the insulin response and increased fat oxidation both important features to reduce 
metabolic risk in  overweight and T2DM patients (Munsters and Saris, 2014). 
The current studies identifying that endotoxin is raised in patients with 
weight gain and T2DM following a high fat meal confirms and extends previous data 
on this area (Miller et al, 2009; Creely et al, 2007).  Particularly elevated endotoxin 
levels amongst Middle-Eastern patients with T2DM are also consistent across ethnic 
groups such as African women (Hawkesworth et al, 2013), Chinese (Liu et al, 2013) 
and Caucasians (Monte et al, 2012). Whilst endotoxin is seen as important mediator 
of sub-clinical inflammation Piya and colleagues suggest that the gut flora appears to 
act as an essential determinant in the development of sub-chronic inflammation 
induced by obesity and T2DM, and that endotoxin may act as the systemic insult that 
triggers the inflammatory cycle (Piya et al, 2013). These current studies highlight 
that in Saudi women given a high fat meal both those with significant weight gain 
and T2DM appears to raise their endotoxin levels without a clear difference between 
the two groups in contrast to previous studies in white Caucasians (Harte et al 2012).  
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Whilst is it not clear why there should be a difference between the two groups in 
endotoxin levels post high fat feeding several explanation can be offered. Animal 
studies have shown that continuous infusion of endotoxin increases gut permeability, 
as does high-fat dietary feeding therefore one possible explanation for the difference 
between the two studies could be due to the dietary difference in fat consumption 
that the obese subjects eat in Saudi compared with the UK (Cani et al, 2007; Brun et 
al, 2007). Secondly from mouse model data it has been shown that in the ob/ob mice 
and db/db mice have an increased leaky gut which is thought to relate to the effect of 
insulin resistance of gut endothelium, as such whilst the Saudi women do not appear 
overly insulin resistant at baseline feeding increases this insulin resistant phenotype 
much more than observed with the control non-diabetic subjects (Cani et al, 2007; 
Brun et al, 2007). As such, Saudi women may have a more continual snack habit 
which may consequentially effect how they handle a high fat feed which could be 
different to the white Caucasians in the other study given a high fat feed. 
Furthermore ethnicity may clearly impact on individual sub-clinical inflammatory 
risk. Previous studies have shown that endotoxin can be stratified by gender and 
ethnicity therefore these data could help to explain why ethnicities may have a 
resulting high risk due to their post-feeding increase in endotoxin (Miller et al, 
2009).  
The different cardiometabolic changes across the group pre- and post-feeding 
showed that the T2DM group had significantly higher glucose, triglycerides, insulin 
and HOMA-IR as well as significantly lower HDL-cholesterol throughout the high 
fat challenge as compared to overweight+ and control subjects. Whilst these 
significant differences were expected since the baseline levels of T2DM subjects 
were already significantly different from other groups, the significant persistence of 
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dysmetabolism in the T2DM group highlights that baseline glycemic and lipid 
parameters tend to be exacerbated following fat load. Such an increased response 
may heighten the increased production of reactive oxygen species (ROS) which 
would further exacerbate existing oxidative stress and endothelial dysfunction 
secondary to impaired vasoreactivity, increased coagulation and vascular 
permeability (Tushuizen et al, 2005; Ceriello 2005). The postprandial increments in 
glucose and lipids observed in the present study confirms previous findings utilising 
women and even adolescents with T2DM as subjects in other ethnicities (Alssema et 
al, 2008; Schindhelm et al, 2007; Umpaichitra et al, 2004) and also reaffirms the 
requirement to effectively manage the postprandial glucose and lipid response in 
T2DM subjects through diet intervention to lower the increased CVD risk (Ceriello 
2005; Charpentier et al, 2006; Leiter et al, 2005). 
In conclusion, the present findings highlight the difference in glucose, lipids 
and endotoxin levels after exposure to a high-fat meal regardless of metabolic status. 
Although lipidaemia is more evident than endotoxemia, the present findings support 
previous observations that metabolic endotoxemia is exacerbated after a high fat 
intake. As such dietary interventions that can reduce the glycaemic and lipidomic 
response as well as provide a healthy gut microbiota, which may improve gut barrier 
function, appear important in Saudi patients with weight gain and/or T2DM. 
 
 
 
 
 
 
Chapter Four 
 
Effect of high-fat meal (pre-post) dietary 
intervention in subjects (T2DM, Overweight+ 
and Healthy subjects) 
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4.1 Introduction 
Lipopolysaccharide (LPS, also known as endotoxin) has been identified as a 
triggering factor for the onset of insulin resistance, obesity and type 2 diabetes 
mellitus (T2DM), where normal circulating endotoxin levels were observed to be 
increased during the feeding state and decreased during fasting. In addition, studies 
in 4-week high-fat fed mice have shown an increase in metabolic endotoxemia 
(raised endotoxin levels associated in conditions of obesity, T2DM and CVD) 
coupled with intestinal microbiota changes, where the gram negative–to–gram 
positive ratio increased during high-fat feeding (Cani et al., 2007a), which 
collectively appeared to be normalised by dietary fibers (Cani et al, 2007b). 
Furthermore, in a rodent study where continuous subcutaneous infusion of endotoxin 
occurred in mice for 4 weeks, fasting glycaemia and insulinaemia and whole body, 
liver and adipose tissue weight gain were increased to a similar extent as mice on a 
high-fat fed diet. Furthermore markers of inflammation and liver triglyceride content 
were observed to increase with endotoxin infusion increased (Cani et al 2007a). 
Several studies have shown that postprandial lipidaemia that emerges 
following ingestion of high-fat meal causes an increase in a wide range of 
inflammatory mediators (Aljada et al, 2004; Blanco-Colio et al, 2000; Van Oostrom 
et al, 2004; Van Oostrom et al, 2003; Piya et al., 2013a; Piya et al., 2013b). For 
instance, circulating leukocytes increase their expression of the activated form of 
nuclear transcription factor-κB (NF-κB) (Aljada et al, 2004; Blanco-Colio et al, 
2000), and up-regulate several markers of leukocyte activation, such as 
CD11A,CD11B, and CD62L (Van Oostrom et al, 2004). Circulating neutrophil 
counts and plasma level of interleukin-8 also increase after high-fat meal but not 
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after water ingestion (Van Oostrom et al, 2003; Van Wijk et al, 2006). Low grade 
endotoxemia was suggested to contribute to such a post prandial inflammatory state 
(Erridge et al, 2007). 
Evidence linking chronic endotoxemia to insulin resistance and T2DM has 
arisen from research studying the metabolic consequences of bariatric surgery. In a 
clinical study, where roux-en-Y gastric bypass (RYGB) surgery resulted in profound 
weight loss, that was accompanied resolution of T2DM in a majority of patients. 
Moreover, endotoxin, NF-κB DNA binding, TLR-4, TLR-2, CD14 expression, CRP, 
MMP-9, and MCP-1 were all observed to be significantly decrease after RYGB 
surgery. The mechanism underlying the resolution of insulin resistance and T2DM 
after RYGB was in part believed to be attributable to the reduction of endotoxemia 
and associated pro-inflammatory mediators (Monte et al, 2012). 
Amar and colleagues conducted a dietary survey in 1015 subjects in France 
to evaluate the relation between plasma endotoxin and food intake. The participants 
were given a 3-day food record. Plasma endotoxin was measured in a subsample of 
201 men. Moreover, to assess, under controlled conditions, the differential impact of 
various high-energy diets, plasma endotoxin concentrations were measured in mice 
fed a high fat or a high-carbohydrate diet over a 4-wk period. In humans, Plasma 
endotoxin concentration was positively correlated with fat and energy intake. 
Furthermore experimental rodent data showed that compared with the control mice, 
mice fed a high-energy diet also increased their plasma endotoxin. However, the 
increase in plasma endotoxin was blunted in mice fed high-carbohydrate diet as 
compared with mice fed a high-fat diet suggesting that fat is more efficient in 
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transporting bacterial endotoxin from the gut lumen into the bloodstream (Amar et 
al, 2008). 
Lowering plasma endotoxin levels could be a potent strategy for the control 
of metabolic disease. The above described findings support the concept that the 
digestion of dispersed dietary lipids can enhance absorption of endogenous 
endotoxins. As such the long-term consequences of such postprandial endotoxemia 
in the context of high fat diets in humans, and the underlying mechanisms, could be 
important be remain to be further explored. Therefore, optimizing the quantity, 
composition, physicochemical properties and emulsification state of dietary fats can 
support possible strategies to limit postprandial endotoxemia, with the aim to lower 
the systemic inflammatory response. 
To date few studies have addressed the effects on dietary intervention such as 
changing dietary fat intake, or life style changes and its impact on circulating 
endotoxin levels and their correlation with inflammation and insulin resistance. 
Therefore this chapter will examine the effectiveness of dietary intervention in 
decreasing inflammatory markers related to obesity among metabolically 
dysfunction states. 
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4.2 Research Design and Methods  
This was a multi-center, randomized interventional study conducted at the 
primary care centers of the Riyadh city, involved 92 Saudi women, consisted of 18 
healthy non-diabetic (ND) control subjects (n=18), overweight plus (overweight+) 
subjects (n= 24) and patients with T2DM (n= 50).  
As detailed earlier in chapter 2, only Saudi women who met the previously 
described inclusion criteria were recruited for this prospective diet intervention 
study. Anthropometric data and fasting blood samples were taken at pre- and 3 
months post-intervention with glucose, lipid profile, insulin, HOMA-IR and 
endotoxin measured. Ethical approval had been granted by the Ethics Committee of 
King Saud University, Riyadh, Kingdom of Saudi Arabia, prior to the 
commencement of the research (Appendix I) and all patients gave written consent 
(Appendix II). 
4.2.1 Clinical intervention (dietary regimen) 
Patients were brought to the clinic two times over a three month-period. For 
each visit the subjects had fasted overnight (12–14 hours) and blood samples were 
collected pre and post meal at 4 time points. A standardized high-fat meal consists of 
whipping cream and contains 75g of fat, 5 g of carbohydrates, and 6 g of protein 
(Ceriello et al., 2002) was allocated to the subjects to drink it within 10 minutes. 
Baseline blood samples and post fat meal blood samples were taken through a 
cannula over a 4 hour period (0, 1, 2, 3, 4 hours), with blood pressure noted. The 
same process was repeated after a 3 month period to repeat blood collection. Food 
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frequency questionnaire was obtained from the subjects in each group at baseline and 
after 3 months of follow up visit. 
Overweight+ and subjects with T2DM were instructed to follow a 500 kcal 
deficit diet to enhance weight loss of 5% or more. Energy intake was set at the levels 
recommended by the dietary reference intake for subjects with low levels of physical 
activity at the same gender and age (DRI, 2008/2011). Targeted macronutrient 
composition was 20%-30% fat, <10% of saturated fatty acids, 50%-60% 
carbohydrates, 15%-20% protein and at least 15g per 1000kcal fibres (Appendix V).  
As described earlier in chapter 2, a 3 month dietary intervention was 
provided to overweight+ and subjects with T2DM, involving group and individual 
meetings to achieve and maintain weight loss through decreased caloric intake. 
Printed dietary materials and handouts were designed by the researcher and provided 
to all participants to go home according to their assigned dietary regimen to facilitate 
implementation of the dietary interventional program (Appendix V). To support 
their compliance health advice was followed by weekly phone calls, messages and 
visits during the study if needed. In addition, the food frequency questionnaire (FFQ) 
which has been used previously (Al Disi et al., 2010) was the dietary tool that has to 
assess the food intake of the subjects prior to and post the dietary intervention 
(Appendix IV). The researcher interviewed the participants individually and the 
information was collected using a pre-designed questionnaire to assess the 
qualitative and the quantitative aspects of the food consumed by the participants over 
a period of 7 days (Appendix IV). 
    Nutrient intake was calculated using USDA database (18th - 21st Ed, 2009, 
2010) Program, as for the Saudi Arabic traditional dishes were analyzed using the 
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Arabic food analysis program (version 1, 2006). The evaluation of the daily food 
intake was made by the means of the total energy and the total nutrient intake, the 
percentage of the total calories derived from fat, protein and carbohydrates. 
Dietary nutrients values were compared with dietary reference intake (DRI) 
for specified age and gender for macronutrients (carbohydrates and protein) as well 
as for micronutrients (DRI, 2008/2011).  
As for daily energy requirement (Kcal/day) was estimated using WHO 
equation (Sylvia Escott-Stump, 2011) according to age group and metabolic status. 
Dietary fat percentage has been estimated as 25% from daily energy requirement 
(Hooper et al., 2011) (Appendix VI). 
4.2.2 Biochemical assessment  
All subjects were requested to submit an over-night fasting blood samples 
(12-14 hours fasting) from which the different metabolic parameters were assessed 
which included: Fasting blood glucose, complete lipid profile, insulin, HOMA-IR 
and endotoxin. These parameters were measured at baseline for all the groups and 
repeated after 3 months period for overweight+ and T2DM subjects. 
4.2.2.1 Blood Sample Collection 
These were collected with the patients in the fasting state using sterile 
vacutainer blood collection apparatus (BD). Whole blood, serum, EDTA plasma and 
fluoride tubes were collected from subjects. All samples were aliquoted and stored in 
–20oC freezer facilities in preparation for subsequent analysis. 
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4.2.2.2 In vivo assessment of the biochemical profile 
On the assigned date, fasting blood samples were collected from participating 
subjects, and both plasma glucose and lipid profiles (Triglycerides, total cholesterol, 
HDL and LDL) were determined using routine laboratory methods undertaken in the 
biochemistry laboratory. In brief, glucose was measured using a glucose oxidase 
method in an auto-analyzer (Konelab, Espoo, Finland). Serum free insulin 
concentrations were determined by electro-chemiluminescence method (COBAS-E-
411; Roche Diagnostics, Mannheim, Germany). The instruments were calibrated 
prior to analysis using quality control samples provided with the kits. Homeostasis 
model assessment for insulin resistance (HOMA-IR) was then calculated for all 
patients using the HOMA formula: HOMA-IR = fasting insulin (mU/L) x plasma 
glucose (mmol/L)/22.5 (Bonora et al, 2002). 
4.2.2.3 Analysis of circulating endotoxin  
Serum endotoxin was analyzed using a commercially available QCL-1000 
LAL End Point Assay (Lonza, Allendale, NJ). The assay, and the values given by the 
manufacturer for intra-assay coefficient of variation (CV) (3.9  0.46%) and 
interassay CV (9.6  0.75%), have been validated in the biochemistry laboratory at 
university hospital Coventry and Warwickshire, as detailed previously. (Creely et al, 
2007). 
Endotoxin concentration was measured using a chromogenic kinetic Limulus 
amebocyte assay (LAL assay, BioWhitaker, Walkersville MD) which had been 
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validated previously (Creely et al., 2007), which is a quantitative test for Gram-
negative bacterial endotoxin. Gram-negative bacterial endotoxin catalyzes the 
activation of a proenzyme in the LAL, and the initial rate of activation is directly 
determined by the concentration of endotoxin. The activated enzyme catalyzes the 
splitting of p-nitroaniline (pNA) from the colorless substrate Ac-lle-Glu-Ala-Arg-
pNA, and the released pNA was measured photometrically at 405–410 nm following 
termination of the reaction. The correlation between the absorbance and the 
endotoxin concentration was linear in the range of 0.1–1.0 EU/ml. For the purposes 
of this study, all samples were run in duplicate within the same plate; therefore, no 
interassay variability was observed in this study. 
4.3 Data Analysis 
Data was analyzed using SPSS version 16.5 (SPSS, Chicago, IL, USA). All 
continuous variables were presented as mean ± standard deviation and were 
normalized prior to parametric analyses. For comparison between groups, univariate 
general linear model (GLM) was used with Bonferroni post-hoc comparisons. Age 
and BMI were used as covariates. For comparison between pre- and post-
intervention, paired T-test was used for normally distributed variables and Wilcoxon 
Signed Ranks test for insulin and HOMA-IR. Bivariate linear regression analysis 
was used to determine associations between endotoxin variables of interest. 
Significance was set at p<0.05. 
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4.4 Results 
4.4.1 Effects of 500kcal deficit/day in the anthropometric variables 
of Overweight+ and T2DM Subjects 
After 3 months of dietary intervention for both the overweight+ and T2DM 
groups, anthropometric variables were reassessed and significant improvements were 
observed in both groups as noted in terms of significantly lower mean follow-up 
BMI as compared to baseline (Overweight+ Group baseline: 28.54±1.49kg/m2 versus 
follow-up: 27.95±2.25 kg/m2, p<0.05; T2DM group baseline: 35.24±7.67kg/m2 
versus follow-up: 35.04±8.07kg/m2, p<0.05) and significantly lower mean hip 
circumference as well (Overweight+ group baseline: 109.67±5.01cm versus follow-
up: 108.07±4.07cm, p<0.05; T2DM group baseline: 112.3±13.43cm versus follow-
up: 109.21±12.71cm, p<0.01). Moreover, no significant changes were observed in 
the mean waist circumference group over time in the overweight+ group, yet a 
significantly higher WHR was noted after follow-up (baseline: 0.87±0.05 versus 
follow-up: 0.88±0.06, p<0.05). Contrary to the overweight+ group, the T2DM group 
showed a more favourable response to the dietary intervention as noted by the 
significantly lower mean waist circumference (baseline: 112.3±13.43cm versus 
follow-up: 109.21±12.71cm, p<0.01) and WHR (baseline: 0.96±0.07cm versus 
follow-up: 0.93±0.06cm, p<0.01) after 3 months follow-up (Table 4.4.1.1).  
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Table 4.4.1.1 Anthropometric Changes over Time According to Group 
 Overweight+ T2DM 
N 24 50 
Age (years) 32.04 ± 7.78 41.50 ± 6.23 
DM Duration 
(years) 
-- 2.04 (0-9)  
 Baseline Post-Intervention Baseline Post-Intervention 
BMI (Kg/m2) 28.54 ± 1.49 27.95 ± 2.25 * 35.24 ± 7.67 35.04 ± 8.07* 
Waist (cm) 95.75 ± 7.42 95.87 ± 7.78 112.3 ± 13. 43 109.21 ± 12.71 ** 
Hip (cm) 109.67 ± 5.01 108.07 ± 4.07 * 117.11 ± 11.59 116.7 ± 13.18 ** 
WHR 0.87 ± 0.05 0.88 ± 0.06 * 0.96 ± 0.07 0.93 ± 0.06 ** 
Note: P-values at extreme right denote significance for baseline comparisons 
according to group; * denotes significance at p < 0.05 as compared to visit 1; ** 
denotes significance at p < 0.01 as compared to visit 1. 
4.4.2 Effects of 500kcal deficit/day in the cardiometabolic variables 
and endotoxin levels in Overweight+ and T2DM Subjects 
Fasting serum glucose, insulin, lipids and endotoxin were also quantified in 
all subjects after the 3-month dietary intervention. In the T2DM group, there was a 
significant decrease in fasting glucose (baseline 7.9±2.7mmol/l versus follow-up 
7.0±1.8mmol/l; p<0.05), triglycerides (baseline 1.9±1.0mmol/l versus follow-up 
1.6±0.8mmol/l; p<0.05), total- (baseline 5.4±1.1mmol/l versus follow-up 
4.6±1.0mmol/l; p<0.01) and LDL-cholesterol (baseline 3.7±0.8mmol/l versus 
follow-up 2.9± 0.8mmol/l; p<0.01) in follow-up as opposed to baseline. A 
significant increase was also found in HDL-cholesterol (baseline 0.96±0.2mmol/l 
versus follow-up 1.01±0.2mmol/l; p<0.01) in the T2DM group. No significant 
changes were noted in fasting insulin, HOMA-IR and endotoxin levels in the T2DM 
group over time.  
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In the overweight+ group, a significant decrease was observed in total- 
[baseline 4.5±1.0mmol/l versus follow-up 3.7±0.8mmol/l; p<0.01] and LDL-
cholesterol [baseline 2.8±0.7mmol/l versus follow-up 2.2±0.6mmol/l; p<0.01] 
overtime. However, a significant increase was observed in fasting insulin [baseline 
5.0±3.4IU/ml versus follow-up 12.0±6.6IU/ml; p<0.05] in follow-up as compared to 
baseline. No changes were observed in the fasting glucose, HOMA-IR and endotoxin 
levels overtime (Table 4.4.2.1). 
Table 4.4.2.1 Metabolic Changes over Time According to Group 
 Overweight+ T2DM 
N 24 50 
Age (years) 32.04 ± 7.78 41.50 ± 6.23 
DM Duration 
(years) 
-- 2.04 (0-9)  
 Baseline Post-Intervention Baseline Post-Intervention 
Glucose (mmol/l) 5.15 ± 3.5 4.65 ± 2.85 7.9 ± 2.73 7.0 ± 1.79* 
Insulin (IU/ml)# 5.0 ± 3.4 12.7 ± 6.6* 11.7 ± 5.5 10.8 ± 6.0 
HOMA-IR# 1.1 ± 0.7 0.93 ± 1.9 3.7 ± 2.0 3.1 ± 2.2 
Triglycerides 
(mmol/l) 
1.27 ± 0.8 1.4 ± 0.5** 1.9 ± 1.0 1.6 ± 0.8* 
Total Cholesterol 
(mmol/l) 
4.5 ± 0.98 3.7 ± 0.8** 5.4 ± 1.07 4.6 ± 0.96** 
HDL-Cholesterol 
(mmol/l) 
1.1 ± 0.4 0.91 ± 0.15* 0.96 ± 0.2 1.01 ± 0.2** 
LDL-Cholesterol 
(mmol/) 
2.8 ± 0.67 2.2 ± 0.6** 3.66 ± 0.8 2.9 ± 0.8** 
Endotoxin  3.0 ± 0.5 3.27 ± 1.1 3.4 ± 0.9 3.2 ± 1.1 
Note: P-values at extreme right denote significance for baseline comparisons 
according to group;  
* denotes significance at p<0.05 as compared to visit 1; ** denotes significance at 
p<0.01 as compared to visit 1. 
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4.4.3 Post-prandial effects of high fat intake in the variables 
measured at baseline and follow-up in the T2DM group  
Comparisons between post-prandial fat intake at baseline and 3-month 
follow-up visits in the T2DM are shown in Table 4.4.3.1. Differences at 0 hour were 
previously mentioned in tables 4.4.1.1 and 4.4.2.1. For HOMA-IR, a significant 
difference was noted at 2 hours post-prandial (p<0.05) with the follow-up visit being 
significantly lower than baseline. For total- and LDL cholesterol levels, significant 
differences persisted in baseline and follow-up values through-out hours 1-4 
(p<0.05), with 0-hour having stronger significance (p<0.01). Endotoxin values at 
follow-up 2 hour post-prandial was also significantly lower than baseline post-
prandial of the same hour (p<0.05). The rest of the comparisons per hour were not 
significantly different from one another (Table 4.4.3.1). Linear figures were plotted 
to show trends in baseline and follow-up post-prandial values for glucose (Figure 
4.4.3.1), triglycerides (Figure 4.4.3.2), total cholesterol (Figure 4.4.3.3), HDL-
cholesterol (Figure 4.4.3.4), LDL-cholesterol (Figure 4.4.3.5), endotoxin (Figure 
4.4.3.6), insulin (Figure 4.4.3.7) and HOMA-IR (Figure 4.4.3.8).  
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Table 4.4.3.1 Post-Prandial Fat Meal Changes in Glucose, Insulin and HOMA-IR, Lipids and Endotoxin in T2DM Subjects at Baseline 
and 3 Months Follow Up 
 
 0 Hour 1 Hour 2 Hours 3 Hours 4 hours 
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up 
Glucose 7.9 ± 2.7 7.0 ± 1.8* 7.8 ± 2.5 7.3 ± 2.2 7.5 ± 2.5 7.0 ± 2.2 7.3 ± 2.7 6.9 ± 1.9 7.0 ± 2.8 6.9 ± 1.8 
Insulin# 11.7 ± 5.5 10.8 ± 6.0 21.9 ± 17.7 15.8 ± 8.5 19.3 ± 12.6 14.9 ± 9.9 16.2 ± 12.3 15.5 ± 9.0 14.3 ± 8.2 13.5 ± 7.3 
HOMA-IR# 3.7 ± 2.0 3.1 ± 2.2 8.7 ± 12.0 5.3 ± 3.3 6.6 ± 6.0 4.7 ± 3.8* 5.6 ± 5.4 4.8 ± 2.7 3.9 ± 2.4 3.9 ± 2.3 
Triglycerides# 1.9 ± 1.0 1.6 ± 0.8* 1.8 ± 0.7 1.7 ± 0.8 2.4 ± 0.9 2.2 ± 1.0 2.7 ± 1.1 2.6 ± 1.2 2.7 ± 1.3 2.7 ± 1.3 
Total Cholesterol 5.4 ± 1.1 4.6 ± 1.0** 5.3 ± 1.0 4.5 ± 1.0* 5.4 ± 1.1 4.6 ± 1.0* 5.3 ± 1.1 4.6 ± 1.0* 5.4 ± 1.1 4.7 ± 1.0* 
HDL-Cholesterol 0.96 ± 0.2 1.0 ± 0.2** 0.96 ± 0.2 0.98 ± 0.2 0.94 ± 0.2 0.97 ± 0.2 0.91 ± 0.2 0.92 ± 0.2 0.89 ± 0.2 0.9 ± 0.2 
LDL-Cholesterol  3.7 ± 0.8 2.9 ± 0.8** 3.6 ± 0.8 2.8 ± 0.9* 3.4 ± 0.9 2.6 ± 0.8* 3.2 ± 0.9 2.6 ± 0.8* 3.3 ± 0.9 2.6 ± 0.8* 
Endotoxin 3.4 ± 0.9 3.2 ± 1.1 3.0 ± 0.9 3.0 ± 1.0 3.4 ± 0.9 3.0 ± 1.0* 3.5 ± 1.2 3.2 ± 0.7 3.6 ± 1.5 3.4 ± 1.3 
 
Note: Data presented as mean ± standard deviation; * denotes significance at 0.05 level; ** denotes significant at 0.01 level. 
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Figure 4.4.3.1 Mean glucose levels pre- and post-intervention (T2DM group). * 
denotes p-value < 0.05. 
 
 
 
Figure 4.4.3.2 Mean triglyceride levels pre- and post-intervention (T2DM group). 
  
 
 
 
 
* 
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Figure 4.4.3.3 Mean total cholesterol levels pre- and post-intervention (T2DM 
group). ** denotes p-value < 0.01. 
 
 
 
Figure 4.4.3.4 Mean HDL-cholesterol levels pre- and post-intervention (T2DM 
group). 
 
 
 
 
 
 
* 
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Figure 4.4.3.5 Mean LDL-cholesterol levels pre- and post-intervention (T2DM 
group). ** denotes p-value < 0.01. 
 
 
 
 
Figure 4.4.3.6 Mean endotoxin levels pre- and post-intervention (T2DM group). * 
denotes p-value < 0.05. 
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Figure 4.4.3.7 Mean insulin levels pre- and post-intervention (T2DM group). 
 
 
 
 
Figure 4.4.3.8 Mean HOMA-IR pre- and post-intervention (T2DM group). 
 
 
115 
 
4.4.4 Post-prandial effects of high fat intake in the variables 
measured at baseline and follow-up in the Overweight+ group  
Comparisons between post-prandial fat intake at baseline and follow-up visits 
in the overweight+ group are shown in Table 4.4.4.1. Differences at 0 hour were 
previously mentioned in Tables 4.4.1.1 and 4.4.2.1. Glucose levels were significantly 
lower at 1 hour follow-up than baseline 1 hour post-prandial (p<0.05). Similar to the 
T2DM group, a significantly lower total- and LDL-cholesterol values were observed 
in follow-up across all hours (p<0.05) as compared to baseline. Contrary to the 
T2DM group however, a significantly lower HDL-cholesterol values were also noted 
in the follow-up and TG was significantly higher at baseline (p<0.05). The rest of the 
variables were not significantly different from one another. Linear figures were 
plotted to show trends at baseline and follow-up post-prandial values for glucose 
(Figure 4.4.4.1), triglycerides (Figure 4.4.4.2), total cholesterol (Figure 4.4.4.3), 
HDL-cholesterol (Figure 4.4.4.4), LDL-cholesterol (Figure 4.4.4.5), endotoxin 
(Figure 4.4.4.6), insulin (Figure 4.4.4.7) and HOMA-IR (Figure 4.4.4.8).  
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Table 4.4.4.1 Post-Prandial Fat Meal Changes in Glucose, Insulin and HOMA-IR, Lipids and Endotoxin in Overweight+ Subjects at 
Baseline and 3 Months Follow Up 
 
 0 Hour 1 Hour 2 Hours 3 Hours 4 hours 
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up 
Glucose 5.15 ± 3.5 4.65 ± 2.8 4.6 ± 0.4 4.3 ± 0.4* 4.6 ± 0.4 4.3 ± 0.6 4.6 ± 0.4 4.5 ± 0.4 4.6 ± 0.8 4.6 ± 0.5 
Insulin# 5.0 ± 3.4 12.7 ± 6.6* 15.6 ± 16.2 20.4 ± 20.4 16.9 ± 16.0 19.0 ± 15.3 13.1 ± 8.0 11.4 ± 7.4 10.3 ± 5.3 12.5 ± 7.7 
HOMA-IR# 1.1 ± 0.7 0.93 ± 1.9 3.5 ± 4.1 4.2 ± 4.3 3.9 ± 4.1 4.3 ± 3.6 2.8 ± 1.9 2.4 ± 1.7 2.1 ± 1.2 2.8 ± 2.0 
Triglycerides# 1.3 ± 0.8 1.4 ± 0.5 1.4 ± 0.8 1.4 ± 0.6 1.7 ± 0.9 1.8 ± 0.9 2.0 ± 1.1 2.0 ± 1.0 1.9 ± 1.3 2.0 ± 0.9 
Total Cholesterol 4.5 ± 1.0 3.7 ± 0.8* 4.5 ± 0.9 3.6 ± 0.8* 4.4 ± 0.8 3.4 ± 0.9* 4.4 ± 0.8 3.5 ± 0.8* 4.4 ± 1.0 3.6 ± 0.8* 
HDL-Cholesterol 1.2 ± 0.3 0.9 ± 0.2* 1.1 ± 0.3 0.9 ± 0.2* 1.1 ± 0.3 0.82 ± 0.2* 1.1 ± 0.4 0.8 ± 0.2* 1.1 ± 0.4 0.8 ± 0.2* 
LDL-Cholesterol  2.8 ± 0.7 2.2 ± 0.6* 2.7 ± 0.6 2.1 ± 0.6* 2.5 ± 0.6 1.9 ± 0.5* 2.4 ± 0.6 1.8 ± 0.5* 2.4 ± 0.6 1.9 ± 0.5* 
Endotoxin 3.0 ± 0.5 3.2 ± 1.1 2.9 ± 1.4 3.1 ± 1.3 3.5 ± 0.9 3.2 ± 1.3 3.8 ± 1.6 3.3 ± 0.8 3.5 ± 1.9 3.5 ± 1.7 
 
Note: Data presented as mean ± standard deviation; * denotes significance at 0.05. 
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Figure 4.4.4.1 Mean glucose levels pre- and post-intervention (Overweight+ group). 
 
 
 
 
Figure 4.4.4.2 Mean triglyceride levels pre- and post-intervention (Overweight+ 
group). 
 
 
 
 
* 
* 
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Figure 4.4.4.3 Mean total cholesterol levels pre- and post-intervention (Overweight+ 
group). ** denotes p<0.01. 
 
 
 
 
 
Figure 4.4.4.4 Mean HDL-cholesterol levels pre- and post-intervention 
(Overweight+ group). * denotes p<0.05; ** denotes p<0.01. 
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Figure 4.4.4.5 Mean LDL-cholesterol levels pre- and post-intervention 
(Overweight+ group). ** denotes p<0.01. 
 
 
 
Figure 4.4.4.6 Mean endotoxin levels pre- and post-intervention (Overweight+ 
group).  
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Figure 4.4.4.7 Mean insulin levels pre- and post-intervention (Overweight+ group). * 
denotes p<0.05 
 
 
 
Figure 4.4.4.8 Mean HOMA-IR pre- and post-intervention (Overweight+ group). 
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4.4.5 Mean fold changes in endotoxin values 
Figure 4.4.5.1 shows that there has been a modest increase in circulating 
endotoxin in both T2DM and overweight+ group at 0 hour after the dietary 
intervention, albeit these changes were not significant. Despite the non-significance, 
comparing the mean fold changes in both groups showed that the T2DM group were 
lower for the rest of the hour series than the overweight+ group with the exception of 
0 hour. 
 
 
Figure 4.4.5.1 Mean fold change in endotoxin levels in overweight+ and T2DM 
groups 
 
4.4.6 Associations of Endotoxin to Cardiometabolic Parameters 
Measured at Baseline  
Figures 4.4.6.1 and 4.4.6.2 show the baseline associations of endotoxin in all 
subjects. Endotoxin was positively and significantly associated with both total- and 
LDL-cholesterol (R values 0.33 and p=0.02, respectively). A near significant 
association was also observed between triglycerides and endotoxin (R=0.28; 
p=0.06). No significant difference was noted between BMI and endotoxin. Worthy 
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to note was the inverse yet non-significant association between endotoxin and HDL-
cholesterol (R=-0.15; p=NS). Upon stratification, endotoxin was found to be 
significantly associated with BMI in the T2DM group (R=0.38; p=0.03) (not shown 
in Figure). The rest of the endotoxin associations with other parameters in both 
T2DM and overweight+ group were not significant.  
 
Figure 4.4.6.1 Baseline Associations of Endotoxin in All Subjects versus A. BMI, 
B. Total Cholesterol, C. LDL-Cholesterol 
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Figure 4.4.6.2 Baseline Associations of Endotoxin in All Subjects versus D. 
LogTriglycerides and E. HDL-Cholesterol 
 
4.4.7 Associations of Endotoxin to Glycaemic parameters Measured 
at Baseline  
Figure 4.4.7.1 shows no significant associations between endotoxin and 
fasting glucose, log insulin and log HOMA-IR in all subjects. When split according 
to groups, no associations were elicited (data not included). 
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Figure 4.4.7.1 Baseline Associations of Endotoxin in All Subjects versus A. 
Glucose, B. log Insulin and C. log HOMA-IR 
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4.4.8 Associations of Endotoxin to BMI and Lipid parameters 
Measured at Follow-Up  
Figure 4.4.8.1 shows no significant associations between endotoxin, BMI and 
lipids after follow-up visit. A borderline significant association between endotoxin 
and triglycerides was noted (R=0.29; p=0.07). This borderline significance persisted 
in the overweight+ group after stratification (R=0.52; p=0.08). No other significant 
associations were elicited for the rest of the lipids in both groups (not included in 
Figure). 
 
Figure 4.4.8.1 Follow-Up Associations of Endotoxin in All Subjects versus A. BMI, 
B. Total Cholesterol, C. LDL-Cholesterol 
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Figure 4.4.8.2 Follow-Up Associations of Endotoxin in All Subjects versus D. 
LogTriglycerides and E. HDL-Cholesterol 
4.4.9 Associations of Endotoxin to Glycaemic parameters Measured 
at Follow-Up  
Figure 4.4.9.1 shows the associations of endotoxin to glycemic parameters 
after 3 months dietary intervention. In all groups, a significant positive association 
was observed between endotoxin and glucose (R=0.30; p=0.05) while no 
associations were observed between endotoxin, log insulin and log HOMA-IR. After 
splitting into groups, the association of endotoxin was apparent only in the T2DM 
group (R=0.49; p=0.008), as well as the near significant association between 
endotoxin and log HOMA-IR (R=0.45; p=0.07) (not shown in Figures). The rest of 
the associations of endotoxin post-intervention were unremarkable. 
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Figure 4.4.9.1. Follow-Up Associations of Endotoxin in All Subjects versus A. 
Glucose, B. Insulin, C. Homa-IR  
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4.5 Discussion 
This current chapter has highlighted the differences observed in lipids, 
glycaemic and endotoxin profiles of both the overweight+ and T2DM groups after 
the dietary intervention. The cardiometabolic changes in post-prandial high fat intake 
between baseline and follow-up and the associations of endotoxin to these variables 
will also be evaluated. 
The dietary intervention of 500 kcal deficit/day was observed to be beneficial 
in the reduction of total- and LDL cholesterol levels in both the T2DM and 
overweight+ groups. In addition, fasting glucose and HDL-cholesterol levels also 
improved in the T2DM group. Endotoxin levels remained stable in both groups. 
These favourable changes observed can be attributed to the over-all caloric 
restriction and improved quality of diet introduced in both cohorts.  
Previous studies with caloric restriction diets have consistently shown to be 
beneficial in the prevention and management of T2DM (Ley et al, 2014). Our results 
are in agreement with several recent clinical trials and intervention studies that also 
observed significant improvements in cardiovascular disease risk factors, particularly 
total- and LDL-cholesterol owing to a 3-month diet-induced weight loss (Brekke et 
al, 2014; Mateo-Gallego et al, 2014). Given that the duration of the dietary 
intervention is short, advice has been dutifully given to the subjects to consistently 
maintain the type of beneficial diet introduced to them in the study. Adoption to the 
type of diet used in the present study, even in the absence of exercise (Bekkouche et 
al, 2014), has been proven to be more effective, if not modestly beneficial, in the 
longer term (Thompson et al, 2014; Bhattarai et al, 2013; Rees et al, 2013; Gotsis et 
al, 2014). The concomitant improvement in the glucose levels of the T2DM group 
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and not the overweight+ group further confirms that the type of intervention used 
appears to have glucose-lowering affects that appears favourable for the T2DM 
population (Juanola-Falgarona et al, 2014).  
 The post prandial effects between groups were anticipated, since the 
metabolic and BMI-status of subjects are important factors on how the subjects 
respond to high fat meals (Schwander et al, 2014). Nevertheless and with the 
exception of isolated and select variables, the effects of post-prandial high fat intake 
was fairly consistent for both the baseline and follow up visits in both the 
overweight+ and T2DM groups. This can be partially explained by the uniform dose 
of high fat meal given at baseline and follow-up. The more improved health benefits 
in weight and metabolic status in the T2DM group could be explained by a greater 
compliance to the intervention given. 
 It is important to highlight the associations of endotoxin in the variables 
measured in the present study. In the previous chapter it was observed that endotoxin 
levels were significantly lower in the control group than both the overweight+ and 
T2DM groups, and that endotoxin levels were comparable for both the overweight 
and T2DM groups, suggesting that perhaps the overweight+ group had impaired 
insulin resistance. In this chapter we noted a significant association between 
endotoxin and BMI, particularly in the T2DM group, a group which falls well within 
the obese category. This association confirms the sub-clinical inflammation existing 
in obese patients and the role of endotoxins in exacerbating low-grade inflammation 
and insulin resistance (Cani et al, 2012). While observational studies are inconsistent 
in showing an association between BMI and endotoxin, this has not been the case for 
obese subjects. Mechanisms that may highlight the association with increasingly 
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adiposity may occur through changes in gut permeability during weight gain, in 
which patients have a “leakier” gut mucosa in obese subjects than those with insulin 
resistance (Piya et al, 2013). Furthermore differences in the microbiota composition 
between obese and non-obese individuals (Boroni-Moreira et al, 2012), and the post 
prandial inflammation induced by high fat diets have been observed (Herieka and 
Erridge, 2014). These same mechanisms may also partially explain the other 
borderline significant associations seen in the study such as the association between 
endotoxin, triglycerides, total and LDL-cholesterol in all subjects, and the 
association of endotoxin and insulin resistance in T2DM subjects. The higher 
number of associations to the T2DM group as compared to the overweight+ group 
also reinforces the role of endotoxemia in insulin resistance. 
 One of the clear caveats in the present study is the small sample size which, 
with increase may produce stronger associations between endotoxin and the 
variables measured. As it stands, the borderline significance elicited are best affirm 
previous studies. Further investigations with the inclusion of more inflammatory 
markers may provide insights on how a diet-induced weight loss programme may 
improve inflammatory status and gut permeability. 
 In summary, a 500 kcal deficit/day, in the absence of exercise, for 3 months, 
resulted in improved glucose levels and lipid profile which is more obvious in the 
T2DM group than the overweight+ group. Endotoxin levels in both groups, while 
stagnant even after dietary intervention, were associated with lipid profile, 
particularly total and LDL-cholesterol in both groups; and with BMI and insulin 
resistance in the T2DM group, reinforcing the exacerbating role of endotoxemia in 
obese and insulin resistant subjects. Lastly, the effects of a high fat meal did not 
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confer many changes in the post-prandial evaluation of cardiometabolic parameters 
of both groups at baseline and follow-up assessments suggesting the importance of a 
low fat diet to improve cardiometabolic health. Further studies are warranted to 
assess the protective effects of the present dietary intervention to reduce subclinical 
inflammation in the longer-term. 
 
 
 
 
 
Chapter Five 
 
The Effectiveness of Dietary Intervention 
among Type 2 Diabetes Mellitus, Overweight 
plus (overweight+) and lean Saudi Women 
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5.1 Introduction  
If the prevalence of type 2 diabetes mellitus (T2DM) continues to increase at 
the current rate, the global burden of this disease will swell between from 171 
million in 2000, to 366 million patients in 2030 (Wild et al., 2004). In 2011, Al-
Daghri and colleagues revealed that the age-adjusted prevalence of T2DM amongst 
urban Saudis was 31.6%, with another 10.2% having impaired fasting glucose (IFG) 
(Al-Daghri et al., 2011), confirming yet again that Saudi Arabia has one of the 
highest prevalence of T2DM on a global scale. If left ignored, this already heavy 
burden will overwhelmingly affect the nation’s limited resources in the near future, 
as half of the population will be deemed handicapped with the presence of T2DM. 
5.1.1 Effectiveness of Medical Nutrition Therapy in Treatment and 
Prevention of Diabetes 
The effectiveness of medical nutritional therapy (MNT) in the management 
of T2DM has been well established (Franz et al., 2008). MNT is defined as a 
“nutritional diagnostic, therapy, and counseling services for the purpose of disease 
management, which are furnished by a registered dietitian or nutrition professional” 
(U.S. Department of Health, 2001). Furthermore, the American Diabetes Association 
(ADA) currently recommends that “individuals who have pre-diabetes or diabetes 
should receive individualized MNT as needed to achieve treatment goals, provided 
by registered dietitian familiar with components of MNT for diabetes" (ADA, 2009). 
MNT interventions, both short and long term, were found to be beneficial in 
improving metabolic and behavioral outcomes. Pastors et al. summarized that 
"randomized, controlled nutrition therapy outcome studies have documented  
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decreases in [A1C] of ~1% in newly diagnosed type 1 diabetes mellitus (T1DM), 2% 
in newly diagnosed T2DM  and 1% in T2DM with an average duration of 4 years.” 
(Pastors et al, 2002). 
To achieve an effective MNT, it is important to explore the nutritional status 
and estimate the food intake of the general population. Most methods for measuring 
food intake have limitations that must be taken into account to determine which is 
most appropriate for the study aims. Self-reporting of food intake can lead to a 
certain degree of measurement error that may bias the relationship between nutrient 
and/or food intake and the disease of interest. Suggested errors of measurement can 
stem from variability within subject in food intake, difficulties in remembering 
which and how much food was consumed (Fernández-Ballart et al., 2010). 
Food frequency questionnaires (FFQ) are widely accepted and most 
frequently used method to assess food intake in large epidemiological studies which 
associate diet with chronic diseases because they provide a convenient assessment of 
the habitual dietary intake of an individual over a long period of time without 
altering usual food habits and are relatively inexpensive when self-administered 
(Willett, 1998). 
5.1.2 Eating Patterns and Weight loss   
Studies designed to reduce excess body weight have used a variety of energy-
restricted eating patterns with various macronutrient intakes and occasionally 
included a physical activity component and ongoing follow-up support. Studies 
achieving the greatest weight losses, 6.2 kg and 8.4 kg, respectively, included the 
Mediterranean-style eating pattern (Esposito et al., 2009) and a study testing a 
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comprehensive weight loss program that involved diet (including meal replacements) 
and physical activity (Pi-Sunyer et al., 2007).  
Dietary patterns are influenced by food availability, perception of 
healthfulness of certain foods and by the individual’s preferences, culture, religion, 
knowledge, health beliefs, and access to food and resources (e.g., budget/income) 
(Jones-McLean et al., 2010), these factors should be considered when 
individualizing eating pattern recommendations. Unfortunately there are limited 
studies in Saudi Arabia and the Middle-East in general, with regards to prospective 
dietary interventions. To fill this gap, we aim to examine the effect of comprehensive 
MNT and dietary intervention using energy deficit diet (500Kcal/day deficit) among 
Saudi women with various metabolic states to develop strategies that enhance 
adherence and to determine if certain nutritional approaches promote greater 
adherence than others. To the best of our knowledge this is the first study to 
investigate the influence of hypocaloric diet among adult Saudi women with various 
metabolic states. 
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5.2 Research design and methods  
5.2.1 Site and Duration of the Study 
This is a multi-center, randomized interventional study conducted at the 
primary care centers of the Riyadh city, involved 92 Saudi women, consisted of 18 
healthy control subjects (n=18), overweight plus (overweight+) subjects (n= 24) and 
patients with early onset of T2DM (n= 50).  
5.2.2 Selection of the Volunteers and Ethics Approval 
5.2.2.1 Inclusion/Exclusion Criteria 
Participants were eligible if they were women aged between 18-50 years, 
non-smokers, pre-menopausal, with a normal resting ECG and blood pressure and 
with no history of vascular disease. Candidates were excluded if they have acute 
medical illness; malignancy, a history of cardiovascular disease (CVD) or those on 
chronic medication, as well as patients with hypertriglyceridemia (as steroids and 
lipid lowering drugs may affect the intervention trial), previous myocardial 
infarction to established CHD, and other chronic inflammatory disorders e.g. 
rheumatoid arthritis, crohn’s disease, age under 18 and inability to give informed 
consent on grounds of competency. In addition, subjects with known long standing 
diabetes and receiving medication, or those with fasting glucose > 11 mmol/l or/and 
fasting triglycerides > 4 mmol/l were excluded from the study. 
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5.2.2.2 Ethical approval  
Ethical approval was granted by the Ethics Committee of King Saud 
University, Riyadh, Kingdom of Saudi Arabia, prior to the commencement of the 
research (Appendix I). 
5.2.3 Medical Screening  
Subjects were medically screened at primary health care centers where a 
physician completed a medical examination of vital signs and clinical interview 
which include questions to determine eligibility based on inclusion and exclusion 
criteria, detailed health information obtained from all subjects using preset heath 
questionnaire. For collecting data for the study, a pre-coded questionnaire was 
designed. The interview questionnaire which was previously used in large-scale 
epidemiologic survey in Saudi Arabia consisted of socio-demographic data, past 
medical and treatment history, sleeping hours and level of physical activity (Al-
Daghri et al, 2011) (Appendix III). 
5.2.4 Clinical Assessment 
Anthropometric measurements with emphasis on clinical markers of 
adiposity were assessed. These measurements included height (cm) and weight (kg) 
from which BMI will be calculated [weight (kg)/height (m2)]. Waist (cm) and hips 
(cm) were also measured and its ratio was determined. Blood pressure (mmHg) was 
taken using the conventional mercurial sphygmomanometer. All these measurements 
were repeated after 3 months period. 
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5.2.5 Biochemical Assessment  
All subjects were requested to submit an over-night fasting blood samples 
(12-14 hours fasting) from which the different metabolic parameters were assessed 
which included: Fasting blood glucose and complete lipid profile. These parameters 
were measured at baseline and after 3 months (3 months study duration). 
5.2.5.1 Blood Sample Collection 
These were collected with the patients in the fasting state using sterile 
vacutainer blood collection apparatus (BD). Whole blood, serum, EDTA plasma and 
fluoride tubes were collected from subjects. All samples were aliquoted and stored in 
–20oC freezer facilities in preparation for subsequent analysis. 
5.2.5.2 Laboratory Techniques 
Serum samples were stored in a -20 °C freezer prior to analysis. Fasting 
glucose and lipid profiles were measured using a chemical analyzer. This 
biochemical analyzer was calibrated routinely prior to the analysis of all serum 
samples using quality control samples provided by the manufacturer (ThermoFisher 
Scientific, Espoo, Finland). 
5.2.6 Clinical Intervention (Dietary Regimen) 
To enhance weight loss of 5% or more, participants were prescribed a 500 
Kcal deficit energy diet less than their daily recommended dietary allowances which 
were set at the levels recommended by the dietary reference intake for subjects with 
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low levels of physical activity at the same gender and age (DRI, 2008/2011). 
Targeted macronutrient composition was 20%-30% fat, <10% of saturated fatty 
acids, 50%-60% carbohydrates, 15%-20% protein and at least 15g per 1000kcal 
fibres  (Appendix V).  
As described earlier in chapter 2, participants with T2DM (n= 50) and 
overweight+ subjects (n= 24) received group and individualized dietary consultation. 
This was provided by the dietician researcher at baseline visit followed by monthly 
group sessions. Topics discussed include dietary regimen plan, healthy eating habits, 
general dietary guidelines, goal setting, modeling, social support, and relapse 
prevention and management. Subjects in the dietary intervention group were 
instructed to keep a written record of their daily food intake using a designed sheet 
developed by the researcher (Appendix VII) to be collected by the end of the study 
period of intervention.  
Dietary interventional program prescribed to selected subjects was initiated 
during 3 month period consisted of baseline in-person counselling sessions lasting 1 
hour with subsequent dietician phone calls and messages (once/week). In addition, 
printed dietary materials and handouts were designed by the researcher and provided 
to all participants to go home according to their assigned dietary regimen to facilitate 
implementation of the dietary interventional program (Appendix V).  Food 
frequency questionnaire (FFQ) which has been used previously (Al Disi et al., 2010) 
was the dietary tool to assess the food intake of the subjects pre- and post the dietary 
intervention (Appendix IV). 
    Nutrient intake was calculated using USDA database (18th - 21st Ed, 2009, 
2010) Program, as for the Saudi Arabic traditional dishes were analyzed using the 
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Arabic food analysis program (version 1, 2007). The evaluation of the daily food 
intake was made by the means of the total energy and the total nutrient intake, the 
percentage of the total calories derived from fat, protein and carbohydrates. 
Dietary nutrients values were compared with dietary reference intake (DRI) 
for specified age and gender for macronutrients (carbohydrates and protein) as well 
as for micronutrients (2008/2011).  
As for daily energy requirement (Kcal/day) was estimated using WHO 
equation (2005, 2007) (Sylvia Escott-Stump, 2011) according to age group and 
metabolic status. Dietary fat percentage has been estimated as 25% from daily 
energy requirement (Hooper et al., 2011) (Appendix VI). 
5.3 Data Analyses 
Data was analyzed using SPSS, version 16.5 (SPSS Inc, Chicago, IL, USA). 
Data were presented as mean±standard deviation for all continuous variables. 
Analysis of variance (ANOVA) was done to compare differences between control, 
overweight+ and T2DM group. Paired T-test was done to assess difference between 
baseline and follow-up visits in both the overweight and T2DM groups. Spearman 
correlation was done to determine associations between macronutrient intake and all 
parameters measured in all groups at baseline and follow-up. Significance was set at 
p<0.05. 
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5.4 Results 
5.4.1 Baseline Comparisons in Anthropometry in all Groups 
Table 5.4.1.1 shows the comparison of controls, overweight+ and T2DM 
groups according to anthropometry as well as observed changes between 
overweight+ and T2DM groups over time. Across all groups, T2DM patients had the 
highest measures in terms of mean BMI, waist and hip circumferences and WHR. It 
was noted that 40% of the T2DM subjects were receiving metformin whilst the rest 
where on diet alone advice. 
 
Table 5.4.1.1 Anthropometric Characteristics According to Groups 
 Control Overweight+ T2DM 
N 18 24 50 
Age (years) 24.39 ± 7.92 32.04 ± 7.78** 41.50 ± 6.23** 
DM Duration 
(years) 
-- -- 2.04 (0-9) 
Metformin Use -- -- 40% (20/50) 
BMI (kg/m2) 22.20 ± 2.21 28.54 ± 1.49** 35.24 ± 7.67** 
Waist (cm) 80.64 ± 7.23 95.75 ± 7.42** 112.3 ± 13. 43** 
Hip (cm) 98.69 ± 7.26 109.67 ± 5.01** 117.11 ± 11.59** 
WHR 0.82 ± 0.05 0.87 ± 0.05** 0.96 ± 0.07** 
Note: Data presented as mean ± standard deviation; * denotes significance at 0.05 
level; ** denotes significance at 0.01 level. 
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5.4.2 Baseline Comparisons in the Dietary Intake of all Groups 
The overweight+ group had significantly higher carbohydrate consumption 
and total calories than both T2DM and control (p<0.01), and this was also evident in 
the % DRI (Figure 5.4.2.1). No significant differences were observed in the protein 
and fat intake in all groups (Table 5.4.2.1) (Figures 5.4.2.2 and 5.4.2.3, respectively). 
On the other hand, the control group had the highest intake (Table 5.4.2.1) and % 
DRI (Figure 5.4.2.4) of fiber followed by the overweight+ group and lowest from the 
T2DM group at baseline (p = 0.003). Total caloric intake and % DRI (Figure 5.4.2.5) 
was significantly higher in the overweight+ group than T2DM and control   
(p = 0.011). 
Table 5.4.2.1 Dietary Intake Characteristics According to Groups 
 Control Overweight+ T2DM 
N 18 24 50 
Carbohydrates 
     Grams 
     Calories 
 
94.0 ± 5.5 
375.8 ± 22.0 
 
210.3 ± 9.2** 
841.1 ± 36.8** 
 
192.7 ± 12.9** 
770.9 ± 51.6** 
Protein 
     Grams 
     Calories      
 
64.4 ± 5.5 
257.7 ± 22.0 
 
66.1 ± 5.2 
264.4 ± 20.9 
 
59.3 ± 3.9 
237.3 ± 15.6 
Fats 
     Grams 
     Calories 
 
67.3 ± 7.3 
606.0 ± 65.8 
 
93.8 ± 5.9 
844.3 ± 53.1 
 
84.3 ± 4.0 
758.5 ± 36.0 
Fiber 
     Grams      
 
18.5 ± 1.7 
 
13.1 ± 2.2* 
 
12.9 ± 0.6** 
Total Calories  
     Kilocalories      
 
1239.6 ± 95.9 
 
1949.7 ± 63.7** 
 
1766.7 ± 61.8* 
Note: Data presented as mean ± standard deviation; * denotes significance at 0.05 
level; ** denotes significance at 0.01 level. 
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Figure 5.4.2.1 Percentage DRI (%) in carbohydrate intake according to groups at 
baseline; ** denotes significance compared to control. 
 
 
Figure 5.4.2.2 Percentage DRI (%) in protein intake according to groups at baseline. 
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Figure 5.4.2.3 Percentage DRI (%) in fat intake according to groups at baseline. 
 
 
Figure 5.4.2.4 Percentage DRI (%) in fibre intake according to groups at baseline; * 
denotes significance compared to control at 0.05 level; ** denotes significance 
compared to control at 0.01 level. 
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Figure 5.4.2.5 Percentage DRI (%) in total caloric intake according to groups at 
baseline; * denotes significance compared to control at 0.05 level.  
 
5.4.3 Changes in Anthropometry after 3 Months Follow-Up  
Prospectively, significant improvements were observed in both the 
overweight+ and T2DM group in terms of decreased mean BMI [Overweight+ Group 
28.54±1.49kg/m2 versus 27.95±2.25kg/m2, p<0.05; T2DM group 35.24±7.67kg/m2 
versus 35.04±8.07kg/m2, p<0.05] and hip circumference [Overweight+ group 
109.67±5.01cm versus 108.07±4.07cm, p<0.05; T2DM group 112.3±13.43cm versus 
109.21±12.71cm, p<0.01] at follow-up visit as compared to baseline. Only the 
T2DM group showed significant improvements in waist circumference 
(112.3±13.43cm versus 109.21±12.71cm, p<0.01) and WHR (0.96±0.07cm versus 
0.93±0.06cm, p<0.01) after 3 months follow-up. In the overweight+ group, there was 
no significant difference in the waist circumference group over time, while a 
significantly higher WHR was noted after follow-up (0.87±0.05 versus 0.88±0.06, 
p<0.05) (Table 5.4.3.1). 
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Table 5.4.3.1 Anthropometric Changes in Overweight+ and T2DM Groups Overtime  
 
 Overweight+ T2DM 
N 24 50 
Age (years) 32.04 ± 7.78 41.50 ± 6.23 
DM Duration 
(years) 
-- 2.04 (0-9)  
 Baseline Post-
Intervention 
Baseline Post-
Intervention 
BMI (kg/m2) 28.54 ± 1.49 27.95 ± 2.25* 35.24 ± 7.67 35.04 ± 8.07* 
Waist (cm) 95.75 ± 7.42 95.87 ± 7.78 112.3 ± 13. 43 109.2 ± 12.7** 
Hip (cm) 109.67 ± 5.01 108.07 ± 4.07* 117.11 ± 11.59 116.7 ± 13.18** 
WHR 0.87 ± 0.05 0.88 ± 0.06* 0.96 ± 0.07 0.93 ± 0.06** 
 
Note: Data presented as mean ± standard deviation; * denotes significance at 0.05 
level; ** denotes significance at 0.01 level. 
 
5.4.4 Changes in Dietary Intake after 3 Months Follow-Up  
In the overweight+ group, significant improvements were observed after 3 
months intervention in terms of decreased carbohydrate intake (210.3±9.2 versus 
181.7±8.8; p<0.01), increased protein intake (66.1±5.2 versus 71.5±5.3; p<0.05), 
decreased fat intake (93.8±5.9 versus 92.6±9.4; p<0.05) and decreased total caloric 
consumption (1949.7±63.7 versus 1326.8± 165.5; p<0.01) (Table 5.4.4.1). Similar 
significant improvements were also noted in the T2DM group in 2 macronutrients, 
namely carbohydrate intake (192.7±12.9 versus 163.9±11.2; p<0.01) and decreased 
fat intake (84.3±4.0 versus 61.5±2.9; p<0.01). A significant decrease in protein 
(59.3±3.9 versus 45.4±3.1; p<0.01) and total caloric intake (1766.7±61.8 versus 
1391.0±49.3; p<0.01) were also observed in the T2DM group. There was a modest 
increase in fiber intake in both the overweight+ and T2DM group, though it did not 
reach statistical significance (Table 5.4.4.1). 
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Table 5.4.4.1 Dietary Changes in Overweight+ and T2DM Groups Overtime  
 Overweight+ T2DM 
N 24 50 
 Baseline Post-Intervention Baseline Post-
Intervention 
Carbohydrates 
     Grams 
     Calories 
 
 
210.3 ± 9.2 
841.1 ± 36.8 
 
 
181.7 ± 8.8** 
726.8 ± 35.3 
 
 
192.7 ± 12.9 
770.9 ± 51.6 
 
 
163.9 ± 11.2** 
655.7.0 ± 44.8 
 
Protein 
     Grams 
     Calories 
      
 
66.1 ± 5.2 
264.4 ± 20.9 
 
 
71.5 ± 5.3* 
286.3 ± 21.2 
 
 
59.3 ± 3.9 
237.3 ± 15.6 
 
 
45.4 ± 3.1** 
181.5 ± 12.4 
 
Fats 
     Grams 
     Calories 
 
 
93.8 ± 5.9 
844.3 ± 53.1 
 
 
92.6 ± 9.4* 
833.4 ± 84.6 
 
 
84.3 ± 4.0 
758.5 ± 36.0 
 
 
61.5 ± 2.9** 
553.8 ± 26.1 
 
Fiber 
     Grams 
      
 
13.1 ± 2.2 
 
 
18.9 ± 4.3 
 
 
12.9 ± 0.6 
 
 
14.0 ± 0.9 
 
Total Calories  
     Kilocalories 
      
 
1949.7 ± 63.7 
 
 
1326.8 ± 165.5** 
 
 
1766.7 ± 61.8 
 
 
1391.0 ± 49.3** 
 
Note: Data presented as mean ± standard deviation; * denotes significance at 0.05 
level; ** denotes significance at 0.01 level. 
 
5.4.5 Associations of macronutrients to Cardiometabolic Indices 
Table 5.4.5.1 highlights the significant baseline and post-intervention 
associations of the macronutrients to the anthropometric and lipid indices measured 
across groups. In the control group, carbohydrate intake had significant negative 
effects on LDL-cholesterol (R = -0.52; p<0.05). Moving on to the overweight+ 
group, a significant association was observed in baseline HDL-cholesterol and 
protein intake (baseline R = 0.64; p<0.01). Finally in the T2DM group, baseline 
carbohydrate intake was significantly associated with BMI (R = 0.30; p<0.05. The 
rest of the coefficients for all groups were non-contributory (Table 5.4.5.1). Figure 
5.4.5.1 shows the mean fold changes in the BMI and WHR of both the overweight+ 
and T2DM group. 
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Table 5.4.5.1 Association of Dietary Intake (grams) to Cardiometabolic Indices 
 
 Control Overweight+ T2DM 
 CHO CHON FATS Kcal CHO CHON FATS Kcal CHO CHON FATS Kcal 
BMI 
    Baseline 
    Post-Intervention 
 
0.30 
-- 
 
-0.01 
-- 
 
-0.04 
-- 
 
0.14 
-- 
 
0.34 
0.21 
 
0.10 
0.01 
 
-0.08 
0.10 
 
0.01 
0.30 
 
0.30* 
0.17 
 
0.16 
0.03 
 
-0.04 
-0.08 
 
0.21 
0.10 
Waist 
    Baseline 
    Post-Intervention 
 
0.08 
-- 
 
0.10 
-- 
 
-0.02 
-- 
 
0.07 
-- 
 
-0.04 
0.12 
 
-0.17 
0.14 
 
0.26 
0.35 
 
-0.10 
0.35 
 
0.23 
0.15 
 
0.16 
-0.07 
 
0.03 
0.08 
 
0.17 
0.14 
Hips 
    Baseline 
    Post-Intervention 
 
0.28 
-- 
 
0.10 
-- 
 
-0.02 
-- 
 
0.07 
-- 
 
-0.01 
0.28 
 
0.32 
0.21 
 
0.05 
0.30 
 
-0.10 
0.38 
 
0.26 
0.12 
 
0.05 
-0.14 
 
0.01 
0.03 
 
0.21 
0.08 
WHR 
    Baseline 
    Post-Intervention 
 
-0.13 
-- 
 
0.03 
-- 
 
0.22 
-- 
 
-0.20 
-- 
 
-0.03 
-0.14 
 
-0.12 
-0.20 
 
0.30 
0.13 
 
0.19 
-0.04 
 
0.05 
0.07 
 
-0.20 
-0.08 
 
-0.06 
-0.07 
 
-0.02 
0.03 
Glucose 
    Baseline 
    Post-Intervention 
 
-0.20 
-- 
 
-0.27 
-- 
 
0.14 
-- 
 
-0.04 
-- 
 
0.39 
-0.02 
 
0.43 
-0.35 
 
-0.22 
0.43 
 
0.11 
0.21 
 
-0.17 
-0.12 
 
-0.04 
0.03 
 
0.09 
0.05 
 
-0.05 
-0.09 
Triglycerides 
    Baseline 
    Post-Intervention 
 
0.04 
-- 
 
0.19 
-- 
 
0.31 
-- 
 
0.32 
-- 
 
0.12 
-0.03 
 
-0.03 
-0.24 
 
0.04 
0.21 
 
0.21 
0.35 
 
-0.18 
-0.18 
 
-0.01 
0.18 
 
-0.12 
-0.23 
 
-0.13 
-0.32 
HDL-Cholesterol 
    Baseline 
    Post-Intervention 
 
-0.10 
-- 
 
0.02 
-- 
 
-0.29 
-- 
 
-0.36 
-- 
 
0.33 
0.08 
 
0.64** 
0.03 
 
-0.38 
0.42 
 
0.13 
0.20 
 
-0.13 
0.31 
 
0.21 
-0.23 
 
0.06 
-0.21 
 
0.02 
0.13 
LDL-Cholesterol 
    Baseline 
    Post-Intervention 
 
-0.52* 
-- 
 
-0.30 
-- 
 
0.36 
-- 
 
-0.29 
-- 
 
0.18 
0.27 
 
-0.06 
-0.26 
 
0.15 
0.08 
 
0.18 
0.29 
 
0.10 
0.07 
 
-0.09 
-0.13 
 
0.25 
0.21 
 
0.15 
0.02 
Total Cholesterol 
    Baseline 
    Post-Intervention 
 
-0.46 
-- 
 
-0.25 
-- 
 
-0.27 
-- 
 
-0.42* 
-- 
 
0.34 
0.20 
 
0.18 
-0.32 
 
0.12 
0.20 
 
0.38 
0.31 
 
0.08 
0.08 
 
-0.07 
-0.23 
 
0.23 
0.18 
 
0.14 
-0.02 
 
Note: Data presented as coefficient (R); * denotes significance at 0.05 level; P-value significant at p < 0.05. 
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Figure 5.4.5.1 Mean fold changes in BMI and WHR in Overweight+ Patients and the 
T2DM group 
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5.5 Discussion 
The main finding in the present study is that significant changes in the 
macronutrient consumption (500 kcal/day deficit) in both the overweight+ and 
T2DM groups during the 3-month dietary intervention led to favorable effects in 
both anthropometric and cardiometabolic indices of both groups, although 
improvements were more pronounced in the T2DM group. These findings highlight 
the importance of diet in the prevention and control of T2DM, even in the absence of 
modified physical activity. Previous work by Salas-Salvado and colleagues has 
recommended that the best strategy to accompany maintenance of ideal body weight 
is the implementation of the "prudent diet", which is similar to the dietary intake 
used in the present study, characterized by an increased intake of plant-based 
food groups that are generally recommended for health promotion, and a decreased 
intake of red meat and its products, sweets, high-fat dairy, refined grains and/or a 
Mediterranean diet known for its high olive oil content, fruits and vegetables, 
including whole grains, pulses, nuts and low-fat dairy minus the moderate alcohol 
and red wine consumption because of religious restrictions (Salas-Salvado et al, 
2011; Lazarou et al, 2012, ADA, 2012). The Mediterranean diet has received special 
attention because of its ability to reduce cardiovascular risk and its complications 
aside from the already known prevention of other major non-chronic communicable 
diseases (Bonnaciio et al, 2012). It has also been proven effective even as a single 
intervention (the absence of physical activity modification) in altering a favourable 
metabolic profile (Kontogianni et al, 2012) since it is known that pre-diabetic states 
already manifest several abnormal anthropometric, lipid and adipocytokine (leptin) 
profile (Al-Daghri et al, 2007). 
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The significant associations elicited between macronutrient intake and the 
different cardiometabolic parameters in the present study are worthy of mention. 
Carbohydrate intake was negatively associated with LDL-cholesterol in the control 
group, suggesting first, that these significant associations may grossly reflect which 
among the groups were more adherent and compliant to the dietary intervention 
used, and second, that there are several types of carbohydrates that provide beneficial 
metabolic effects when consumed in regulated amounts. The level of adherence to 
healthy dietary patterns influences the risk of T2DM, with the highest adherence 
having the lowest risk (Alhazmi et al, 2013). In the present cohort, it seemed that 
whilst both the overweight+ and T2DM groups significantly improved their dietary 
intake, the significant improvements were more pronounced in the T2DM subjects, 
which also corresponded with more significant improvements in anthropometric 
parameters elicited after follow-up. The most likely reason for this discrepancy in 
response among groups is that some of the T2DM subjects were on metformin 
monotherapy, an established standard care drug for T2DM known to decrease food 
consumption and induce weight loss (Lee and Morley, 1998). This metformin mono-
therapy advantage of the T2DM group may have boosted the effects of a 500 
kcal/day deficit with apparent results as early as 3 months as observed in the present 
study. As for the second point, Song and colleagues demonstrated that in the Korean 
population, refined-grain and white rice were observed to be associated with 
metabolic syndrome in women only (Song et al, 2014). The same refined-grain 
intake also increases risk of metabolic syndrome in the South Asian population 
(Radhika et al, 2009). In our study, whole-grain intake was encouraged as the main 
carbohydrate source since this has been consistently proven to be beneficial among 
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patients with T2DM in various studies conducted using the Middle-Eastern 
population (Al-Khudairy et al, 2013, Esmaillzadeh et al, 2005, Issa et al, 2011).  
The authors acknowledge several limitations. Despite the significant 
associations elicited between macronutrient intake and anthropometrics measures, 
the results should still be interpreted with caution, as these were based on self 
administered food frequency questionnaires, which are highly subjective. The 
findings cannot be applied to men with T2DM since gender is a confounder and 
differences in dietary intake and pattern have been recently demonstrated (Leblanc et 
al, 2014). The lack of follow-up in the lean control group also limits the findings to 
the overweight+ and T2DM groups in terms of the beneficial effects following 
dietary intervention. 
In summary, this study showed that a 500 kcal/day deficit over a 3-month 
period dietary is clinically beneficial among adult Saudi females with T2DM than 
the overweight+ subjects that seem to swap their fat diet for more protein that didn’t 
translate to a better health impact. Longer prospective studies are needed taking into 
consideration other subgroups, such as those with pre-diabetes, to determine whether 
the dietary intervention alone can reduce progression of T2DM among high-risk 
adult Arabs. 
 
 
 
 
 
 
Chapter Six 
 
Effect of Diet type (low-fat vs balanced diet 
[prudent diet]) on weight loss, metabolic status 
and endotoxin among type 2 diabetes and 
overweight plus (overweight+) Saudi Women  
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6.1 Introduction 
6.1.1 Nutrition therapy for the management of diabetes   
Life-style modifications are effective tools to prevent type 2 diabetes Mellitus 
(T2DM), and weight loss is critical to success (Bantle et al., 2008). The impact of 
healthy, calorie-restricted diet together with physical activity on subjects with 
impaired glucose tolerance, which is a pre-diabetic state, have been studied in 5 
clinical trials (Pan et al., 1997; Tuomilehto et al., 2001; Kosaka et al., 2002; Knowler 
et al., 2002; Ramachandran et al., 2006). The risk reductions reported in these trials 
were between 30 and 70%. Moreover, and in four of these studies (Pan et al., 1997; 
Tuomilehto et al., 2001; Kosaka et al., 2002; Knowler et al., 2002) T2DM rates were 
lowered in relation to weight loss whereas in the Indian trial lifestyle modification 
was successful despite no weight loss. Observational studies have also shown that 
diets rich in red meat, processed foods, refined grains and sweets increase diabetes 
risk, while diets low in red meat and whole-fat dairy products and rich in vegetables 
are associated with decreased risk of diabetes (Kastorini and Panagiotakos, 2009).  
Generally, a low-fat diet (LFD) has been recommended to patients with T2DM to 
achieve weight loss (Becker et al., 2008) particularly, low dietary saturated fat has 
been recommended for that purpose such as the Mediterranean diet (Margetts, 2003; 
Bantle et al., 2008). 
The classical Mediterranean diet (MedDiet), includes high intake of legumes, 
vegetables, fruits, olive oil, grains and nuts, moderate intake of sea food and wine, 
and low intake of red meat, processed foods, and whole-fat dairy products is largely 
considered a healthy dietary pattern (Martínez-González et al., 2009). It was recently 
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demonstrated that MedDiet acheives better glycemic control and delayed the need 
for T2DM medication in newly diagnosed T2DM patients compared with the LFD 
(Esposito et al., 2009).  
Further evidence on the benefit of MedDiets over LFD has obtained in the 
Prevención con Dieta Mediterránea (PREDIMED) study, a large nutrition 
interventional trial for primary cardiovascular prevention in individuals at high 
cardiovascular disease (CVD) risk. In this trial, 418 non-diabetic subjects aged 55-88 
years were randomly assigned to education on a LFD (control group) or to one of 
two MedDiets, supplemented with either free virgin olive oil (1 liter/week) or nuts 
(30 g/day)  . No advice on physical activity was given to the study’s participants. The 
primary end-point was diabetes incidence diagnosed by the 2009 American Diabetes 
Association (ADA) criteria. The study results demonstrated that MedDiet -without 
calorie restriction-seem to be effective in the prevention of diabetes in subjects at 
high CVD risk (Salas-Salvadó et al., 2011b). This was in line with results from other 
research groups demonstrating that MedDiets seem more effective in inducing 
clinically relevant long-term reduction in CVD risk factors and inflammatory 
mediators as compared to LFD (Nordmann et al., 2011). 
In another community-based study looking at the differential effect of 3 types 
of diets; a low carbohydrate Mediterranean (LCM), a traditional Mediterranean 
(TM), and the 2003 ADA diet on the CVD risk factors in 259 diabetic patients (with 
their mean age = 55 years, and mean BMI = 31.4 kg/m2 over a duration of 12-
months, Elhayany and colleagues (2010) have demonstrated that this dietary 
intervention was effective in improving most modifiable cardiovascular risk factors 
(fasting plasma glucose, HbA1c and triglyceride (TG) levels) in all the dietary 
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groups. While only the LCM improved HDL levels and was superior to both the 
ADA and TM in improving glycaemic control (Elhayany et al., 2010). 
Dietary Approaches to Stop Hypertension (DASH) diet has been proposed in 
T2DM patients as well since CVD complications are the most frequent problem 
among those patients (Kalofoutis et al., 2007). This diet, which is rich in fruits, 
vegetables, whole grains, low-fat dairy products and low in saturated fat, total fat, 
cholesterol, refined grains and sweets with sodium intake of 2,400 mg/day (Buse et 
al., 2007), has demonstrated  beneficial effects on cardiometabolic risks amongst 
T2DM patients (Azadbakht et al., 2011). 
From the above brief discussion on various diet studies, it is apparent which 
dietary intervention should be undertaken for overweight and T2DM patients 
remains a matter of choice which is further hampered by the fact that studies that 
compare the effectiveness of various diets are frequently limited by short follow-up 
period and high dropout rates.  
As described in earlier chapters, diet can affect the inflammatory response to 
exogenous lipopolysaccharide (LPS) as supported by recent studies showing that 
high fat diet can result in increased endotoxemia. The latter can in turn be triggered 
by repeated ingestions of single high fat meals with subsequent inflammatory 
response (Harte et al., 2012; Laugerette et al., 2009; Ghoshal et al., 2009; Amar et 
al., 2008; Cani et al., 2007; Erridge et al., 2007). LPS has been implicated as a potent 
inducer of tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6). LPS also 
reduces adiponectin. In normal conditions, as in healthy individuals, the absorbed 
endotoxin is rapidly removed by monocytes, particularly resident Kupffer cells 
within the liver. Emerging evidence has indicated that chronic endotoxemia plays a 
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role in insulin-resistant state and obesity (Al-Attas et al., 2009; Creely et al., 2007; 
Pimentel et al., 2012). However to date no previous study has explored the role of 
different types of dietary regimens as possible strategies to reduce postprandial 
endotoxin absorption and/or the metabolic consequences as regard low-grade 
inflammation amongst T2DM and overweight subjects. Therefore this study will 
examine the importance of dietary intervention, what might work, and how diets may 
impact on inflammatory risk. 
156 
 
6.2 Research Design and Methods  
  A total of 74 Saudi women aged between 18-50 years were enrolled in a 
randomized interventional study at primary care centers of different regions of 
Riyadh city. Fifty subjects were with type 2 diabetes mellitus, and 24 subjects were 
overweight plus (overweight+). All subjects were matched for age, BMI, and lipid 
profile as closely as possible. Only females, non-smokers, pre-menopausal, with a 
normal resting ECG and blood pressure and with no history of vascular disease were 
selected. In addition, subjects with known long standing diabetes and receiving 
diabetes medication, or those with fasting glucose > 11 mmol/L, were excluded. 
Moreover subjects with a fasting triglycerides > 4 mmol/L were excluded from the 
study. Ethical approval had been granted by the Ethics Committee of King Saud 
University, Riyadh, Kingdom of Saudi Arabia, prior to the commencement of the 
research (Appendix I), and each subject signed an informed consent form prior to 
being included in the study (Appendix II). 
6.2.1 Medical screening  
Subjects were medically screened at primary health care centers where a 
physician completed a medical examination of vital signs and clinical interview 
which included questions to determine eligibility based on inclusion and exclusion 
criteria. Detailed health information was obtained from all subjects using preset 
heath questionnaire which was previously used in large-scale epidemiologic survey 
in Saudi Arabia (Al-Daghri et al, 2011). The interview questionnaire consists of 
socio-demographic data, past medical history, treatment history, sleeping hours and 
level of physical activity (Appendix III). 
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6.2.2 Anthropometric measurements  
After signing an informed consent form, each participating subject was 
requested to return to her respective primary health care centre after an overnight fast 
(12-14 hours) two times over a three months-period (the study duration). 
Anthropometry and blood withdrawal were collected in the first visit. 
Anthropometry included height (to the nearest 0.5 cm), weight (to the nearest 0.1 
kg), waist and hip circumference measurements utilizing a standardized measuring 
tape in cm. Systolic and diastolic blood pressure measurements were taken, as well 
as BMI (calculated in kg/m2). These measurements were repeated in the second visit, 
after 3 months. 
6.2.3 Dietary interventional program  
Subjects were divided according to the assigned dietary regimen into low fat 
and balanced diet groups (described in a later section). In addition, food frequency 
questionnaire (FFQ) was the dietary tool that had been used to assess the subjects’ 
food intake prior and post the dietary intervention (i.e. at baseline and follow up 
visit).  
All subjects were given health advice according to their assigned dietary 
regimen. Energy intake was set at the levels recommended by the dietary reference 
intake (DRI) for female subjects with low levels of physical activity at the same age 
(DRI, 2008/2011). 
The dietary intervention program was delivered with a combination of group, 
individual, and telephone contacts. Participants received monthly group sessions as 
158 
 
well as 1 individualized consultation at baseline visit. The group sessions were 
interactive between the dietitian researcher and the subjects, allowing questions to be 
answered and explained. Main topics discussed were: healthy eating pattern, low 
calorie and low fat choices, importance of fruits, vegetables and fiber, functional 
foods, information on food pyramid, goal setting and relapse prevention and 
management. Women in the intervention group were given an individualized dietary 
consultation according to their assigned dietary regimen (Appendix V). Subsequent 
dietician contacts (phone calls and messages) occurred every week during the study 
to support their compliance. The researcher interviewed the participants individually 
and the information was collected using a pre-designed FFQ questionnaire 
(Appendix IV) to assess the qualitative and the quantitative aspects of the food 
consumed by the participants over a period of 7 days ( Al-Disi et al., 2010).  
    Nutrient intake was calculated using Food Processor USDA (18th - 21st Ed, 
2009, 2010) Program, as for the Saudi Arabic traditional dishes were analyzed using 
the Arabic food analysis program (version 1, 2006). The evaluation of the daily food 
intake was made by means of the total energy and the total nutrient intake, as well as 
the percentage of the total calories derived from fat, protein and carbohydrates. 
Dietary nutrients values were compared with DRI for specified age and gender for 
macronutrients (carbohydrates and protein) as well as for micronutrients 
(2008/2011). Daily energy requirement (Kcal/day), were estimated using WHO 
equation (2005, 2007) (Sylvia Escott-Stump, 2011) according to age group and 
metabolic status. Dietary fat percentage has been estimated as 25% from daily 
energy requirement (Hooper et al., 2011) (Appendix VI). 
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6.2.3.1 Prescribed Dietary regimen  
The project dietitian enrolled participants and randomly allocated them to 
their assigned dietary regimen as follows, because this was a dietary intervention, 
patients were not blinded. 
1. Low fat diet group: fat is the most energy-rich of all energy-providing nutrients, 
therefore reducing fat intake results in reducing total energy intake to induce 
weight loss. This diet defined as total fat intake < 30% of total energy intake and 
saturated fat intake <10%. This diet emphasizes on the intake of vegetables, 
fruits, starches (e.g., breads/crackers, pasta, whole grains, starchy vegetables), 
lean protein, and low-fat dairy products (National Heart, Lung, and Blood 
Institute, 2005). Participants in this group were directed to avoid fried and 
processed foods and were provided with low fat recipes and substitutes.  
2. Balanced diet (the composition of this diet was similar to the Mediterranean diet 
style, so-called prudent diet) which includes abundant plant foods (fruits, 
vegetables, breads, other forms of cereals, potatoes, beans, nuts, and seeds), fresh 
fruit as the typical daily dessert, olive oil as the principal source of fat, dairy 
products (principally cheese and yogurt), and fish and poultry consumed in low 
to moderate amounts, zero to four eggs consumed weekly, red meat consumed in 
low amounts, and normally with meals. This diet is low in saturated fat (≤7-8% 
of energy), with total fat ranging from < 25% to > 35% of energy (Willett et al., 
1995). 
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Figure 6.2.3.1.1 The different arms of the interventional trial proposed: T2DM 
and overweight+ subjects were subdivided into two groups according to the assigned 
dietary regimen (LF = Low fat diet) group and (BD = Balanced diet) group. 
6.2.4 Biochemical assessment 
All subjects were requested to submit an over-night fasting blood samples 
from which the different metabolic parameters were assessed. Serum samples were 
stored in a -20 °C freezer prior to analysis. Fasting glucose and lipid profiles were 
measured using a chemical analyzer (Konelab, Vantaa, Espoo). Fasting insulin was 
determined using by electrochemiluminescence method (ECLIA) (COBAS E 
411; Roche Diagnostics, Mannheim, Germany). The instruments were calibrated 
prior to analysis using quality control samples provided with the kits. Serum 
Endotoxin was analyzed using a commercially available QCL-1000 LAL Endpoint 
Assay (Lonza, New Jersey, USA). Homeostasis model assessment of insulin 
resistance (HOMA-IR) was calculated as fasting insulin (µU/mL) × fasting glucose 
(mmol/L)/22.5 (Bonora et al, 2002). These parameters were measured at baseline 
and after 3 months (3 months study duration). 
 
 
 
Type 2 DM
N=50
LF=25 BD= 25
Overweight+
N=24
LF=12 BD= 12
161 
 
6.3 Data Analysis 
Data was analyzed using SPSS version 16.5 (SPSS, Chicago, IL, USA). All 
variables were presented as mean ± standard deviation. For comparison between 
baseline and post-intervention, paired T-test (for normally distributed variables) and 
Wilcoxon signed-rank tests (for insulin, TG and HOMA-IR) were used. Bivariate 
correlation was used to test associations between macronutrients and 
cardiometabolic risk factors. Significance was set at p<0.05. 
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6.4 Results 
6.4.1 Effects of Low Fat versus Balanced Diet in the Anthropometric 
and Clinical Parameters of the T2DM Group  
Table 6.4.1.1 shows the comparison between low fat and balanced diet 
interventions in the T2DM group. In the low fat diet program, significant 
improvements were noted in the anthropometric measures in terms of significantly 
lower weight [baseline 85.4±3.1kg versus follow-up:84.1±3.2kg; p<0.05], BMI 
[baseline 34.5±4.9kg/m2 versus follow-up: 34.0±5.0kg/m2; p<0.05], waist 
circumference [baseline 115.1±11.9cm versus follow-up: 110.0±12.1cm; p<0.01], 
and WHR [baseline 0.98±0.01 versus follow-up: 0.95±0.1; p<0.05] in the follow-up 
as compared to baseline. Furthermore, with the exception of HDL-cholesterol which 
modestly increased after follow-up, all the measured lipids, including glucose, 
decreased after 3 months of intervention. These improvements were most notable in 
the total cholesterol [baseline 5.4±1.2mmol/l versus follow-up: 4.7±1.1mmol/l; 
p<0.05] and LDL-cholesterol levels [baseline 3.7±0.9mmol/l versus follow-up: 
3.1±0.9mmol/l; p<0.05]. The rest of the differences were not significant. 
 In contrast, only modest improvements in all parameters were observed 
among the T2DM subjects under the balanced diet program. Only two lipid 
parameters achieved statistical significance, namely total [baseline 5.3±0.9mmol/l 
versus follow-up: 4.5±0.8mmol/l; p<0.01] and LDL-cholesterol [baseline 
3.5±0.8mmol/l versus follow-up: 2.8±0.7mmol/l; p<0.01], after comparing baseline 
and follow-up values (Table 4.6.1.1). 
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Table 6.4.1.1 Differences in Anthropometric and Clinical Parameters According to 
Diet Type (T2DM Group) 
 
 
Parameters 
Low Fat Diet N = 25 Balanced Diet N = 25 
 Baseline  Post-Intervention  Baseline  Post-Intervention 
Weight (kg) 85.36 ± 3.11 84.11 ± 3.18* 79.41 ± 12.4 78.7 ± 11.6 
BMI (kg/m2) 34.51 ± 4.94 34.01 ± 5.0* 33.8 ± 4.63 33.53 ± 4.47 
Waist (cm) 115.1 ± 11.9 110.03 ± 12.1** 110.53 ± 14.9 106.81 ± 10.7 
Hips (cm) 117.9 ± 11.9 116.03 ± 12.55 115.47 ± 10.4 115.5 ± 10.55 
WHR 0.98 ± 0.08 0.95 ± 0.07* 0.96 ± 0.08 0.93 ± 0.06 
Glucose (mmol/l) 7.51 ± 2.58 6.6 ± 1.2 8.63 ± 2.83 7.73 ± 2.02 
Insulin (IU/ml)# 11.1 ± 5.0 8.1 ± 5.3 12.8 ± 6.8 13.4 ± 6.6 
HOMA-IR# 3.2 ± 1.6 2.2 ± 1.5 4.5 ± 2.4 4.3 ± 2.5 
Triglycerides (mmol/l)# 2.04 ± 1.32 1.77 ± 0.92 1.78 ± 0.77 1.5 ± 0.71 
Total Cholesterol (mmol/l) 5.44 ± 1.24 4.72 ± 1.11* 5.29 ± 0.91 4.48 ± 0.81** 
HDL-Cholesterol (mmol/l) 0.95 ± 0.26 0.98 ± 0.25 0.98 ± 0.18 1.01 ± 0.24 
LDL-Cholesterol (mmol/l) 3.71 ± 0.91 3.06 ± 0.94* 3.5 ± 0.75 2.79 ± 0.69** 
Endotoxin (EU/ml) 3.3 ± 0.72 3.3 ± 0.73 3.3 ± 1.0 3.3 ± 1.4 
 
Note: Data presented as mean ± standard deviation; # not normally distributed; * 
denotes significance at 0.05 level; ** denotes significance at 0.01 level. 
6.4.2 Effects of Low Fat versus Balanced Diet in the Dietary Intake 
of the T2DM Group  
 Table 6.4.2.1 shows the differences in the macronutrient intake of T2DM 
subjects assigned in low fat versus balanced diet. In the low fat diet, there were 
strong significant decreases in the follow up visit than baseline in terms of 
carbohydrate [baseline 182.1±72.9g versus follow-up: 148.7±60.0g; p<0.01], protein 
[baseline 60.9±19.7g versus follow-up: 45.8±14.9g; p<0.01], and dietary fat 
[baseline 83.2±23.4g versus follow-up: 57.6±14.7g; p<0.01] intakes as well as total 
calories [baseline 1720.5±396.7kcal versus follow-up: 1295.9±294.1kcal; p<0.01]. 
Similar significant differences were also observed in the balanced diet group, except 
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that the significantly lower carbohydrate intake [baseline 220.2±89.2g versus follow-
up: 183.3±73.6g; p<0.05] after 3 months was statistically weaker than the 
significance achieved by the low fat diet group in the same macronutrient. In both 
groups, there were no statistically significant differences in fibre intake in baseline 
and follow-up. Worthy to note however was the modest increase in the post 
intervention fibre intake of T2DM subjects from the low fat diet group as compared 
to baseline [baseline 13.4±3.4g versus follow-up: 14.2±6.1g; p=NS] (Table 6.4.2.1). 
Table 6.4.2.1 Differences in Dietary Intake According to Diet Type (T2DM Group) 
 
 
Parameters 
Low Fat Diet N = 25 Balanced Diet N = 25 
Baseline Post-Intervention Baseline  Post-Intervention 
Carbohydrates 
     Grams 
     % DRI 
 
182.1 ± 72.9 
140.1 ± 56.1 
 
148.7 ± 60.0** 
114.4 ± 46.1** 
 
220.2 ± 89.2 
165.9 ± 29.6 
 
183.3 ± 73.6* 
149.2 ± 36.8* 
Protein 
     Grams 
     % DRI 
 
60.87 ± 19.7 
132.3 ± 42.9 
 
45.75 ± 14.9** 
99.5 ± 32.4** 
 
63.3 ± 28.2 
137.5 ± 61.3 
 
44.6 ± 22.6** 
96.9 ± 49.1** 
Fats  
     Grams 
     % DRI 
 
83.19 ± 23.4 
194.3 ± 50.8 
 
57.6 ± 14.69** 
134.0 ± 32.4** 
 
89.3 ± 24.3 
137.5 ± 61.3 
 
66.0 ± 20.6** 
96.9 ± 49.1** 
Fibre 
     Grams 
     % DRI  
 
13.4 ± 3.4 
53.7 ± 13.7 
 
14.2 ± 6.1 
56.9 ± 6.3 
 
13.9 ± 3.5 
55.7 ± 14.2 
 
13.7 ± 3.7 
54.8 ± 14.7 
Total Calories 
    Kilocalories 
     % DRI  
 
1720.5 ± 396.7 
115.4 ± 23.0 
 
1295.9 ± 294.1** 
86.2 ± 18.1 ** 
 
1937.5 ± 323.0 
117.9 ± 26.3 
 
1505.9 ± 271.9** 
98.7 ± 19.9** 
 
Note: Data presented as mean ± standard error; * denotes significance at 0.05 level; 
** denotes significance at 0.01 level. 
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6.4.3 Effects of Low Fat versus Balanced Diet in the Anthropometric 
and Clinical Parameters of the Overweight+ Group  
Table 6.4.3.1 shows the comparison between low fat and balanced diet 
interventions in the overweight+ group. With 24 overweight subjects, 12 subjects 
were assigned for each dietary intervention. In the low fat diet program, significant 
improvements were most noted in the total [baseline 4.8±0.9mmol/l versus follow-
up: 3.9±0.8mmol/l; p<0.05] and LDL-cholesterol levels [baseline 3.0±0.4mmol/l 
versus follow-up: 2.5±0.6mmol/l; p<0.05]. The rest of the differences were not 
significant. Other observed, but not statistically significant changes include modest 
decreases in weight [baseline 73.8±0.9kg versus follow-up: 71.9±4.4kg; p=NS], BMI 
[baseline 28.6±0.6kg/m2 versus follow-up: 27.8±2.8kg/m2; p=NS], triglycerides 
[baseline 1.8±1.2mmol/l versus follow-up: 1.7±0.6mmol/l; p=NS] and HDL-
cholesterol [baseline 1.2±0.4mmol/l versus follow-up: 0.9±0.2mmol/l; p=NS] (Table 
6.4.3.1). 
The overweight+ subjects in the balanced diet group had a more favourable 
outcome anthropometrically than their low fat diet counterparts in terms of improved 
weight [baseline 68.9±5.7kg versus follow-up: 67.0±5.8kg; p<0.05], BMI [baseline 
28.5±1.6kg/m2 versus follow-up: 27.7±2.1kg/m2; p<0.05] and hip circumference 
[baseline 111.6±4.8cm versus follow-up: 107.9±2.9cm; p<0.01] after 3 months of 
intervention. In terms of glucose and lipid measures, both the low fat diet and 
balanced diet are similar with respect to significantly lower total [baseline 
4.3±1.0mmol/l versus follow-up: 3.7±0.8mmol/l; p<0.05] and LDL-cholesterol 
[baseline 2.7±0.8 versus follow-up: 2.2±0.6; p-value<0.05] in the follow-up as 
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compared to baseline. The rest of the changes in lipids, including glucose, were 
m o d e s t . 
Table 6.4.3.1 Differences in Anthropometric and Clinical Parameters According to 
Diet Type (Overweight+ Group) 
 
Parameters 
Low Fat Diet N = 12 Balanced Diet N = 12 
Baseline Post-Intervention Baseline Post-Intervention 
Weight (kg) 73.82 ± 0.94 71.92 ± 4.36 68.87 ± 5.7 67.0 ± 5.8* 
BMI (kg/m2) 28.58 ± 1.0 27.8 ± 2.8 28.48 ± 1.57 27.73 ± 2.08* 
Waist (cm) 94.3 ± 7.9 94.3 ± 8.9 99.12 ± 7.78 95.94 ± 8.28 
Hips (cm) 110.5 ± 5.6 109.2 ± 6.1 111.56 ± 4.8 107.88 ± 2.94** 
WHR 0.86 ± 0.07 0.87 ± 0.07 0.89 ± 0.04 0.89 ± 0.06 
Glucose (mmol/l) 4.78 ± 0.47 4.57 ± 0.55 4.67 ± 0.43 4.49 ± 0.52 
Insulin (IU/ml)# 5.3 ± 3.6 4.6 ± 2.4 5.0 ± 3.4 4.7 ± 3.3* 
HOMA-IR# 1.1 ±  0.8 0.93 ± 0.6 1.1 ± 0.7 0.93 ± 1.89 
Triglycerides (mmol/l)# 1.81 ± 1.16 1.66 ± 0.62 0.95 ± 0.41 1.08 ± 0.35 
Total Cholesterol (mmol/l) 4.84 ± 0.86 3.91 ± 0.85* 4.32 ± 1.05 3.71 ± 0.76* 
HDL-Cholesterol (mmol/l) 1.22 ± 0.42 0.88 ± 0.19 1.16 ± 0.33 0.98 ± 0.05 
LDL-Cholesterol (mmol/l) 3.0 ± 0.42 2.48 ± 0.55* 2.73 ± 0.79 2.24 ± 0.61* 
Endotoxin (EU/ml) 3.1 ± 0.47 3.18 ± 0.53 2.9 ± 0.5 2.5 ± 0.82 
 
Note: Data presented as mean ± standard deviation; # not normally distributed * 
denotes significance at 0.05 level; ** denotes significance at 0.01 level. 
 
6.4.4 Effects of Low Fat versus Balanced Diet in the Dietary Intake 
of the Overweight+ Group  
Table 6.4.4.1 shows the differences in the macronutrient intake of 
overweight+ subjects under low fat versus balanced diet intervention. In the low fat 
diet, there were strong significant decreases in the follow up visit than baseline in 
terms of fibre intake [baseline 8.2±1.7g versus follow-up: 6.1±2.3g; p<0.01] as well 
as total calories [baseline 1921.2±167.6kcal versus follow-up: 1629.4±166.7kcal; 
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p<0.01]. A significantly lower fat intake post intervention was also observed 
[baseline 94.8±14.9g versus follow-up: 75.0±17.4g; p<0.05]. Both carbohydrate and 
protein intake were lower in follow up than baseline, but did not achieve statistical 
significance. In the balanced diet group, a lower but not significant difference was 
noted in the carbohydrate, protein and fat intake in follow-up than baseline. In 
contrast to the low fat diet group, which had significantly lower fibre intake post 
intervention, a modest increase in the fibre intake was noted in the balanced diet 
group. Only total calories achieved a statistically lower value in follow-up than 
baseline [baseline 2023.6±365.2kcal versus follow-up: 1713.9±461.6kcal; p<0.05] 
(Table 6.4.4.1). 
Table 6.4.4.1 Differences in Dietary Intake According to Diet Type (Overweight+ 
Group) 
 
 
Parameters 
Low Fat Diet N = 12 Balanced Diet N = 12 
Baseline Post-Intervention Baseline  Post-Intervention 
Carbohydrates 
     Grams 
     % DRI 
 
198.9 ± 42.7 
153.1 ± 32.9 
 
179.1 ± 34.2 
137.8 ± 26.3 
 
215.6 ± 38.4 
165.9 ± 29.6 
 
194.0 ± 47.8 
149.2 ± 36.8 
Protein 
     Grams 
     % DRI 
 
68.0 ± 29.5 
147.86 ± 64.2 
 
59.5 ± 19.2 
129.4 ± 41.8 
 
62.0 ± 20.1 
134.8 ± 43.8 
 
53.4 ± 15.9 
116.2 ± 34.6 
Fats  
     Grams 
     % DRI 
 
94.8 ± 14.9 
173.76 ± 33.86 
 
75.0 ± 17.44* 
136.2 ± 28.7* 
 
101.4 ± 32.5 
134.8 ± 43.8 
 
80.4 ± 33.6 
116.2 ± 34.6 
Fibre 
     Grams 
     % DRI  
 
8.2 ± 1.69 
32.7 ± 6.77 
 
6.13 ± 2.29** 
24.6 ± 9.2** 
 
12.3 ± 9.4 
49.3 ± 37.9 
 
13.1 ± 8.6 
52.5 ± 34.4 
Total Calories 
    Kilocalories 
     % DRI  
 
1921.2 ± 167.6 
101.9 ± 9.7 
 
1629.4 ± 166.7** 
86.3 ± 7.7** 
 
2023.6 ± 365.2 
117.9 ± 26.3 
 
1713.9 ± 461.6* 
99.6 ± 28.6* 
 
Note: Data presented as mean ± standard error; * denotes significance at 0.05 level; 
** denotes significance at 0.01 level. 
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6.4.5 Associations of macronutrient intake to variables measured 
post intervention 
Bivariate associations were examined in both the T2DM and overweight+ 
group to determine existing correlations between the macronutrient intake, 
anthropometrics, lipid profiles, glucose and endotoxin. A significant inverse 
association between endotoxin and dietary fibre intake was observed in all subjects 
at baseline (R=-0.34; p=0.024) but was lost after follow-up (Figure 6.4.5.1). 
Furthermore, a near significant positive association was noted between dietary fibre 
intake and HDL-cholesterol also at baseline, but not after intervention (Figure 
6.4.5.2). These associations were lost after stratification to T2DM and overweight+. 
No other associations were elicited. 
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Figure 6.4.5.1 Inverse association between endotoxin and dietary fibre intake at 
baseline (A) and post intervention (B) 
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Figure 6.4.5.2 Positive association between dietary fibre intake and HDL-
Cholesterol at baseline (A) and post intervention (B) 
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6.5 Discussion 
 In this chapter the effects of two types of 3-month dietary interventions (low 
fat versus balanced diet) were examined to determine the effects on anthropometric, 
lipids, glucose and endotoxin profile of overweight+ and T2DM patients. Upon 
comparing baseline and follow-up results, it appeared that T2DM patients had a 
more favourable response to the low fat as opposed to the balanced diet, while the 
overweight+ group seemed to benefit more from the balanced diet rather than the low 
fat diet. The more improved metabolic profile in the T2DM group receiving the low 
fat diet may have been the result in part due to significant weight loss, a finding not 
observed in the balanced diet group. Hypocaloric diets aimed at reducing dietary fat 
intake has been shown to sustain a modest but significant weight loss, which in turn 
may reduce the pathogenesis of T2DM complications such as cardiovascular 
diseases (Swinburn et al, 2001; Hooper et al, 2012). However, while the intervention 
in the study itself implied “low fat diet”, the significant caloric restrictions was not 
limited to dietary fat alone, since significantly lower differences were also observed 
in carbohydrates and proteins and total caloric intake, which, cumulatively, 
improved the over-all metabolic profile of T2DM patients in this group. This is 
important to note since reductions in dietary fat intake with no change in total caloric 
intake, for example, is an ineffective weight loss strategy (Walker and Parker, 2014). 
 On the same premise weight loss also led to a better cardiometabolic profile 
in the overweight+ group and although the group benefited from both dietary 
interventions, the improvements were more apparent with the balanced diet 
intervention. A well-balanced diet, on its own, has been shown to induce fat loss in 
both animal and human studies (Gerbaix et al, 2013; Di Daniele et al, 2013). 
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Furthermore, while the low fat diet intervention in the present study significantly 
reduced the total caloric intake post intervention, this did not translate to significant 
weight loss. One explanation for the lack of weight loss may be due to changes in 
dietary fibre intake, which significantly decreased in the low fat group after 3 
months. Dietary fibre is important for weight loss, since it increases total energy 
expenditure by providing the added thermic heat in foods (Higgins, 2014). 
Furthermore, recently identified genetic variants that influence weight loss such as 
TCF7L2 have been shown to be modulated by dietary fibre intake (Haupt et al, 2010; 
Heni et al, 2012). Several meta-analyses studies also showed an independent 
association between dietary fibre intake and coronary heart disease risk, with a dose 
dependent cardioprotective effect (Wu et al, 2014; Pereira et al, 2014). Another 
notable finding from this current study was the inverse association between 
endotoxin and dietary fibre intake in all subjects at baseline. Dietary fibre has been 
shown to improve intestinal barrier and decrease bacterial translocation secondary to 
endotoxinaemia in animal studies (Hou et al, 2010; Wan et al, 2010; Sherry et al, 
2010). In humans, a high fibre diet has been shown to prevent increases in endotoxin 
levels, most likely through the modulation of certain gut hormones which in turn, 
strengthens the intestinal wall (Weickert and Pfeiffer, 2008). Compared to a high fat 
meal challenge, which causes acute rise in circulating endotoxin levels, a high fibre 
diet does not seem to alter endotoxin concentrations (Ghanim et al, 2009; Harte et al, 
2012). Aside from the protective effect of dietary fibre against endotoxinaemia, the 
present study also noted a borderline significant association between HDL-
cholesterol and dietary fibre intake. This confirms the well-established benefits of 
increased fibre consumption in improving certain blood lipid components and even 
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T2DM, secondary to its viscous and gel forming properties (Weickert and Pfeiffer, 
2008; Isken et al, 2010; Nutall, 1993).  
 In both the T2DM and overweight+ groups, the first metabolic risk factors to 
improve were total and LDL-cholesterol independent of weight loss. These 
favourable changes in cholesterol levels affirm other similar short term intervention 
studies (Milsom et al, 2014; Chen et al, 2009; Kim et al, 2012). It has been well 
known that plasma lipids are subject to fairly rapid changes depending on the dietary 
fatty acid intake in energy-balance states, with decreases in total and LDL-
cholesterol apparent for active weight loss and improvements HDL-cholesterol 
depending on energy restriction duration as well as type of dietary fat (Noakes and 
Clifton, 2000). 
 The present study was limited by the small sample size. Several modest 
improvements including HDL-cholesterol and other anthropometric measures may 
have been more apparent if a larger cohort was used. The findings of the study are 
also limited to women who were overweight+ and/or had T2DM. As such, findings 
may not be applicable to men and children. How the type of diet restriction affects 
other markers (inflammation, aging, immunity) aside from the conventional 
biomarkers used in the present study warrant future investigations.  
Nevertheless and as it stands, there is scarcity of information with regards to 
dietary intervention studies among patients with T2DM in Saudi Arabia and in the 
Gulf region in general. Thus, findings from this chapter have significant strengths 
and clinical implications, especially in the kingdom of Saudi Arabia where the 
prevalence of T2DM and obesity is high (Al-Daghri et al, 2011).  
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In conclusion, a 3-month low fat diet without exercise resulted to a more favourable 
metabolic profile in the T2DM group, while a balanced diet, again without exercise, 
seems to be more favourable amongst the overweight+ group, suggesting that a 
uniform weight loss strategy through dietary interventions may not apply in all high 
risk groups. A customized approach may prove effective in the over-all aim of 
T2DM prevention in this population. Further studies on a larger scale, taking into 
consideration other populations such as men, high-risk children and the elderly are 
needed to identify which dietary interventions will prove most beneficial. 
 
 
 
 
 
 
Chapter 7 
 
 
Final Discussion 
 
 
 
  
175 
 
7.1 Discussion 
The increasing importance of endotoxin (metabolic endotoxinaemia) as a 
mediator of sub-chronic inflammation amongst patients with obesity and insulin 
resistance has been gaining supportive evidence over the past few years. Metabolic 
endotoxinaemia appears a causal factor in obesity- and insulin resistance-related 
inflammatory states (Boroni Moreira and de Cassia Goncalves Alfenas, 2012), and 
this factor appears to be regulated through diet and dietary interventions that can 
change the gut microbiota and endotoxin over load (Kemp, 2013). Furthermore, 
there is also increasing evidence that suggests that the endotoxin binding protein, 
known as the lipoprotein-binding protein, which is found both systemically and at 
the surface of adipocytes, when coupled with endotoxin can promote inflammation 
in insulin-resistance states and enhance adipose tissue dysfunction (Liu et al, 2014; 
Moreno-Navarrete et al, 2011; Moreno-Navarrete et al, 2013). As such the ability to 
change microbiota appears key and previous studies recommend exploration of diet 
and nutrient intake which improve the microbial imbalance known as dysbiosis, 
which is observed in patients with obesity and T2DM. To date however, there are 
limited studies focusing on the effects of dietary interventions on circulating 
endotoxin levels in either animal (Oz et al, 2013; Luyer et al 2004) or human studies 
(Lira et al, 2012, Xiao et al, 2014). Consequently and to the best of our knowledge, 
population-based studies utilising the Arab population, who are at heightened 
metabolic risk, as not been undertaken before and represents a novel and urgent 
study.   
From early investigations of the dietary intervention that was undertaken for 
this thesis it was observed that the cardiometabolic parameters of adult Saudi women 
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per se was significantly different from one another, and that this was largely 
dependent on their current metabolic state. From the analysis of the patients it was 
observed the anthropometric measurements, glucose and lipids were higher in T2DM 
subjects than overweight and control subjects secondary to the underlying insulin-
resistance and metabolic syndrome present in these subjects (Boden and Laakso, 
2004). It has also been observed that the aforementioned risk factors appear to 
impact on intestinal permeability, translating to a weakened epithelial barrier 
function in the T2DM subjects and to some extent, the overweight group, leading to 
a significantly higher circulating endotoxin capability as compared to control 
subjects as noted in other studies as well (de Kort et al, 2011).   
Furthermore following a standardized high fat meal, post prandial lipidaemia 
was evident in all groups but more so for the overweight+ and T2DM group, 
confirming previous studies on high fat meal’s exacerbating effects in the lipid 
profiles of at-risk groups (Madhu et al, 2008; Kumar et al, 2010) secondary to the 
lower peripheral clearance of high fat meals in patients with obesity and insulin 
resistance as compared to lean healthy subjects (Lambert and Parks, 2012). Post 
prandial endotoxemia was also evident in the T2DM and overweight+ groups 
compared with the control group suggesting there is a heightened sub-inflammatory 
risk following a high fat meal in Arab women in a similar fashion so the previous 
studies on South Asian women with and without obesity and T2DM (Harte et al, 
2012). The findings from the early results chapter reinforce previous findings on 
metabolic endotoxemia, its associations to known cardiometabolic indices and its 
response to a high fat meal challenge. To the best of our knowledge, these 
observations are the first of its kind in the Middle-Eastern region. Clinical 
implications of these findings are therefore far-reaching, especially in a region where 
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existing culture and traditions are already favorable to the development of non-
chronic communicable diseases, and only made worse by the rapid industrialization 
and burgeoning rise of fast food chains. 
In the subsequent chapters of the thesis it was observed how a 3-month 
caloric restriction diet can induced beneficial cardiometabolic effects in the 
overweight+ and T2DM subject groups. Whilst is was already anticipated that there 
would be weight loss on such a diet it was interesting to observe how dietary 
modifications could also improve the cardiometabolic health of subjects (Wygant et 
al, 2014; Soare et al, 2014; Speakman and Mitchell 2011). Although the study may 
seem relatively simple in outlook there is a severe lack of dietary intervention studies 
in the region, specifically in Saudi Arabia, where most prospective studies focus on 
the effects of health during the holy month of Ramadan which has nothing to do with 
caloric restriction (Aljabnoor et al, 2014; Al-Mendalawi, 2011; Khatib and Shafagoj 
2004). Furthermore most other studies in the region appear to provide review 
analysis or cross-sectional studies on the dietary habits of the population (Al-
Muammar et al, 2014; Al-Khudairy et al, 2013; Al-Daghri et al, 2013). Thus these 
studies were undertaken to provide the first pieces of evidence that such dietary 
intervention can work in a Saudi culture to fill the gaps in existing knowledge. 
Interestingly, the responses of both the T2DM and overweight+ groups varied 
depending on the type of dietary intervention provided (low fat versus balanced-
diet), with the low fat diet being more favorable in the T2DM group and the 
balanced diet more compatible with the overweight group, suggesting a tailored 
strategy in the management of these metabolic conditions in the Middle-Eastern 
population. 
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Further findings also explored the significance of dietary components, such 
as protein and carbohydrate on health which observed that fibre contents appeared to 
be important. These current studies highlighted the significant inverse relationships 
between dietary fibre, HDL-cholesterol and circulating endotoxin. Dietary fibre has 
been previously observed to strengthen the intestinal barrier and inhibit endotoxin 
release in the circulation in animal studies (Hou et al, 2010; Wan et al, 2010) and is 
known to be protective against a plethora of gastronintestinal diseases in humans 
(Otles and Ozgoz, 2014). Inulin, which is a form of dietary fibre, was observed to 
improve metabolic endotoxemia and other inflammatory markers in women with 
T2DM (Dehghan et al, 2014; Poughassem et al, 2013), and increased dietary fibre 
intake through supplementation on its own or in addition to caloric restriction can 
induce beneficial weight loss (Reichert et al, 2014). The ability of dietary fibre to 
induce weight loss is due its properties to increase production of glucagon-like 
peptide (GLP-1) and peptide YY (PYY), hormones that induce satiety, as well as its 
ability to decrease both energy and fat intake (Lattimer and Haub, 2010), making it 
clinically useful as a non-pharmacologic intervention in improving cardiovascular 
health in obese and T2DM patients (Fujii et al, 2013). Taken together, it appears that 
the promotion of dietary fibre intake in the overweight, obese and T2DM population 
in the Middle East has a potential role in decreasing risk of metabolic endotoxemia 
and improving their over-all cardiometabolic conditions.  
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7.2 Limitations of the Current Studies 
Some of the caveats have already been mentioned in the previous chapters, 
however the subjects used in these studies were all women this was due to religious 
and cultural reasons that prohibit the student from interacting with the opposite 
gender. Hence, the findings may not be applicable to overweight and T2DM Arabic 
men. Furthermore whilst adipose tissue is important in the inflammation response 
and the inflammatory gene expression could have changed over a 3 month dietary 
intervention study, no adipose tissue biopsies were obtained. This lack of adipose 
tissue biopsies was in part as there was a lack of previous Arab studies to determine 
whether the dietary intervention would work successfully in a Saudi environment, 
Furthermore it was considered that an additional procedure may have significantly 
impacted on subject recruitment and jeopardized the principal study objectives. As 
such, there are limited mechanistic insights from the studies undertaken; although 
subsequent studies could examine this aspect which was felt to be beyond the scope 
of this thesis. The lack of control subjects in the intervention study could be 
considered another limitation as we could not assess the direct effect with the control 
group at three months. Nevertheless it was deemed inappropriate for the control 
healthy lean group to go on such a diet by the ethics committee. With respect to the 
methods, the validity of the technique used for the quantification of endotoxin (LAL 
assay) has been previously questioned despite being the most widely used assay for 
this type of investigation and validated in the labs on my thesis research; however as 
with all studies, findings should be interpreted with caution (Creely et al, 2007; 
Hansen et al, 2013). Lastly, although the dietary questionnaires used have been 
previously utilized in several publications from the group, it has not been validated 
and this may still introduce bias in the results. Nevertheless, the studies conducted 
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have considerable merits in being the first dietary intervention study in the Middle 
East focusing on metabolic endotoxemia among women with varying metabolic 
states.  
7.3 Future Directions 
This thesis has highlighted the clinical importance of diet and nutrition as an 
important strategy in the reduction of obesity and T2DM in the women of Middle 
Eastern region. As one of the first dietary interventional studies performed in the 
Arab region, the thesis suggests that despite the lack of readily definable portion 
sizes due to the buffet style of eating in Saudi there are opportunities to undertake 
future successful prospective investigations. One of these studies could extend the 
time the Saudi women were studied for, as due to time restrictions the current thesis 
studies only examined diet over a 3 month duration with avoidance of Ramadan 
noting the second study would have to involve Ramadan as part of the study time. 
Furthermore the current studies were only undertaken in women and may not be 
applicable to men or the same success might not have been achieved. Therefore now 
with this baseline study it would be of interest to see whether men show the same 
levels of benefit over the 3 month period. Furthermore the effect of a high fat oral 
challenge should be investigated in Arab men subjects as well to see gender-specific 
differences in cardiometabolic parameters, including endotoxin. It would also be 
important to investigate in detail how different nutritional compositions in the diet 
can alter endotoxin levels and the gut microbiota in general which in turn will lead to 
over-all improvement in the cardiovascular health of at risk patients. Future 
interventional clinical trials are warranted to serve as compelling evidence of the role 
of subtle dietary intervention to improve health and lower the economic burden of 
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metabolic disease in the Saudi health system. Finally, the exploration on the roles of 
dietary fibre appears important as well as other products such as probiotics that can 
promote beneficial bacterial floras, improve gut barrier integrity lowering systemic 
metabolic endotoxinaemia. Subjects that can undertake subtle dietary interventions 
to begin to lower metabolic risk could have a large impact on health. Such studies 
may also help patients to reduce food intake and boost the already clear benefits of 
caloric restriction observed in the present thesis. A clinical trial on the use of 
probiotics in an Arab population has just begun and the results of this will be 
interested and may support further ways to promote metabolic health in Saudi 
(Alokail et al, 2013). 
7.4 Conclusion 
This current thesis undertaken exclusively on Saudi Arabian women with 
varying metabolic states, has sought to expand our knowledge and understanding on 
how metabolic endotoxemia differs in the presence of T2DM, obesity and weight 
loss compared to lean, non-T2DM subjects. Also these studies have examined how 
an acute high fat oral challenge exacerbates cardiometabolic and inflammatory 
conditions of at risk groups, and how a 3-month caloric restriction in the absence of 
exercise and other pharmacologic interventions may still confer beneficial weight 
loss that translates to immediate improvement in cardiometabolic health. Whilst it is 
clear that longer prospective studies, with the inclusion of other populations such as 
men and children at risk are necessary to reinforce the present findings, the current 
observations from this present study offer tremendous clinical potential in the over-
all aim of curbing the prevailing obesity and T2DM epidemic engulfing the Middle 
East region. 
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Appendix II: Consent form 
 
Title of the Research Project 
A dietary interventional moderating fat intake in Saudi subjects with metabolic 
disease. 
 
You are being asked to participate voluntarily in a Research Study. If you decide to 
take part in this study, please sign this consent form and return it. 
STUDY PURPOSE: to study the effect of fat rich meal, diet and dietary supplement 
on inflammatory biomarkers among Saudi subjects with metabolic disease. 
STYDY PLAN: Informed consent will be obtained from all participants. Subjects 
will be grouped into one of the following: Type 2 diabetes (on diet alone), 
overweight subjects and insulin resistant group. These subjects will eat, on different 
days: (1) a high-fat meal (whipping cream) and (2) glucose solution. Blood samples 
will be drawn at 0,1,2,3, and 4 hours (5 times), and the following biomarkers will be 
assayed: endotoxin, blood glucose level, plasma lipid level, insulin resistance. 
BENEFITS: The result of this study may help you to improve your life style by 
adapting a healthy dietary regimen that is considered a mean to reduce the risk of 
metabolic disease and their complications. In addition, in the future with God's will 
the patients will benefit from the knowledge acquired. 
SIDE EFFECT: There are no side effects. Your participation in this study does not 
have any further risks or discomfort to you. If you are diabetic; the meal provided 
may increase the blood glucose level which will be controlled by the researcher. 
REFUSEL: If you refuse to participate, in this study will be kept confidential. The 
results of this research may be published, however your identity will never be 
revealed. 
APPROVAL: I fully understand the information and the consent form; therefore I 
agree to participate in this study. In addition, I do not mind using the all the 
components of the samples obtained from me in this and in future studies by the 
investigators in the Obesity Research Center and their collaborators. This form has 
been explained to the participant by one of the investigators before his signature. 
I sign freely and voluntarily. A copy has been given to me. 
Investigator or Associate: 
                           Dr. 
Signature Date: 
Patient Name: 
Signature Date: 
Witness Names: 
Signature Date: 
 
If you have any further concerns or questions, you can contact Dr. Assim A. Al-
Fadda (email: aalfadda@ksu.edu.sa) 
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Appendix III: Interview Questionnaire 
 
Serial No. :……………………………... Date:     /     / 201 
National ID: …………………………… Name: ………………………………. 
Sex:   (     ) M                 (       ) F   Age: ………………………………… 
Birth Date:    /     /   Place: ……………………… Telephone: ………………………….. 
Marital status Single Married Divorced Widowed Child 
*If you married is your wife or husband your relative?  
No                                Yes   
Relative Degree   1st  degree        2nd degree     
Socio-economic 
status 
 
Annual income Job  Education  
No income   Government Uneducated  
 5000 SAR > Private  Pre. College 
1000 – 5000 SAR Retired  College   
10000 – 20000 SAR No work  High Edu.  
20000 SAR<   
Family history 
Diabetes 1st degree 
 
Diabetes 2nd degree 
                 
Father   Mother   Brother/Sisters Uncle Grandpa/ma    Grandchildren 
Hypertension Hyperlipidemia Asthma Obesity CHD Cancer: ……………… 
……………………… 
Others: _________________________________________________________________________ 
 
Subject Medical history 
CHD  (       )   
 
HTN (      )  (    )  Dyslipidemia     (    ) Diabetes       (    ) Asthma (     ) Cancer    
(    ) Liver 
Disease 
(    ) Kidney 
Disease 
 
Others: 
_____________________________________________________ 
Smoking: (adults): 
(     ) Smoker       (      ) Sheshan          (   ) Ex-Smoker      
(     ) Never smoked # of packs/day 
_____________ 
# of packs/day 
____________ 
Duration (years): 
……………… 
Years quitted: …………... 
Examination: 
Wieght 
_______ (cm) 
Height      
_______ (cm)  
     
Waist   
_______ (cm)      
   
Hip  
_______ (cm) 
SAD 
_______ (cm) 
Blood Pressure: /  
Type of Diabetes: 
Type 1 Diabetes Type 2 Diabetes IGT GDM Other types         
     
Duration:_____ 
years 
Complications: 
 
DKA                    Per year…………        Hyperglycemia       Per year……… 
Nephropathy Retinopathy Nephropathy Vasculopathy Laser 
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Foot ulcer 
 
Dialysis Cataract IHD CVA PVD 
Handicap: Blindness 
Amputation Stroke  
 
Dialysis 
 
Heart failure Deafness Muteness 
Treating Physician:       
General practitioner Internist Endocrinologist 
Physical activity (adults):           
                     
(      ) Yes (      ) No    
If yes, please answer the following questions: 
 
Frequency of physical activity: 
 
Daily         3-4 times a week         1-2 times a week          Few times a month          Once a month 
Types of activity   Frequency (minutes) 
Hard physical exercise (e.g. Running, bicycling……..)     
High physical exercise (Tennis, Handball,)                             
                      
    
Middle (1) physical exercise (Volleyball walking, house 
cleaning……) 
    
Middle (2) physical exercise (Table tennis, housekeeping,)    
                                                    
    
Low physical exercise (Normal walking, ironing, dish 
washing,)                                            
    
No. of sleeping hours (       )     (        ) separated (       ) connected 
For female Subjects Only 
Age at Menarche________________  
 
Years of Menopause (For menopausal only): ____________  
 
Are you pregnant?             [    ] Yes   [     ] No           [      ] week   
 
Age at 1st pregnancy: ____________ 
 
History of Hormone Replacement Therapy (HRT):   
 
[     ] Yes     [    ]  No  
History of GDM                
 
[    ] Yes         [    ]  No 
History of mammogram    
 
[    ] Yes         [     ]   No 
History of Breast Lesions         
 
[    ] Yes [     ]  No       (Specify)_________                                                                                                           
History of Breast Surgery  
 
[    ] Yes        [     ]  No        Date   /     /    
Breast Examination           
 
[     ] Never    [   ] Occasional      [     ] Regular 
186 
 
List of Medications 
(Place a check on all medications used by the subject) 
Anti-diabetic Agents 
 
 [    ] Warfarine    
[    ] Insulin – insulin analogues Statins [    ] Heparin  
 
[    ] Tolbutamide – Orinase 
 
[    ] Clopidogrel 
 
[    ] Tolazamide – Tolinase 
 
[    ] Amiodarone – Amiodarone, Cordarone 
 
[    ] Chlorpropramide – Diabenese 
 
[    ] Disopyramide – Rythmodan 
 
[    ] Glipizide – Glucotrol 
 
[    ] Flecainide acetate – Apo – Flecainide 
 
[    ] Glyburide – Micronase, Diabeta 
 
[    ] Mexiletine – Novo – Mexiletine 
 
[    ] Glimepiride – Amaryl 
 
[    ] Procainamide – Procan 
 
[    ] Gliclazide – Diamicron 
 
[    ] Propafenone – Rhythrnol, Nu, Apo, Gen, PMS 
 
[    ] Repaglinide 
 
[    ] Digoxin 
 
[    ] Acarbose 
 
[    ] Clonidine 
 
[    ] Metformin – Repaglinide Thiazolidinediones 
 
[    ] Methyldopa 
 
[    ] Pioglitazone – Actos 
 
[    ] Diazoxide 
 
[    ] Rivoglitazone 
 
[    ] Hydralazine 
 
[    ] Rosiglitazone – A vandia 
 
[    ] Isosarbide dinitrate 
 
[    ] Troglitazone 
 
[    ] Nitroglycerin 
 
Anti-Hyperlipidemics 
 
[    ] Prazosin, Terazosin, Dozazosin 
 
[    ] Atorvastatin – Lipitor, Torvast 
 
[    ] Atenolol, Acebutolol, Bisoprolol, Labetalol, 
Metaoprolol, Nadolol, Oxprenolol, Pndolol, 
Propranolol, Sotalol, Timolol 
[    ] Cerivastatin – Lipobaby 
 
[    ]  Amlodipine, Felodipine, Nifedipine 
[    ] Fluvastatin – Lescol, Lescol XL 
 
[    ] Diltiazem, Verapamil 
 
[    ] Lovastatin – Mevacor, Altocor, Altoprev 
 
[    ] Captopril, Benazepril, Enalapril, Cilazapril, 
Perindopril, Quinapril, Ramipril, Lisinopril 
[    ] Mevastatin 
 
[    ] Candesartan, Irbesartan, Losartan, Telmisartan, 
Valsartan 
[    ] Pitavastatin – Livalo, Pitava [    ] Spironolactone 
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[    ] Pravastatin – Pravachol, Selektine, Lipostat 
 
[    ] Hydrochlorothiazide 
 
[    ] Rosuvastatin – Crestor 
 
[    ] Furosemide 
 
[    ] Simvastatin – Zocor, Lipex 
 
[    ] Pentoxyphylline 
 
[    ] Simvastatin + Ezetimibe – Vytorin 
 
Other (Please specify)  
 
_________________________________ 
_________________________________ 
_________________________________ 
_________________________________ 
_________________________________ 
 
[    ] Atorvastatin + Amlodipine – Caduet 
 
[    ] Simvastatin + Niacin – Simcor 
 
[    ] Cholestyramine 
[    ] Colestipol 
 
 
[    ] Benzafibrate, fenofibrate 
 
 
[    ] Gemfibrozil 
 
 
Cardiovascular drugs 
 
 
[    ] Aspirin    
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Appendix IV: Food frequency questionnaire 
 
Please circle the appropriate number to the number of times the consumption 
of food or drink daily or weekly, and tick the box when you choose rarely. 
 
Food Item                    Daily         Weekly          Rarely Weight (gm) 
White bread          1 2 3                     1 2 3 4 5 6  
Brown bread  1 2 3                     1 2 3 4 5 6  
Rice 1 2 3                     1 2 3 4 5 6  
Pasta     1 2 3                     1 2 3 4 5 6  
Potatoes  1 2 3                     1 2 3 4 5 6  
 Algreesh   1 2 3                     1 2 3 4 5 6  
Alsliq  1 2 3                     1 2 3 4 5 6  
Alqursan  1 2 3                     1 2 3 4 5 6  
Almarquq 1 2 3                     1 2 3 4 5 6  
Lamb  1 2 3                     1 2 3 4 5 6  
Beef  1 2 3                     1 2 3 4 5 6  
Chicken 1 2 3                     1 2 3 4 5 6  
Burger   1 2 3                     1 2 3 4 5 6  
Pizza  1 2 3                     1 2 3 4 5 6  
Fried chicken       1 2 3                     1 2 3 4 5 6  
French Fries  1 2 3                     1 2 3 4 5 6  
Sausage  1 2 3                     1 2 3 4 5 6  
Fish         1 2 3                     1 2 3 4 5 6  
Tuna          1 2 3                     1 2 3 4 5 6  
Shrimp       1 2 3                     1 2 3 4 5 6  
Liver  1 2 3                     1 2 3 4 5 6  
Eggs  1 2 3                     1 2 3 4 5 6  
Cheese        1 2 3                     1 2 3 4 5 6  
Milk   1 2 3                     1 2 3 4 5 6  
Buttermilk        1 2 3                     1 2 3 4 5 6  
Yoghurt  1 2 3                     1 2 3 4 5 6  
Beans          1 2 3                     1 2 3 4 5 6  
Lentils   1 2 3                     1 2 3 4 5 6  
Chickpeas     1 2 3                     1 2 3 4 5 6  
Nuts     1 2 3                     1 2 3 4 5 6  
Apples        1 2 3                     1 2 3 4 5 6  
Dates  1 2 3                     1 2 3 4 5 6  
Watermelon  1 2 3                     1 2 3 4 5 6  
Oranges      1 2 3                     1 2 3 4 5 6  
Bananas         1 2 3                     1 2 3 4 5 6  
Melon  1 2 3                     1 2 3 4 5 6  
Grapes        1 2 3                     1 2 3 4 5 6  
Mango       1 2 3                     1 2 3 4 5 6  
Pear           1 2 3                     1 2 3 4 5 6  
Tangerine      1 2 3                     1 2 3 4 5 6  
Apricot  1 2 3                     1 2 3 4 5 6  
Strawberries   1 2 3                     1 2 3 4 5 6  
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Dried fruits        1 2 3                     1 2 3 4 5 6  
Tomatoes           1 2 3                     1 2 3 4 5 6  
Cucumber   1 2 3                     1 2 3 4 5 6  
Lettuce      1 2 3                     1 2 3 4 5 6  
Watercress         1 2 3                     1 2 3 4 5 6  
Zucchini          1 2 3                     1 2 3 4 5 6  
Eggplant      1 2 3                     1 2 3 4 5 6  
Orange Juice     1 2 3                     1 2 3 4 5 6  
Other Juices      1 2 3                     1 2 3 4 5 6  
Soft drinks  1 2 3                     1 2 3 4 5 6  
Black Tea   1 2 3                     1 2 3 4 5 6  
Green Tea   1 2 3                     1 2 3 4 5 6  
Coffee       1 2 3                     1 2 3 4 5 6  
Chocolate  1 2 3                     1 2 3 4 5 6  
Chilled desserts  1 2 3                     1 2 3 4 5 6  
Popcorn  1 2 3                     1 2 3 4 5 6  
Cake  1 2 3                     1 2 3 4 5 6  
Doughnuts  1 2 3                     1 2 3 4 5 6  
Grain corn  1 2 3                     1 2 3 4 5 6  
Unsweetened grain corn    1 2 3                     1 2 3 4 5 6  
Biscuits  1 2 3                     1 2 3 4 5 6  
Honey     1 2 3                     1 2 3 4 5 6  
Jam        1 2 3                     1 2 3 4 5 6  
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Appendix V: Diets 
Low Fat Diet 
1000 calories (25% fat, 27 g of fat) 
Breakfast 
 One egg or 30 g cheese or three spoons of beans 
 Half a loaf of Arabian bread or two slices of bread 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Cup of fresh vegetables salad 
 Half a spoon of oil 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Dinner 
 30 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 A cup of boiled vegetables 
 Fresh vegetables salad 
 Coffee or tea without sugar 
Bed-time snack 
 One cup of low-fat milk, butter milk or yogurt without sugar 
 
 
1200 calories (25% fat 35 g of fat) 
Breakfast 
 One egg or 30 g of cheese or 3 spoons of beans 
 Half a loaf of Arabian bread or two slices of bread or half a cup of cornflakes 
 One cup of low-fat milk, butter milk or yogurt without sugar 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Cup of fresh vegetables salad 
 Half a spoon of oil 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Dinner 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
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 Half a cup of boiled vegetables 
 Fresh vegetables salad 
 One serving of fruits or half a cup of fruit juice without sugar 
 Coffee or tea without sugar 
Bed-time snack 
 3 pieces of tea biscuit or shaboura 
 
1400 calories (25% fat 37 g of fat) 
Breakfast: 
 One serving of fruits or half a cup of fruit juice without sugar 
 One egg or 30 g of cheese or 3 spoons of beans 
 Half a loaf of Arabian bread or two slices of bread or half a cup of cornflakes 
 One cup of low-fat milk, butter milk or yogurt without sugar 
 Coffee or tea without sugar 
Snack: 
 3 pieces of tea biscuit or shaboura 
Lunch 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 6 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Cup of fresh vegetables salad 
 Half a spoon of oil 
 Coffee or tea without sugar 
Snack 
 3  dates with coffee 
Dinner 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Fresh vegetables salad 
 One serving of fruits or half a cup of fruit juice without sugar 
 Coffee or tea without sugar 
Bed-time snack 
 One serving of fruits or half a cup of fruit juice without sugar 
 Half a cup of low-fat milk, or yogurt 
 
1600 calories (25% fat 45 g of fat) 
Breakfast: 
 One cup of low-fat milk 
 1 slice of cheese or 3 spoons of beans or 1 boiled egg twice a week or a piece 
of liver hand size once a week 
 Quarter loaf of Arabian bread medium size or one slice of bread or half of 
white bread 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 One cup of butter milk, or half cup of low fat yogurt 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
(hand size) 
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 6 spoons of rice or macaroni gursan or greeish or cooked potato or quarter 
loaf of brown bread 
 A cup of cooked vegetables 
 A plate of fresh vegetables unsliced 
 One serving of fruits or half a cup of fruit juice without sugar 
Snack 
 3  dates with coffee 
Dinner 
 One cup of  milk or butter milk, or half cup of low fat  
 One serving of fruits or half a cup of fruit juice without sugar 
 2 slices of cheese or 6 spoons of beans or 60 g of meat or chicken without fat 
 Cup of cooked vegetables without fat 
 Quarter loaf of Arabian bread 
 Coffee or tea without sugar 
Bed-time snack 
 One serving of fruits or half a cup of fruit juice without sugar 
 Quarter loaf of brown bread  or one slice of toast or half slice of white bread 
 One slice of low fat cheese or one cup of low fat milk 
 
1800 calories (25% fat 52 g of fat) 
Breakfast 
 One cup of low-fat milk 
 1 slice of cheese or 3 spoons of beans or 1 boiled egg twice a week or a piece 
of liver hand size once a week 
 Quarter loaf of Arabian bread medium size or one slice of bread or half of 
white bread 
 One serving of fruits or half a cup of fruit juice without sugar 
Snack 
 3 pieces of tea biscuit or shaboura 
Lunch 
 One cup of butter milk, or half cup of low fat yogurt 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
(hand size) 
 6 spoons of rice or macaroni gursan or greeish or cooked potato without fat 
or quarter loaf of brown bread 
 A cup of cooked vegetables without fat 
 A plate of fresh vegetables unsliced 
 One serving of fruits or half a cup of fruit juice without sugar 
 One spoon of oil  
Snack 
 3  dates with coffee 
Dinner 
 One cup of  milk or butter milk, or half cup of low fat  
 One serving of fruits or half a cup of fruit juice without sugar 
 2 slices of cheese or 6 spoons of beans or 60 g of meat or chicken without fat 
 Cup of cooked vegetables without fat 
 half loaf of Arabian bread 
 Coffee or tea without sugar 
 One spoon of oil  
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Bed-time snack 
 One serving of fruits or half a cup of fruit juice without sugar 
 Quarter loaf of brown bread  or one slice of toast or half slice of white bread 
 One slice of low fat cheese or half cup of low fat milk 
 
2000 calories (25% fat 57 g of fat) 
Breakfast 
 One cup of low-fat milk 
 1 slice of cheese or 3 spoons of beans or 1 boiled egg twice a week or a piece 
of liver hand size once a week 
 Half loaf of Arabian bread medium size or one slice of bread or half of white 
bread 
 One serving of fruits or half a cup of fruit juice without sugar 
Snack 
 3 pieces of tea biscuit or shaboura 
Lunch 
 One cup of butter milk, or half cup of low fat yogurt 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
(hand size) 
 6 spoons of rice or macaroni gursan or greeish or cooked potato without fat 
or quarter loaf of brown bread 
 A cup of cooked vegetables without fat 
 A plate of fresh vegetables unsliced 
 One serving of fruits or half a cup of fruit juice without sugar 
 One spoon of oil  
Snack 
 3  dates with coffee 
Dinner 
 One cup of  milk or butter milk, or half cup of low fat yogurt 
 One serving of fruits or half a cup of fruit juice without sugar 
 2 slices of cheese or 6 spoons of beans or 60 g of meat or chicken without fat 
 Cup of cooked vegetables without fat 
 half loaf of Arabian bread 
 Coffee or tea without sugar 
 One spoon of oil  
 Bed-time snack: 
 One serving of fruits or half a cup of fruit juice without sugar 
 Half loaf of brown bread  or one slice of toast or half slice of white bread 
 One slice of low fat cheese or half cup of low fat milk 
 
Balanced Diet 
1000 calories (30% fat 32g of fat) 
Breakfast 
 One egg or 30 g cheese or three spoons of beans 
 Half a loaf of Arabian bread or two slices of bread 
 Coffee or tea without sugar 
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Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Cup of fresh vegetables 
 Half a spoon of oil 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Dinner 
 30 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Fresh vegetables salad 
 Half a spoon of oil 
 Coffee or tea without sugar 
Bed-time snack 
 One cup of low-fat milk, butter milk or yogurt without sugar 
 
1200 calories (30% fat 30 g of fat) 
Breakfast 
 One serving of fruits or half a cup of fruit juice 
 One egg or 30 g of cheese or 3 spoons of beans 
 Half a loaf of Arabian bread or two slices of bread or half a cup of cornflakes 
 One cup of low-fat milk, butter milk or yogurt without sugar 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Cup of fresh vegetables salad 
 1 spoon of oil 
 Coffee or tea without sugar 
Snack 
 3  dates with coffee 
Dinner 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Fresh vegetables salad 
 1 spoon of oil 
 Coffee or tea without sugar 
Bed-time snack 
 11/2 pieces of tea biscuit or shaboura 
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1400 calories (30% fat 47 g of fat) 
Breakfast 
 One egg or 30 g of cheese or 3 spoons of beans 
 Half a loaf of Arabian bread or two slices of bread or half a cup of cornflakes 
 One cup of low-fat milk, butter milk or yogurt without sugar 
 Coffee or tea without sugar 
Snack 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Half a cup of boiled vegetables 
 Cup of fresh vegetables salad 
 1 spoon of oil 
 One serving of fruits or half a cup of fruit juice without sugar 
 Coffee or tea without sugar 
Snack 
 3 pieces of tea biscuit or shaboura 
Dinner 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
 3 spoons of rice or macaroni gursan or greeish or cooked potato 
 Fresh vegetables salad 
 One serving of fruits or half a cup of fruit juice without sugar 
 Coffee or tea without sugar 
Bed-time snack 
 One serving of fruits or half a cup of fruit juice without sugar 
 Half a cup of low-fat milk, or yogurt 
 
1600 calories (30% fat 52 g of fat) 
Breakfast: 
 One cup of low-fat milk 
 1 slice of cheese or 3 spoons of beans or 1 boiled egg twice a week or a piece 
of liver hand size once a week 
 Quarter loaf of Arabian bread medium size or one slice of bread or half of 
white bread 
Snack: 
 One serving of fruits or half a cup of fruit juice without sugar 
Lunch 
 One cup of butter milk, or half cup of low fat yogurt 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
(hand size) 
 6 spoons of rice or macaroni gursan or greeish or cooked potato or quarter 
loaf of brown bread 
 A cup of cooked vegetables 
 A cup of fresh vegetables unsliced 
 2 spoon of oil 
Snack 
 3  dates with coffee 
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Dinner 
 One cup of  milk or butter milk, or half cup of low fat  
 2 slices of cheese or 6 spoons of beans or 60 g of meat or chicken without fat 
 1 Cup of cooked vegetables without fat 
 Half loaf of Arabian bread 
 Coffee or tea without sugar 
Bed-time snack 
 One serving of fruits or half a cup of fruit juice without sugar 
 Quarter loaf of brown bread  or one slice of toast or half slice of white bread 
 One slice of low fat cheese or one cup of low fat milk 
 
1800 calories (30% fat 62 g of fat) 
Breakfast 
 One cup of low-fat milk 
 1 slice of cheese or 3 spoons of beans or 1 boiled egg twice a week or a piece 
of liver hand size once a week 
 Quarter loaf of Arabian bread medium size or one slice of bread or half of 
white bread 
 One serving of fruits or half a cup of fruit juice without sugar 
Snack 
 11/2 pieces of tea biscuit or shaboura 
Lunch 
 One cup of butter milk, or half cup of low fat yogurt 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
(hand size) 
 6 spoons of rice or macaroni gursan or greeish or cooked potato without fat 
or quarter loaf of brown bread 
 A cup of cooked vegetables without fat 
 A cup of fresh vegetables unsliced 
 2 spoons of oil  
Snack 
 3  dates with coffee or One serving of fruits or half a cup of fruit juice 
without sugar 
Dinner 
 One cup of  milk or butter milk, or half cup of low fat  
 One serving of fruits or half a cup of fruit juice without sugar 
 2 slices of cheese or 6 spoons of beans or 60 g of meat or chicken without fat 
 1 Cup of cooked vegetables without fat 
 half loaf of Arabian bread 
 Coffee or tea without sugar 
 2 spoons of oil  
Bed-time snack 
 One serving of fruits or half a cup of fruit juice without sugar 
 One slice of low fat cheese or half cup of low fat milk 
 
2000 calories (30% 67 g of fat) 
Breakfast 
 One cup of low-fat milk 
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 1 slice of cheese or 3 spoons of beans or 1 boiled egg twice a week or a piece 
of liver hand size once a week 
 Half loaf of Arabian bread medium size or one slice of bread or half of white 
bread 
 2 serving of fruits or a cup of fruit juice without sugar 
Snack 
 3 pieces of tea biscuit or shaboura 
Lunch 
 One cup of butter milk, or half cup of low fat yogurt 
 60 g of boiled or grilled meat or fish or chicken without the skin and fat 
(hand size) 
 6 spoons of rice or macaroni gursan or greeish or cooked potato without fat 
or quarter loaf of brown bread 
 A cup of cooked vegetables without fat 
 A cup of fresh vegetables unsliced 
 2 spoons of oil  
Snack 
 3  dates with coffe 
Dinner 
 One cup of  milk or butter milk, or half cup of low fat yogurt 
 One serving of fruits or half a cup of fruit juice without sugar 
 2 slices of cheese or 6 spoons of beans or 60 g of meat or chicken without fat 
 Cup of cooked vegetables without fat 
 half loaf of Arabian bread 
 Coffee or tea without sugar 
 2 spoons of oil  
Bed-time Snack  
 One serving of fruits or half a cup of fruit juice without sugar 
 Quarter loaf of brown bread  or one slice of toast or half slice of white bread 
 One slice of low fat cheese or half cup of low fat milk 
-------------------------------------------------------------------------------------------------- 
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Food Exchange list  
  
Altenative Alte 1 Alte 2 Alte 3 Alte 4 Alte 5 Alte 6 Alte 7 Alte 8 General notes 
Dairies 
group 
1 cup low 
fat milk 
1 cup low 
fat yogurt 
1 cup low fat 
buttermilk 
1/3 cup 
skimmed dried 
milk 
11/4 skimmed 
milk 
3/4 whole 
fat milk   
Drink low fat diary 
instead of whole 
fat one 
Meat group 
30g 
cooked 
meat 
30g 
cooked 
fish 
30g cooked 
chicken 
1/4 can lite 
tuna 3 egg whites 
30g low fat 
cheese 
2tsp low fat 
labnah 
1 tsp 
peanut 
butter 
Use lean meat 
before cooking 
Boiled or grilled 
meat more likely 
than fried one 
Fruits group 1 medium orange 
1/2 
banana 1 small apple 
1 slice 
watermelon 
1/2 cup 
unsweetened 
juice 
2-3 dates 15 grapes 2 tsp raisins 
Fresh fruits better 
than canned fruits 
or juices 
Vegetables 
 group 1 cup fresh vegetables or 1/2 cup cooked vegetables 
Eat lots of fresh 
vegetables it has 
lower calories 
Carb group 
1 slice 
brown 
toast or 
1/4 arabic 
bread 
1/2 cup 
cornflakes 
4-6 
unsweetene
d biscuits 
6 tsp cooked 
rice 
1/2 cup 
cooked pasta 1 potato 
1/3 cup 
beans or 
lentil 
1/2 cup 
peas 
Carbs with lots of 
fiber slow down 
the absorption of 
blood sugar 
Fat group 1 tsp oil 2 tsp lite mayonnaise 2 tsp tahini 
10 small 
olives 20 peanuts 6 almonds   
Use vegetables oils 
like olive oil 
instead of animal 
fats like ghee and 
butter in cooking 
and in small 
amounts 
 
 Keep your body weight in normal range 
 Eat 3 meals and 2 snacks 
 Eat your specified quantities and do it on time 
 Avoid eating much sugar like honey, jam, and soft drinks 
 Dowhat suit you of physical exercise 
 You are allowed to drink tea, coffee and soft drink but without sugar 
 Look at the alternative table to replace any kind of food from your diet 
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Appendix VI: Tables 
WHO EQUATIONS (2007) 
AGE FEMALE MALE 
3-9 years 22.5 w+499 22.7 w + 495 
10-17 years 12.2 w+746 17.5 w+651 
18-29 years 14.7 w+496 15.3 w + 679 
30-60 years 8.7 w + 829 11.6 w + 879 
>60 years old 10.5 w + 596 13.5 w + 487 
Activity factor 
Confined to bed 1.2 
Low activity 1.3 
Average activity 1.61 
Highly active 2 
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Appendix VII 
Daily Food Record 
 
Name : Date:  
Daily intake goal: 
Dear participants kindly write what you eat to become aware of what and how much 
you are eating 
Saturday Friday Thursday Wednesday Tuesday Monday  Sunday  Menu  
       Breakfast 
       Snack 
       Lunch 
        Snack 
       Dinner 
       Snack 
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Appendix VIII - List of publications and abstracts 
 
- Al-Disi D, Al-Daghri N, Khanam L, Al-Othman A, Al-Saif M., Sabico S, 
Chrousos G. Subjective sleep duration and quality influence diet composition 
and circulating adipocytokines and ghrelin levels in teen-age girls. Endocr J 
2010; 57(10):915-923. 
 
- Metcalfe D, Harte AL, Aletrari MO, Al-Daghri NM, Al-Disi D, Tripathi G, 
McTernan PG. Does endotoxaemia contribute to osteoarthritis in obese patients? 
Clin Sci 2012; 123:627-634. 
 
- Harte AL, Tripathi G, Piya MK, Barber TM, Clapham JC, Al-Daghri N, Al-Disi 
D, Kumsaiyai W, Saravanan P, Fowler AE, O'Hare JP, Kumar S, McTernan, PG. 
NFκB as a potent regulator of inflammation in human adipose tissue, influenced 
by depot, adiposity, T2DM status, and TNFα. Obesity 2013; 21:2322–2330. 
doi: 10.1002/oby.2033 
 
- Al-Disi D, Al-Daghri N, Khan N, Alsaif M, Alfadda A, Sabico S, Tripathi G, 
McTernan PG. A 3-month low fat diet leads to significant lipid profile 
improvement in obese T2DM Saudi subjects, without substantial weight loss, 
and the capacity to manage a damaging high-fat meal challenge more 
appropriately post intervention. Endocrine Abstracts 2014; 34 P223.  
 
- Al-Disi D, Al-Daghri NM, Khan N, Al-Fadda A, Sallam R, Al-Seif M, Sabico S, 
Tripathi G, McTernan PG. A 3-Month Balanced Diet with Complex 
Carbohydrate Improves Cardiometabolic Profile, Metabolic Endotoxaemia, and 
the Capacity to Manage a Damaging High-Fat Meal Challenge More 
Appropriately in Obese T2DM Subjects. P-752, ADA 2014. 
 
- Al-Disi D, Al-Daghri NM, Khan N, Al-Fadda A, Sallam R, Al-Seif M, Tripathi 
G, McTernan PG. Positive influence of a 3-month dietary intervention on 
cardiometabolic health in Saudi women with or without type 2 diabetes mellitus. 
Submitted to Journal of Nutrition (MS 2014/199281). 
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